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ABSTRACT 
Xinming Cai 
Cytoskeletal Signaling Proteins; Complex Regulatory Mechanisms and Roles in Innate 
Immunity 
(Under the direction of Dr. Michael D. Schaller) 
 
In animals, most of the tissues are surrendered by extracellular matrix.  The 
extracellular matrix plays multiple roles in maintaining the function of organs.  It not only 
provides physical support to assemble the cells into an intact tissue but also sends signals to 
surrounding cells to regulate several cellular behaviors, such as proliferation and anti-
apoptosis.  The major contact between extracellular matrix and cells is mediated by focal 
adhesions, a transmembrane protein complex working as a hub to convert the matrix/cell 
interaction into a chemical signaling.  Just like a canonical signaling pathway, focal adhesion 
signaling cascade is composed of receptors, enzymes and scaffolding proteins.  The interplay 
of these elements precisely transmits the extracellular signal into cells to induce downstream 
effects.  The work described here represents a collection of studies to decipher the detail 
mechanism of adhesion signaling.  The activation of FAK is an essential event in adhesion 
signal transduction.  In chapter II, FRET technology was applied to visualize the spatial and 
temporal activation of FAK in living cells.  PIP2 was identified as a FAK binding partner.  
That also promotes the activation of FAK via conformational change.  In addition to the FAK 
regulation mechanism, a novel paxillin modification was identified in chapter III.  
Phosphorylation of paxillin on serine 126 and 130, which is mediated by an ERK/GSK-3 
dual kinase mechanism, regulates the cytoskeleton reorganization. 
 iv 
Adhesion signaling is critical for multiple biological events, such as angiogenesis, 
neurite extension, and inflammation.  Innate immunity works as the first barrier to fight 
against microbe infection.  It not only directly destroys pathogens but also activates the 
antigen specific adaptive immune system.  The roles of adhesion signaling proteins in innate 
immunity were also investigated in chapter II and III.  The paxillin is phosphorylated by 
ERK and GSK-3 following LPS stimulation in macrophages, which is required for LPS 
induced macrophage spreading.  In Fcγ receptor meditated phagocytosis, Pyk2 is activated 
and accumulated to phagocytotic cup during phagocytosis.  The deletion or inactivation of 
Pyk2 impairs phagocytosis in macrophage.  The work presented here expands our 
understanding of how focal adhesion proteins regulate multiple singling pathways. 
 v 
To my parents, Dingyi Cai and Xia Pang, who have always encouraged me to do my best, 
and provided me support.  And to Wenjie Ye, my wife, who has provided endless love and 
care to me. 
  
 vi 
ACKNOWLEDGMENTS 
“Life was like a box of chocolates.  You never know what you’re gonna get.”  When I 
migrated across the Pacific Ocean to a American southern college town four years ago, a box 
of unopened chocolates was waiting for me.  Now I have already eaten all of them.  The taste 
is quite good!  However, I know I can not enjoy this box of chocolates without everyone who 
gave me the tremendous supports during my graduate studies.  
I would like to extend my appreciation to my advisor, Professor Mike Schaller for his 
guidance and support on my research.  I really learn a lot from him, not only just some 
technical skills but the way to think and solve the scientific questions.  Moreover, I also learn 
how to face the challenge, frustration and deal with life work balance from Mike.  He shows 
me a way to understand the essence of life in the past four years.   
I would also like to thank the current and past members of the Schaller lab for their 
help for my research.  They always turn lab into a place where is filled with fun and 
happiness.  I would like to particularly thank Danielle Smith and Dr. Kavita Vadali for their 
kind help for thesis proofreading.    
I would like to express my appreciation to my committee members.  They give me 
invaluable scientific advice and career guidance.  They make me feel that UNC is just like a 
big and warm family.  You can always get what you want from every kind member.  
I am grateful for all my colleagues at UNC or somewhere else, especially to Julie 
Williams and Dr. Andrei Karginov, for their self-giving support and intellectual guidance.  I
 vii 
also want to extend my thanks to Ms. Janice Warfford and Ms. Gina Werner.  Their excellent 
student service makes me never need to worry about anything about class registration and 
graduation application.   
Finally, I would like to thank all my family members and friends for their 
encouragement and friendship throughout my graduate studies.  
   
 viii 
TABLE OF CONTENTS 
LIST OF FIGURES xii 
LIST OF ABBREVIATIONS AND SYMBOLS xiv 
Chapter 
1.  INTRODUCTION 1 
 1.1  The Biological Significance of FAK 2 
 1.2  The Structure of FAK 2 
1.3  The Molecular Mechanism of FAK Regulation 4 
 1.3.1  The Definition of FAK Activation 4 
1.3.2  Phosphorylation Mediated FAK Activation 5 
1.3.3  Conformation Mediated FAK Activation 8 
1.3.4  Other Mechanisms of FAK Regulation 10 
1.3.5  FAK Activation Model 11 
1.4  FAK Regulates Multiple Signaling Pathways 11 
1.4.1  The Role of FAK in Cell adhesion and Cell Migration 12 
1.4.2  The Role of FAK in Cell Survival 13 
1.4.3  The Role of FAK in Mechanotransduction 15 
1.4.4  The Role of FAK in Angiogenesis 19 
1.5  Pyk2 23 
1.6  Other Kinases in Adhesion Signaling 24 
 ix 
1.6.1  Src 25 
1.6.2  Abl 26 
1.6.3  MAPK Family 26 
1.6.4  PKC Family 27 
1.6.5  PAK 28 
1.6.6  ILK 28 
1.6.7  Lipid Kinases 28 
1.7  Adhesion Signaling Proteins in Innate Immunity 30 
1.7.1  Innate Immunity System 30 
1.7.2  TLR Signaling 31 
1.7.3  Phagocytosis 34 
2  GSK-3- AND ERK-DEPENDENT PHOSPHORYLATION OF PAXILLIN  
REGULATES CYTOSKELETAL REARRANGEMENT 44 
2.1  Abstract 45 
2.2  Introduction 45 
2.3  Materials and Methods 48 
2.4  Results 53 
2.5  Discussion 63 
2.6  Acknowledgements 67 
3  SPATIAL AND TEMPORAL REGULATION OF FAK ACTIVITY  
IN LIVING CELLS 80 
3.1  Abstract 81 
3.2  Introduction 81 
3.3  Materials and Methods 84 
 x 
3.4  Results 89 
3.5  Discussion 100 
3.6  Acknowledgements 103 
4  PYK2 REGULATES FCγ RECEPTOR MEDIATED PHAGOCYTOSIS  
IN MACROPHAGES 122 
4.1  Abstract 123 
4.2  Introduction 123 
4.3  Methods 125 
4.4  Results 128 
4.5  Discussion 134 
5  FUTURE DIRECTIONS 144 
5.1  Future Directions For FAK Biosensor 145 
5.1.1  Where Does FAK Change Its Conformation? 145 
5.1.2  When Does FAK Change Conformation? 146 
5.1.3  How Does FAK Change Conformation? 147 
5.1.4.  Why Does FAK Change Conformation? 147 
5.1.5  Other Conformational Measurement Strategies 148 
5.1.6  FRET Biosensor in a High Throughput Screen 149 
5.2  Downstream Effects of Paxillin Serine126/130 Phosphorylation 150 
5.3  Downstream Effects of Pyk2 Activation in Fcγ Receptor  
Mediated Phagocytosis 150 
5.4  The Role of Pyk2 in Other Types of Phagocytosis 150 
5.5  The Role of Pyk2 in Immune Cell Migration 151 
 xi 
REFERENCES 155 
 xii 
LIST OF FIGURES 
Figure 
1.1  Domain structure of FAK/Pyk2 37 
1.2  Regulation of FAK by protein tyrosine phosphatases 38 
1.3  The crystal structure of auto-inhibition status of FAK 39 
1.4  The FAK regulation model 40 
1.5 The role of FAK in multiple signaling 41 
1.6 Stretch Model of FAK Activation 42 
1.7  FAK and Angiogenic Signaling Pathways 43 
2.1  LPS induces paxillin tyrosine and serine phosphorylation 69 
2.2  LPS-induced paxillin serine 126 phosphorylation is ERK dependent 71 
2.3  Paxillin serine and tyrosine phosphorylation are regulated by separate pathways 72 
2.4  Paxillin serine 126 phosphorylation is induced by multiple stimuli 73 
2.5  Phosphorylation of serine 126 is abolished by GSK-3 inhibitors 74 
2.6  Phosphorylation of paxillin is mediated by ERK/GSK-3 dual-kinase mechanism 75 
2.7  Subcellular localization of the serine 126-phosphorylated form of paxillin  
in fibroblasts 76 
2.8  ERK/GSK-3-mediated phosphorylation of paxillin is involved in cell spreading 77 
2.9  ERK/GSK-3-mediated phosphorylation of paxillin is involve  
in NGF-induced neurite outgrowth 78 
3.1  Characterization of FAK auto-phosphorylation biosensor 105 
3.2  Characterization of FAK conformation biosensor 106 
 xiii 
3.3  Biochemical characterization of the FAK conformational biosensor 108 
3.4  Spatial regulation of FAK activity 110 
3.5  Spatial and temporal regulation of FAK conformation 112 
3.6  PIP2 associates with FAK FREM domain 114 
3.7  PIP2 induces conformation change in FAK 116 
3.8  The emission ratio of FAK auto-phosphorylation biosensor 118 
3.9  The expression of FAK biosensors 119 
3.10 FAK auto-phosphorylation in focal adhesions 121 
4.1 Pyk2 is tyrosine phosphorylated in a Src family kinase- and  
Syk-dependent manner during FcγR mediated phagocytosis 137 
4.2 Pyk2 accumulates in phagocytotic cups during FcγR mediated phagocytosis 139 
4.3  Pyk2 interacts with Lyn and Syk via different mechanisms 140 
4.4  Pyk2 and FAK regulate FcγR mediated phagocytosis 141 
4.5  Pyk2 is required for FcγR mediated phagocytosis signaling 143 
  
 xiv 
LIST OF ABBREVIATIONS 
A Alanine 
APC Adenomatous polyposis coli  
ArfGAP Arf GTPase-activating protein 
ASAP1  ARF- GAP containing SH3, ANK repeats, and PH domain1 
ATP Adenosine 5'-triphosphate  
BAEC Bovine aortic endothelial cell 
BODIPY DIPYrromethene BOron Difluoride 
CaMK     Calcium/calmodulin-dependent protein kinase  
CDK         Cyclin-dependent kinase 
CFP Cyan fluorescence protein  
CRMP-2  Collapsin response mediator protein-2  
CSF Colony stimulating factor 
Cys Cysteine 
D Aspartic acid  
DMEM Dulbecco's modified eagle's medium  
DOCK180 180-kDa protein downstream of CRK 
DTT Dithiothreitol 
EGF Epidermal growth factor  
eNOS Endothelial Nitric Oxide Synthase  
ERK Extracellular signal regulated kinases 
F Phenylalanine 
FACS Fluorescence-activated cell sorting  
 xv 
FAK        Focal adhesion kinase 
FAT        Focal adhesion targeting 
FBS Fetal bovine serum 
FERM 4.1 protein/ ezrin/radixin/moesin 
FGF Fibroblast growth factor 
FGFR Fibroblast growth factor receptor 
FIP200 Focal adhesion kinase family interacting protein of 200 kDa 
FlAsH Fluorescein arsenical hairpin binder 
FRET Fluorescence resonance energy transfer  
FRNK FAK related non kinase  
GAP    GTPase Activating Protein 
GFP Green fluorescent protein  
Gly Glycine 
GPCR G protein-coupled receptor 
Grb2    Growth factor receptor-bound protein 2 
GSK-3 Glycogen synthase kinase 3 
GST Glutathione S-transferase 
HEK293 human embryonic kidney cell 293 
HeLa Henrietta Lacks 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HGF Hepatocyte growth factor 
HSF-1  Heat shock factor-1 
 xvi 
HUVEC human umbilical vein endothelial cells 
ICAM-1  Intercellular adhesion molecules 1 
IL Interleukin 
ILK Inhibition of integrin-linked kinase  
IP3 Inositol 1,4,5-trisphosphate  
IRAK Interleukin-1 receptor-associated kinase 
IRF3 Interferon regulatory factor 3 
JNK Jun N-terminal kinase  
K Lysine 
KD Dissociation constant 
kDa KiloDalton 
LAD Leukocyte adhesion deficiency 
LBP Lipopolysaccharide binding Protein 
LD Leucine/aspartate  
Lef1 Lymphoid enhancer-binding factor 1 
LIM Lin11/IsI1/mec3 
LIMK LIM domain kinase 
LPA Lysophosphatidic acid 
LPS Lipopolysaccharide 
LRR          leucine-rich-repeat 
M Methionine 
MAP1B Microtubule-associated protein 1b 
 xvii 
MAPK     Mitogen-activated protein kinases 
MEF2 Myocyte enhancer factor-2 
MEK MAP kinase/ERK kinase 
Met Mesenchymal epithelial transition factor 
MHC Major histocompatibility complex  
MIP-1 Macrophage inflammatory protein 1  
MKK4 Mitogen activated protein kinase kinase 4 
MLCK Myosin light chain kinase  
MyD88 Myeloid differentiation primary response protein (88) 
NF-κB  Nuclear factor-kappa B 
NGF Nerve growth factor  
N-WASP Neural Wiskott-Aldrich syndrome protein  
p130CAS p130 Crk-associated substrate 
PAK p21-activated kinase 
PAMP Pathogen associated molecular patterns 
PBS Phosphate buffered saline  
PC Phosphatidylcholine 
PCR Polymerase chain reaction  
PDGF Platelet derived growth factor  
PE Phosphatidylethanolamine 
PH domain Pleckstrin homology domain 
PI Phosphatidylinositol 
 xviii 
PI3K Phosphoinositide-3 kinase  
PIP2 Phosphatidylinositol(4,5)-bisphosphate 
PIP3 Phosphatidylinositol (3,4,5)-trisphosphate  
PIP5K Phosphatidylinositol-4-phosphate 5-kinase 
PKC Protein Kinase C 
PKL Paxillin kinase linker  
PLCδ Phospholipase C δ 
PMA p-methoxyamphetamine 
Pro Proline 
PRR        Proline rich region 
PTEN Phosphatase and Tensin homolog 
PTP1B Protein tyrosine phosphatase 1B  
PTPα protein tyrosine phosphatase α 
Pyk2 Proline-rich tyrosine kinase 2 
RIPA  Radio-immunoprecipitation assay  
ROCK    Rho-dependent kinase 
ROS Reactive oxygen species  
RPMI 1640  Roswell Park Memorial Institute-1640 
S Serine 
SDF-1 Stromal cell-derived factor-1 
SDS Sodium dodecyl sulfate  
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
 xix 
SFK      Src Family Kinase 
SH2 Src homology 2 domain  
SH3 Src homology 3 domain 
SHP-2 Src homology 2-containing tyrosine phosphatase 
SNP Single nucleotide polymorphism 
TCR        T cell receptor 
TIR Toll-interleukin 1 receptor  
TIRF total internal reflection fluorescence  
TLR Toll like receptor 
TNF-α Tumor necrosis factor-alpha  
TOLLIP Toll-interacting protein 
TRAF6 TNF receptor-associated factor 6 
TRIAP TIR-containing adapter protein  
TRIF TIR domain containing adapter inducing interferon-β 
VE-cadherin Vascular Endothelial Cadherin 
VEGF     Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor receptor 
Wnt Wg (wingless) and Int 
Y Tyrosine 
YFP Yellow fluorescent protein 
ZAP-70 Zeta chain associated protein kinase 70 
 
CHAPTER 1 
Introduction 
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1.1  The Biological Significance of FAK 
FAK was first identified in 1992 by three different groups as a 125kD tyrosine kinase 
in Src transformed cell and breast cancer cell (165,181,389).  Since then, a number of studies 
suggest that FAK is an important regulator that coordinates multiple cell signaling pathways.  
The fak-/- mouse is embryonic lethal and exhibits defects in mesoderm development (215).  
Recently, conditional knock out technology has shed light on the tissue specific function of 
FAK.  Endothelial cell specific deletion of FAK leads to embryonic death with strong defects 
in angiogenesis (31,417).  Myocyte FAK conditional knockout mice exhibit abnormal 
responses to pressure induced hypertrophy (113,354).  In neurons, FAK conditional knockout 
mice exhibit failures in axon branching, sorting and netrin induced axon outgrowth and 
turning (283,308,372,375).  The mammary epithelial-specific conditional knockout mice 
show defects in lobulo-alveolar and mammary gland development (333).  Hence, FAK is 
extensively involved in regulating organogenesis and maintaining regular physiological 
function. 
1.2  The Structure of FAK 
FAK contains three major domains, an N-terminal FERM domain, a central kinase 
domain and a C-terminal FAT domain (Fig 1.1).  The FERM domain is connected to the 
kinase domain with a linker.  There are a number of PRRs (Proline rich region) within the 
hinge areas between domains.  Homologues of FAK have been identified in X. laevis, C. 
elegans, and D. melanogaster (100,143,189,348,506).  These homologues are highly 
conserved in domain arrangement, important motifs and regulatory sites.  This high 
evolutionary conservation implicates the significance of FAK in biological function.  Neuron 
specific FAK isoforms with insertions close to the auto-phosphorylation site were identified 
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(42).  These FAK splice variants exhibit higher kinase activity.  However, the detailed 
function of these isoforms is still unknown.   
The FAT domain contains the targeting motif, which is critical for the focal adhesion 
localization of FAK (190).  However, the mechanism of focal adhesion targeting is very 
complex.  It targets to the focal adhesion via its association with a number of focal adhesion 
proteins, e.g. paxillin and talin (76,434).  Focal adhesion targeting is a critical step for FAK 
activation.  Interestingly, FRNK, an endogenous FAK FAT domain variant, works as a 
natural dominant negative to inhibit FAK activation (374).   
The kinase domain of FAK is quite conserved when compared to other tyrosine 
kinase catalytic domains.  There are two tyrosine residues (Y576/Y577) within the kinase 
domain that are key regulatory sites for FAK activation (50).   
The FERM domain in FAK is an atypical FERM domain when compared with other 
canonical FERM domains (66). For example, the FERM domain lacks the lipid binding 
groove between the F1 and F3 subdomain when compared to other FERM domain crystal 
structures.  The importance of the FAK FERM domain was revealed in recent studies.  First, 
the FERM domain serves as a scaffold to coordinate a number of important events.  The 
domain interacts with P53 to promote a cell survival signal (158).  In the leading edge of 
migrating cells, the FERM domain associates with Arp2/3 to regulate actin nucleation and 
cell protrusion (410).  Second, a number of studies suggest that FERM domain works as a 
“mask” to interact with the kinase domain, which blocks its kinase activity (92,97,296,446).   
In addition to the major conserved domains, a number of other motifs within FAK 
also play important roles.  Three proline rich regions are found at the junctions of the major 
FAK domains.  A number of proteins containing SH3 domains interact with FAK via these 
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motifs.  PRR1 is between the FERM and the kinase domain and provides a secondary 
binding site to promote Src/FAK interaction (439).  A CDK5 phosphorylation site (S732) has 
been identified close to PRR2, which regulates neuronal migration by regulating microtubule 
organization and nuclear movement (490).  PRR2 associates with p130CAS, which is a 
substrate for Src (365).  PRR3 associates with ASAP1 and Graf, both of which are GAPs 
(GTPase Activating Protein) (191,311).  A linker connects the FERM domain and kinase 
domain.  An auto-phosphorylation residue (Y397) within the loop provides a docking site for 
a number of SH2 domain containing proteins, e.g. Src and PI3K (75,393).  The tyrosine 
phosphorylation of Y397 is essential for FAK activation.  Recently tyrosine 407, another Src 
mediated tyrosine phosphorylation residue in the activation loop has been proposed as a 
negative regulatory site (298).  
1.3  The Molecular Mechanism of FAK Regulation 
1.3.1  The Definition of FAK Activation 
As an important tyrosine kinase in multiple signaling pathways, the “on” and “off” 
status of FAK plays a critical role in coordinating the signal transduction pathways.  
However, when compared with other signaling molecules, there are two different definitions 
of FAK activation.  The traditional definition of FAK activation is the enhancement of the 
kinase activity.  The generalized definition of FAK activation is the transition of FAK from 
its resting form to a modified form that facilities signal transduction.  This modification 
results not only in the enhancement of its kinase activity but also in the promotion of its 
scaffold function.  Actually, a number of important modifications of FAK e.g. 
phosphorylation of Serine 732 or tyrosine 925 do not directly change its kinase activity; 
instead they change its binding affinity to a number of binding partners, such as Grb2 
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(403,489).  Here I will review the general definition of FAK activation.  At the same time, I 
will also pay attention to how to “turn off” FAK and FAK inactivation mechanisms are also 
discussed here.  
1.3.2  Phosphorylation Mediated FAK Activation 
FAK was first identified as a tyrosine phosphorylated protein.  Tyrosine 
phosphorylation is a major regulatory mechanism of FAK activation.  In addition to tyrosine 
residues, the serine and threonine residues also play an important role in regulation of FAK.  
Most of the FAK phosphorylation sites are labeled in Fig 1.1.  Here I will review the 
phosphorylation of FAK by upstream kinases. 
1.3.2.1  Auto-Phosphorylation of FAK 
Tyrosine 397 was the first identified phophorylated residue within FAK (392).  It was 
shown to be a FAK auto-phosphorylation site and an SH2 domain binding site, especially for 
SFK (Src family kinase).  The kinase activity of the Y397F mutant is greatly impaired both 
in vivo and in vitro (345,391).  Studies suggest that tyrosine 397 phosphorylation is an early 
event in FAK activation because tyrosine phosphorylation of other residues is abolished in 
the mutant (344).  This result is reasonable since the SFK/FAK interaction was also greatly 
impaired in the mutant and SFK is a major group of kinases that phosphorylate other tyrosine 
residues within FAK.  The FAK Y397F mutant shows defects in focal adhesion turn over, 
cell migration and cell cycle progression (58,467,507).  Moreover, the auto-phosphorylation 
of FAK is not only critical for promoting FAK kinase activity; but it is also required for FAK 
scaffold function.  A number of other signaling molecules, such as PI3K and Grb7, associate 
with FAK via tyrosine 397 and form a signaling complex (74,176).  In addition to SFKs, 
other FAK binding partners are also critical for FAK related signal transduction.  The D395A 
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mutant is capable of binding Src but not PI3K.  Cells expressing the D395A mutant still 
show defects in cell migration (370).   
1.3.2.2  SFK Mediated FAK Phosphorylation 
As the first identified FAK binding partners, SFKs are some of the most important 
FAK activity regulators.  When FAK tyrosine 397 is phosphorylated, SFK associates with 
FAK and phosphorylates other tyrosine residues within FAK.  Tyrosine 576, 577, 407, 861 
and 925 are all SFK mediated phosphorylation sites.  Phosphorylation of tyrosines 576/577 is 
a key step for FAK to achieve maximal kinase activity (49).  Cells expressing FAK 
Y576/577F mutants exhibit defects in spreading and migration (346).  There is no evidence 
that tyrosine phosphorylation of tyrosine 925 effects the FAK kinase activity.  However, the 
phosphorylated tyrosine 925 creates a binding site for the Grb2 SH2 domain.  The assembly 
of a FAK/Grb2 complex activates the Grb2/MAPK pathway (402).  A recent study suggests 
that tyrosine 925 is required for VEGF induced tumor growth via activation of the MAPK 
cascade (328).  Phosphorylation of tyrosine 861 is also not associated with FAK kinase 
activity.  However, it plays multiple roles in FAK signal transduction.  The VEGF induced 
phosphorylation of tyrosine 861 promotes the assembly of the FAK/Integrinαvβ5 complex, 
which might regulate VEGF induced vascular permeability (126).  Other studies also 
suggests that phosphorylation of tyrosine 861 is related to the regulation of cell survival and 
migration (5).  The function of tyrosine 407 phosphorylation is largely unknown.  
Interestingly, a recent study suggests that tyrosine 407 is a negative regulatory site for FAK 
kinase activity (297).  However, the detailed molecular mechanism is still unclear.  Other 
studies also suggest that tyrosine 407 is phosphorylated by Pyk2, which promotes VGEF 
induced cell migration (267).  In brief, SFKs induce FAK phosphorylation on multiple sites.  
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The phosphorylation of each site activates specific downstream pathways, which suggests 
that FAK precisely coordinates the multiple signal transduction pathways.   
1.3.2.3  Other kinases Mediated FAK Phosphorylation  
In addition to tyrosine phosphorylation, a number of serine phosphorylation sites have 
also been identified on FAK.  FAK serine 732 is phosphorylated by CDK5 in neuron cells 
(488).  The phosphorylation of serine 732 is important for microtubule organization, nuclear 
movement, and neuronal migration.  Interestingly, serine 732 is also directly phosphorylated 
by ROCK following VEGF stimulation in HUVECs (266).  ROCK induced phosphorylation 
of serine 732 is required for Pyk2-dependent phosphorylation of tyrosine 407, which 
promotes endothelial cell migration.  Serine 722 was recently identified as a GSK-3 mediated 
phosphorylation site (23).  Similar to other GSK-3 substrates, the phosphorylation of serine 
722 depends upon a preexisting phosphorylation at a nearby site.  Phosphorylation of FAK at 
serine 726 by an unknown kinase creates a docking site for GSK-3 promoting serine 722 
phosphorylation.  Interestingly, FAK kinase activity is inhibited when serine 722 is 
phosphorylated.  Hence the phosphorylation of serine 722 works as a brake to block cell 
migration.  Some other FAK serine phosphorylation sites are also reported, but little is 
known about the specific physiological functions of these sites (235).   
1.3.2.4  FAK and Protein Tyrosine Phosphatases 
FAK is also regulated by various phosphatases.  There are two different regulatory 
mechanisms (Fig 1.2).  In the direct regulation model, the tyrosine phosphatase, such as SHP-
2, impairs FAK activity via direct dephosphorylation of the tyrosine residues within FAK 
(318,450).  SHP-2 associates with FAK via its SH2 domain, which may disrupt the FAK/Src 
complex.  Therefore not only the phosphatase activity of SHP-2 but also its competitive 
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binding promotes FAK inactivation.  However, fibroblasts expressing a SHP-2 mutant 
lacking phosphatase activity exhibits defects in cell spreading and cell migration.  The 
detailed mechanism is still unclear (501).  In the indirect model, some phosphatases, such as 
PTPα, dephosphorylate Src tyrosine 527 (182).  The dephosphorylation of tyrosine 527 
activates Src and promotes Src mediated FAK activation.  This model explains the migration 
defects in PTPα null fibroblasts (504).  Interestingly, PTP1B is reported to regulate FAK 
activity via both direct and indirect mechanisms, which suggests that PTP1B is capable of 
selecting specific substrates in different scenarios (14,307).  Another important dual function 
phosphatase, PTEN is also involved in FAK regulation.  An initial study proposed that PTEN 
directly interacts with and inactivates FAK via dephosphorylation (436).  But recent studies 
suggested that PTEN may not directly regulate FAK.  However, PTEN may indirectly block 
FAK activation via dephosphorylation of PIP3, the PI3K product.  Since PI3K is required for 
FAK activation during cell spreading, the PTEN induced PIP3 hydrolysis may block FAK 
activation (249).     
1.3.3  Conformation Mediated FAK Activation 
1.3.3.1  Kinase Conformation Transition 
Besides phosphorylation, some kinases also use other strategies to regulate their 
activities.  A conformational switch has been proven to be a very common form of kinase 
regulation.  This regulation strategy is especially important in tyrosine kinases.  For Src, 
kinase activity is blocked when it is in a closed conformation.  This auto-inhibited 
conformation is held when the N-terminal SH2 of Src associates with the corresponding 
tyrosine residue (tyrosine 527) within the C-terminus of Src, which is phosphorylated by 
CSK while the cell is in a resting state (16).  Structurally, this closed conformation disrupts 
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the kinase active site and occupies the SH2 and SH3 domains (424,492).  Interestingly, this 
interaction is disrupted in v-Src, a constitutively active mutant identified in Rous sarcoma 
virus.  Other conformational regulatory mechanisms have also been found in other tyrosine 
kinases.  For example, the auto-inhibited conformation of ZAP-70 is held by an interaction 
between the regulatory segment and the hinge region of the kinase domain (103).  This 
interaction is disrupted when the SH2 domain in ZAP-70 associates with the ITAM motif 
within the TCR C-tail following TCR activation (185).  Conformational transition is also a 
major regulatory mechanisms in some other serine/threonine kinases, such as PKA and 
CaMK (155,246). 
1.3.3.2  Molecular Mechanism of FAK Conformational Transition 
Studies within the last five years have suggested that an intra-molecular interaction 
may regulate FAK activity.  Toutant et al suggested that truncation of the FERM domain may 
increase FAK kinase activity (445).  Cohen et al proposed that the FERM domain of FAK 
associates with the kinase domain to inhibit FAK activity (96).  They also identified lysine 38 
within the FERM domain as a critical residue for the FERM/kinase interaction (90).  The 
FAK K38A mutant exhibits higher kinase activity in vivo and in vitro.  Recently, the co-
crystallized FERM/kinase structure revealed the interaction mechanism (Fig 1.3 A) (295).  
The hydrophobic residue phenylalanine 596 projects into a hydrophobic pocket formed 
within the FERM domain (Fig 3.2E).  Introduction of point mutations within these sites 
greatly increases FAK phosphorylation levels and kinase activity.  Moreover, unlike wild 
type FAK, the activity of these FAK mutants is independent of adhesion signaling.  
Interestingly, the activation loop is proposed to be embedded underneath the cleft between 
the FERM and kinase domains.  Based upon the structure, a conformation based FAK 
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activation model has been proposed.  In the inactive condition, both the important regulation 
residues within the linker and activation loop are masked by the FERM domain.  
Displacement of FERM domain via an unknown mechanism unmasks these residues, which 
allows auto-phosphorylation followed by Src mediated phosphorylation.  In general, FAK 
conformation change is an initial step for FAK activation. 
1.3.4  Other Mechanisms of FAK Regulation 
Cleavage of FAK is used as another strategy to regulate FAK activity.  Degraded 
collagen fragments induce calpain dependent cleavage of FAK via the integrin pathway (55).  
In Src transformed cells, FAK works as a scaffold to assemble a FAK/ERK/calpain complex 
(57).  The PRR1 within the linker associates with calpain and is essential for the cleavage of 
FAK.  ERK activity is also required for calpain mediated cleavage of FAK.  Cells expressing 
the FAK PRR mutant exhibit defects in focal adhesion turn over and cell migration, which is 
similar to calpain null cells.  Calpain dependent cleavage of FAK not only removes FAK out 
of focal adhesion but also creates FRNK like fragments, which might work as a dominant 
negative to inhibit the remaining FAK activity in the focal adhesions (54).   
FAK is also cleaved by caspase following apoptotic signals, such as HIV envelope 
induced CD4+ T cell apoptosis (86).  However, both focal adhesion turnover and 
dephosphorylation of FAK are independent of the caspase mediated cleavage of FAK in 
apoptotic cells, which suggests that the disassembly of focal adhesions precedes the cleavage 
of FAK.  Interestingly, recent studies suggest that the FAK FERM domain shuttles into the 
nucleus and works as a scaffold to block P53 induced apoptosis (D. Schlaepfer, personal 
communication).  Cleavage of FAK induced by apoptotic signals may promote nuclear 
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targeting of the FAK FERM domain, which in turn promotes the FERM domain mediated 
survival.      
1.3.5  FAK Activation Model 
Our understanding of the molecular mechanism of FAK activation is always 
developing with the updated collection of data.  The new FAK auto-inhibition structure gives 
us a straightforward view of FAK activation.  Based upon the available biochemical and 
structural data, a novel FAK activation model is proposed (Fig 1.4).  FAK holds a “closed” 
conformation in the resting cells.  The N-terminal FERM domain masks the active site and 
substrate binding.  When integrins are activated by the extracellular matrix, FAK is recruited 
to the nascent focal adhesions where it switches to an “open” conformation.  The unmasked 
kinase domain promotes the auto-phosphorylation of FAK, which provides the binding site 
for Src.  The tyrosine residues within the activation loop are also exposed for 
phosphorylation, which greatly enhances FAK kinase activity. 
 Though an elegant FAK activation picture is presented, there are still some gaps in 
this activation model.  The initial conformation switch is the first step for FAK activation.  
However, we still know little about the factors that trigger this transition.  The cytoplasmic 
tail of integrins is proposed to initiate FAK conformational switch following integrin 
activation (99).  FAK is stretched to an “open” conformation when FAK FERM domain 
associates with the activated integrin.  This hypothesis waits testing in the future. 
1.4  FAK Regulates Multiple Signaling Pathways 
Over the past fifteen years, extensive research into the functions of FAK has 
improved our understanding of the roles of FAK in multiple signaling pathways (349).  Due 
to the specific focal adhesion localization, early studies focused on the role of FAK in 
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regulating integrin signaling, cell adhesion and migration.  However, more and more studies 
suggest that FAK is involved not only in cytoskeleton reorganization but also in most other 
cell behaviors, such as cell division and survival.  Hence, FAK coordinates multiple signaling 
pathways with integrin pathways to make a comprehensive signaling response (Fig 1.5). 
1.4.1  The Role of FAK in Cell adhesion and Cell Migration 
In cells seeded on the extracellular matrix coated surface, FAK is activated following 
integrin activation and regulates cell spreading via multiple mechanisms.  For one, FAK 
mediated substrate phosphorylation is required for cell spreading.  FAK induced tyrosine 
phosphorylation of paxillin promotes cell spreading via the activation of the 
CrkII/DOCK180/Rac pathway (362,397).  On the other hand, though FAK activation 
depends on RhoA-Rock signaling, activated FAK blocks RhoA activity to attenuate the 
intracellular tension, which promotes cell spreading (21,195,505).   
The role of FAK in cell migration is very complex.  It promotes cell movement by 
regulating multiple biochemical/biological events (325).  FAK is implicated in regulating 
focal adhesion dynamics, which is a key factor for cell migration (466).  FAK null cells 
assemble large focal adhesions and exhibit very low focal adhesion disassembly rates (216).  
FAK may regulate focal adhesion dynamics via FAK mediated paxillin phosphorylation 
because similar focal adhesion dynamics were also identified in cells expressing paxillin 
variant (Y31F/Y118F), which lacks the FAK phosphorylation site (469).  FAK also 
suppresses Rho activity to promote the focal adhesion turn over (408).  In addition to the 
regulation of focal adhesion dynamics, FAK also regulates cell protrusion during migration.  
It regulates the subcellular localization of N-WASP by interacting with and phosphorylating 
N-WASP (486).  FAK induced tyrosine phosphorylation of N-WASP promotes its 
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cytoplasmic localization. Cell migration was blocked in cells expressing an N-WASP 
tyrosine phosphorylation site mutant.  Recently FAK has been suggested to promote nascent 
lamellipodial formation by promoting Arp2/3 mediated actin nucleation (409).  Interestingly, 
evidence suggests that FAK could also regulate cell migration via microtubules. Ezratty et al 
reported that FAK regulates microtubule induced focal adhesion turnover via dynamin (131).  
Palazzo et al proposed that FAK maintains cell protrusion via stabilization of microtubules 
(347).  Hence, FAK promotes the two key steps in cell migration: cell protrusion and focal 
adhesion turn over via a number of different mechanisms. 
Interestingly, though it is almost dogma that FAK is essential for cell migration, some 
studies suggests that FAK may work as a brake to block cell migration under specific 
conditions.  FAK is proposed to block Rac activity in N-cadherin based cell adhesions.  HeLa 
cells treated with FAK siRNA show enhanced Rac activation and cell motility (496).  The 
knock down/rescue assay suggests that tyrosine phosphorylation of tyrosine 861 but not FAK 
kinase activity or auto-phosphorylation is critical for FAK mediated down regulation of Rac 
activity in N-cadherin based cell adhesions.  Moreover, FAK null endothelial cells show 
enhanced motility when they are scattered outside of capillaries in the P-Sp explants, which 
suggests that FAK blocks endothelial cell migration in an organ context(30).  The mechanism 
for this is still unknown. 
1.4.2  The Role of FAK in Cell Survival  
Though first identified as a tyrosine kinase that regulates the cytoskeleton 
rearrangement, more and more studies suggest that FAK is an important regulator of cell 
survival.  Braren et al proposed that cell apoptosis is a major reason for the angiogenesis 
defect in the FAK conditional knockout endothelial cells (29,416).  This implicates FAK in 
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promoting a survival signal that plays a critical role in cardiovascular system development.  
FAK regulates multiple survival pathways.  Constitutively activated FAK prevents “anoikis”, 
which is a kind of apoptosis induced when anchorage-dependent cells detach from the 
surrounding extracellular matrix (142).  This study suggests that FAK is required for 
regulating the integrin dependent cell survival signal.  Two possible mechanisms are 
proposed.  Ilic et al proposed that FAK suppresses P53 induced apoptosis via inhibition of 
the PKC/phospholipase A2 pathway (214).  Almeida et al proposed a different model where 
the FAK/p130CAS complex activates JNK via a Ras/Rac1/Pak1/MKK4 pathway (10).  The 
above two mechanisms may work together to maintain cell survival in cells growing on a 
specific extracellular matrix under different stress conditions.  When cells are serum starved, 
the FAK/p130CAS/JNK pathway is activated to promote the cell survival.  When cells are 
stimulated by some “death” cytokines, e.g. TNF-α, FAK blocks the death signal transduction 
via inhibition of P53.  FAK also regulates the activation of the PI3K/AKT pathway, which is 
another important survival signal in some specific scenarios.  FAK is required for PI3K/AKT 
activation to prevent hydrogen peroxide-induced apoptosis in HL-60 cells (429).  Recently, a 
novel FAK mediated cell survival mechanism has been proposed.  The FAK FERM domain 
directly associates with P53, which suppresses P53 dependent transcription activation (157) 
(D. Schlaepfer, personal communication).  Compared to the other mechanisms, the new 
model suggests that FAK may promote cell survival only via the FERM domain but not the 
kinase or FAT domains.  Since the FAK FERM domain is reported to localize to the nucleus, 
it is possible that FAK may regulate apoptosis related transcription in the nucleus instead of 
the cytoplasm (237,430).  These studies raise the possibility that FAK shuttles between 
cytoplasm and nucleus to propagate different signals   
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1.4.3  The Role of FAK in Mechanotransduction 
In addition to chemical stimuli, physical stimuli are another important source that 
regulates the cell behavior (280).  Focal adhesions connect the extracellular matrix to internal 
signaling molecules.  They not only bear the cellular traction force but also sense 
extracellular physical changes.  Hence, focal adhesions play a critical role in cellular 
mechanotransduction.  As a major tyrosine kinase within focal adhesions, FAK is essential 
for focal adhesion mediated mechanotransduction.   
1.4.3.1  The Role of FAK in Fibroblast Mechanotransduction 
FAK is required to maintain normal cell protrusion and directional migration.  When 
normal fibroblasts meet an external force, the cells will turn around and form prominent focal 
adhesions.  FAK null fibroblasts fail to make these responses following physical stimulation.  
This mechanotransduction defect is rescued via the re-expression of FAK (460).  
Interestingly, cells expressing the FAK auto-phosphorylation site mutant (Y397F) only 
exhibit normal focal adhesion dynamics following stimulation by an external force.  
However, the cells still show defects in reorientation.  Another study also suggests that auto-
phosphorylation of FAK is critical to maintain cell directional sensing (441).  
Normal fibroblasts prefer a rigid matrix to maintain a suitable cell tension.  They will 
move away when they sense that the matrix is too soft.  This response to substrate flexibility 
is greatly impaired in FAK null fibroblasts.  This defect is rescued in cells expressing wild 
type FAK or FAK Y397F (459). 
In addition to force and substrate flexibility, matrix topography also influences the 
fibroblast motility.  Normal fibroblasts exhibit multiple protrusions and erratic migration in 
pillar substrates where migrating cells encounter irregular surface.  These responses are 
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greatly impaired in FAK null fibroblasts.  This suggests that FAK is critical for cells to sense 
matrix topography (141). 
1.4.3.2  The Role of FAK in Endothelial Cell Mechanotransduction 
As a barrier of vessel, endothelial cells directly bear the physical stimuli applied by 
blood flow, including shear stress, pressure and circumferential stretch.  In response, they 
regulate cell behavior, such as cytoskeleton rearrangement, cell proliferation and apoptosis 
(286).  A number of receptors and channels are reported to play an important role in sensing 
mechanical signals.  Integrins and the associated focal adhesion proteins work as feet to 
anchor cells to the extracellular matrix.  They are key sensors for endothelial 
mechanotransduction (423).  FAK has also been implicated as a key protein in integrin 
mediated endothelial mechanotransduction.  FAK activation was identified following 
mechanical stimulation in endothelial cells.  An enhancement of FAK tyrosine 
phosphorylation was identified in both BAECs and HUVECs in shear stress condition 
(229,278).  Shikata et al suggested that the cyclic stretch and shear stress induce FAK 
phosphorylation via different mechanisms (422).  Furthermore, FAK also responds 
differently to steady pressure and pulsatile stretch (273).  All these studies suggest that FAK 
is capable of make different responses according to the stimuli.  In addition to activation, 
upregulation of FAK synthesis following shear stress and dual ligands (streptavidin-biotin 
and fibronectin) treatment in endothelial cell was reported by Chan et al (68).  
Mechanotransduction also regulates FAK spatial distribution.  Yano at al proposed that 
mechanical strain induces not only tyrosine phosphorylation but redistribution of FAK.  FAK 
was recruited to the basal level of cells and aligned with the long axis of the stretched 
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endothelial cell (498).  Li et al suggested that FAK is recruited to the lamellipodial protrusion 
induced by shear stress in endothelial cells (279).     
Little is known about how FAK receives mechanical signals.  Both integrin and Src 
are required for FAK activation in mechanical signal transduction (272).  RGD peptides 
abolish FAK auto-phosphorylation and Src mediated FAK phosphorylation.  Src inhibitors 
also block the activation of FAK.  Cyclic stretch induced FAK activation is dependent on 
mitochondrial oxidants (7).  Since the conformational transition is an initial step for FAK 
activation, the physical stimuli may activate FAK via conformation switch.  Interestingly, the 
conformational transition of some integrin signaling proteins is involved in 
mechanotransduction.  For example, p130CAS is stretched to expose some major 
phosphorylation sites following physical stimulation (384,435).  The exposed tyrosine 
residues are phosphorylated by Src.  The phosphorylated p130CAS activates Rap1 to initiate 
downstream signaling.  FAK is possibly activated via a similar mechanism (Fig 1.6).  Just 
like a spring, FAK may be stretched to the “open” conformation by a relative balance 
between the external force and the internal cytoskeleton traction.  FAK conformational 
transition might be a direct response to the external force.  This model implicates FAK not 
only as an intermediate but also as a sensor to directly detect physical stimulation, which may 
explain the quick FAK response (1 min) to shear stress (282).  Visualization of the FAK 
conformational status following mechanical stimulation will be helpful to test this 
hypothesis.  FRET technology is a possible tool to visualize conformational activation in 
living cells (71,312,464).  Wang et al successfully visualized temporal and spatial activation 
of Src following mechanical stimulation in endothelial cells using Laser-tweezers and Src 
FRET biosensor (463).  
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It is important to understand the downstream effects of FAK mediated endothelial cell 
mechanotransduction.  FAK is proposed to regulate ERK and JNK activation following shear 
stress in endothelial cells (281).  However, the detailed mechanism is still unknown.  Also, 
inhibition of flow induced FAK activation by FAK antibody blocks AKT and eNOS 
activation (257).  This result suggests that FAK is required for flow induced NO generation.  
Expression of GFP-FRNK, a FAK dominant negative, blocks the stretch induced up-
regulation of connexin43, N-cadherin and other junction proteins, which implicates FAK in 
regulating cell-cell junctions in mechanotransduction (493).   
Most of the data regarding FAK mediated mechanotransduction is from in vitro 
physical stimulation studies.  Little is known about the in vivo function of FAK in endothelial 
cell mechanical transduction.  The critical angiogenesis defect in the FAK endothelial 
conditional knockout mouse poses a technical problem for investigating FAK function in 
vivo (28,415).  A novel strategy should be developed to inactivate FAK in endothelial cells in 
the late stage of animal development, which may help us to understand the function of FAK 
in mechanotransduction in vivo.  Interestingly, a recent study suggests that osteoblast-specific 
knockout of FAK abolishes the osteogenic response following physical stimulation in vivo 
(275).   
1.4.3.3  The Role of FAK in Cardiomyocyte Mechanotransduction 
The function of cardiomyocyte is to pump blood through the circulatory system by 
contracting.  Physical stimuli are very important signals that regulate the function of 
myocytes.  For one, hypertension induced pressure is a major reason for myocyte 
hypertrophy.  Humans develop cardiac hypertrophy greatly increases the risks of heart attack.  
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For another, stretch will not only induce hypertrophy but also cardiomyocyte apoptosis, 
which is also a major reason to induce heart failure.  
FAK is a major regulator of cardiomyocyte mechanotransduction.  Cardiomyocyte 
stretch induces FAK activation via integrinβ1 signaling (262).  Just like the classical integrin 
signaling, stretch induced FAK activation is dependent on Rho/Rock activity (443).  FAK not 
only induces ERK activation but also that of MEF2 and c-Jun in cell stretch signaling.  This 
suggests that FAK may not only regulate the transit cytoskeleton rearrangements but also the 
longer term transcriptional response to mechanical stimulation (263,332).  Interestingly, the 
stretch induced chloride channel is also regulated via integrin/Src/FAK signaling (32).   
Recent development of two FAK cardiomyocyte conditional knock out mouse models 
suggests that FAK is required for pressure overload induced hypertrophy (112,353).  The 
detailed mechanism remains unclear.  FAK is activated by pressure over load.  Src, Grb2 and 
PI3K are recruited into a complex following pressure stimulation, which suggests that FAK 
may regulate the MAPK and PI3K/AKT signaling pathways upon the overload stimulation 
(140).  Importantly, FAK is required for the restoration of the myocyte sarcomere length after 
uniaxial static strain, which implicates that FAK in involved in strain induced hypertrophy 
(319).  Interestingly, FAK interacts with the C-terminus of the myosin heavy chain in 
cardiomyocytes.  The assembly of this complex is regulated by pressure, implicating FAK in 
regulating myosin mediated myocyte contractility (138).  
1.4.4  The Role of FAK in Angiogenesis 
1.4.4.1  FAK as a Key Regulator in Angiogenesis 
Angiogenesis is a process involving the growth of new blood vessels from pre-
existing vessels, which is a critical step for development.  It is also related to the wound 
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healing and tumor malignant.  Several lines of evidence support FAK as a key regulator in 
endothelial cell angiogenesis.  Overexpression of FAK promotes angiogenesis both in vivo 
and in vitro (256,356).  The FAK knock out endothelial cells exhibits defects in vessel 
formation.  Similar defects are also seen in HUVECs treated with FAK anti-sense oligos or a 
dominant negative form of FAK (217).  Most important of all, two recent studies 
convincingly showed that FAK is a key component in angiogenesis.  FAK endothelial 
conditional knockout mice are embryonic lethal and exhibit serious defects in angiogenesis in 
vivo (27,412).  However, there are some discrepancies between these two reports. Though 
both suggest FAK is required to maintain cell survival in angiogenesis, they have 
inconsistent conclusions about the role of FAK in endothelial cell proliferation and 
migration.  Further investigation is required to solve this discrepancy.  In short, FAK plays an 
important and comprehensive role in angiogenesis.  It regulates not only cell migration, but 
also cell proliferation, survival, and maybe matrix degradation.  Moreover, FAK does not 
seem to be a separate component in the integrin signaling pathway.  Rather, it coordinates the 
crosstalk between integrin signaling with other pathways in angiogenesis.  Here I will review 
various aspects of the molecular mechanism of FAK in regulating angiogenesis (Fig 1.7). 
1.4.4.2  FAK, in Command of the Different Stimuli in Angiogenesis  
1.4.4.2.1  FAK in VEGF Signaling Pathway 
When endothelial cells receive angiogenesis signals, they enter into a highly 
proliferative state from the quiescent state.  FAK is activated by VEGF stimulation through 
VEGFR2 (199).  VEGF signaling first induces Src activation.  Activated Src then induces 
FAK phosphorylation, especially on tyrosine 861, which promotes the interaction between 
FAK and integrinαVβ5.  However, the role of the interaction is still unknown.  It is possible 
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that the FAK/integrinαVβ5 interaction is required for VEGF induced vascular permeability 
since both the Src and Integrin β5 deficient mice show defects in vascular permeability in 
response to VEGF (125,352).  VEGF induced FAK activation is required for the activation of 
the Ras-Raf-ERK pathway (198).  Activated ERK is a key component in regulating 
endothelial cell proliferation, survival and migration during angiogenesis.  This mechanism 
may explain the defects in FAK conditional KO mice where ERK activation is impaired in 
KO cells. The deficiencies exhibited by KO cells might be dependent on ERK activation.  
However, Bryant et al proposed another novel downstream effect of FAK activation (40).  In 
this model, FAK promotes the degradation of cyclin-dependent kinase inhibitors (CDKIs) 
p21/Cip and p27/Kip following VEGF signaling, which accelerates endothelial cell 
proliferation.  In addition to the above mechanisms, FAK may regulate PI3K activation 
following VEGF stimulation (366).  Since PI3K/AKT pathway is required to prevent 
apoptosis, FAK may regulate cell survival through this pathway.   
In addition to Src-dependent FAK activation, a Src independent FAK activation 
pathway is also proposed.  VEGF simulation recruits HSP90 to the VEGFR2 and activates 
Rho and Rho kinase (320).  Serine 732 in FAK is then phosphorylated by Rho Kinase, which 
promotes Pyk2 mediated FAK tyrosine 407 phosphorylation (268).  The Tyrosine 407 
phosphorylation recruits vinculin and paxillin and promotes the VEGF mediated endothelial 
cell migration (265).  Interestingly, this Src independent pathway is dependent on 
integrinαVβ3.  VEGF stimulation promotes the VEGFR2/integrinαVβ3 complex formation 
and transduces the signal (320).  This mechanism is similar to the integrated interaction 
between EGFR/PDGFR and integrins (426).  FAK may also work as an adaptor here to 
integrate two different kinds of receptors.  Interestingly, a direct interaction between the C-
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terminus of FAK and extracellular domain of VEGFR3 is identified both in vitro and in 
breast cancer cells (148).  Disruption of this interaction blocks cancer cell proliferation and 
promotes apoptosis.  VGEFR-3 is involved in lymphangiogenesis (421).  Hence this novel 
interaction provides another mechanism for FAK to regulate atypical VGEF signaling.  
In addition to outside-in signaling, two different mechanisms implicate FAK in a 
positive feedback mechanism to amplify the VEGF signal.  In Src transformed cells, FAK is 
phosphorylated on tyrosine 925, which activates the Src/FAK/Grb2/MAPK cascade and 
enhances VEGF expression (327).  FAK is also required for epithelial cell contact induced 
VEGF expression, which provides another possibility for FAK to boost VEGF signaling 
(419).  
1.4.4.2.2  FAK in Other Angiogenesis Related Signaling 
FAK is involved in some of the other signaling pathways that regulate angiogenesis.   
In the FGFR pathway, activated FAK is required for ERK activation (197).  However, the 
FAK activation mechanism here is different when compared to the VEGF signaling pathway.  
First, FAK mediated ERK activation is independent of Ras activation.  Second, Src is not 
required for FAK mediated ERK activation in the FGFR pathway.  Third, activated Raf 
prevents mitochondria induced apoptosis in an ERK-independent manner, which provides a 
distinct anti-apoptotic mechanism when compared to VEGF signaling.  Serine 910 in FAK 
however is also phosphorylated following FGF stimulation in an ERK dependent manner 
(213).  The function of this phosphorylation is still unknown.  
Angiopoietin-1(Ang-1) is a ligand of the Tie-2 receptor.  The Ang-1/Tie-2 pathway is 
required for the early stage endothelial cell sprouting in angiogenesis.  Integrinα51 forms a 
constitutive complex with Tie-2 and promotes Tie-2 activation (61).  FAK is recruited to this 
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complex and activated following Ang-1 stimulation.  PI3K is also recruited to this complex 
and is required for FAK activation.  FAK may regulate cytoskeleton rearrangement following 
Ang-1 signaling because both integrinα5β1 and PI3K is required for Ang-1 dependent cell 
spouting.  
In short, FAK plays multiple roles in angiogenesis following activation by different 
stimuli.  Integrins directly sense the external matrix condition. Other ligands bring the 
information from the surrounding tissue.  These signals are fine tuned via different 
modifications of FAK, which allows the receptors to cross talk with different integrins 
resulting in “comprehensive” downstream effects.     
1.4.4.2.3  FAK May Regulate the Matrix Degradation in Angiogenesis 
Matrix degradation is one of the early events in angiogenesis, which regulates 
endothelial cell invasion and migration (179).  FAK is proposed to regulate matrix 
degradation via different mechanisms.  Angiopoietin2 interacts with integrinαVβ1 and 
activates the FAK/MAPK pathway.  The activated MAPK induces MMP-2 expression and 
glioma cell invasion (201).  In Src transformed cells, FAK works as a scaffold to promote the 
interaction between Src and endophilin A2.  Src phosphorylated endophilin A2 inhibits the 
endophilin/dynamin interaction and abolishes MT1-MMP endocytosis (485).  Although the 
above data was collected from other systems, a similar mechanism may also exist in 
endothelial cells to regulate angiogenesis.    
1.5  Pyk2 
Pyk2 is a member of the focal adhesion kinase family and it shares a number of same 
characteristics with FAK.  First, just like FAK, Pyk2 contains three domains: an N-terminal 
FERM domain, a central kinase domain, and a C-terminal FAT domain (Fig 1.1).  The 
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tyrosine phosphorylation sites are almost the same between FAK and Pyk2.  They also share 
the same binding partners.  Second, both Pyk2 and FAK are activated by a number of 
common stimuli, such as integrins, growth receptors and GPCRs.  Third, functional assays 
suggest that Pyk2 is also required for cytoskeleton rearrangement (231).  Both Pyk2 and 
FAK regulate cell migration and cell spreading.  However, there are a number of differences 
between FAK and Pyk2.  First, unlike FAK, Pyk2 is not well localized to focal adhesions 
(399).  Second, FAK is expressed in almost all tissues, whereas Pyk2 is expressed only in 
some specific tissues, including the neurons, endothelial cells and hematopoietic cells.  
Interestingly, macrophages predominantly express Pyk2 but not FAK (123).  Third, while 
FAK and Pyk2 may compensate each other in cytoskeleton regulation, they play antagonistic 
roles in cell survival(427).  FAK promotes the cell survival via multiple pathways while 
Pyk2 is required to induce efficient cell apoptosis(156,491).  In knock out animal models, 
FAK null mice are embryonic lethal while pyk2-/- mice are viable.  However, Pyk2 null mice 
exhibit absence of marginal zone B cells and increased bone density (41,151,167).  
Macrophages isolated from Pyk2 null mice exhibit defects in chemotaxis and cytoskeleton 
reorganization (338).  
1.6  Other Kinases in Adhesion Signaling 
In addition to FAK, a number of other kinases are also involved in adhesion 
signaling.  Some of these kinases, such as ILK and PAK, localize to focal adhesions via the 
interaction with focal adhesion components.  Other kinases, such as ERK and PKC, 
transiently translocate to focal adhesions and induce the phosphorylation of focal adhesion 
proteins following multiple stimuli.  These kinases not only regulate adhesion induced 
cytoskeleton reorganization but also other cell behavior, such as survival. 
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1.6.1  Src 
Src is another critical tyrosine kinase in adhesion signaling.  Unlike FAK, Src does 
not predominantly target to focal adhesion.  However, the activated form of Src was observed 
in focal adhesions (241).  Interestingly, a number of focal adhesion proteins including FAK, 
paxillin and p130CAS were identified as Src substrates in v-Src transformed cells, which 
suggests that Src plays a key role in regulating adhesion signaling.  Since FAK and Src form 
a complex in focal adhesions and activate each other following integrin activation, 
sometimes they target the same substrate.  For an example, paxillin is phosphorylated both by 
Src and FAK in vitro.  Moreover, a decrease in paxillin tyrosine phosphorylation is observed 
in both SFK and FAK null cells(253,414).  Both the SFK null cells and fibroblasts treated 
with SFK inhibitors show strong defects in focal adhesion turn over, cell spreading and 
migration, which is similar to the phenotype observed in FAK null cells (465).  However, Src 
is definitely not redundant with FAK in adhesion signaling.  For one, some substrates are 
phosphorylated only by Src but not by FAK.  For example, p130CAS is only phosphorylated 
by Src following integrin activation (457).  Tyrosine phosphorylated p130CAS switches to 
an open conformation and recruits a binding partner to activate the downstream pathway 
(385).  Furthermore, the activation of Src does not always depend on FAK.  Src is recruited 
to the cytoplasmic tail of integrinβ3 and activated following cell adhesion (13).  Biochemical 
assays suggest that the SH3 domain of Src directly associates with the C-terminus of 
integrinβ3, which may facilitate the Src conformational switch.  In addition, Src is activated 
in a FAK independent mode following the activation of integrinα4β1 (200). Activated Src 
induces tyrosine phosphorylation of p130CAS, which finally activates Rac and promotes cell 
migration.                 
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1.6.2  Abl 
Abl was also first isolated as an oncogene and then identified as a tyrosine kinase.  
Interestingly, Abl directly interacts with F-actin, which implicates Abl in the regulation of 
cytoskeleton reorganization (455,461).  Abl is required for cell spreading and maintaining 
cell protrusion (476).  However, Abl inhibits integrin mediated cell migration (240).  In 
fibroblasts seeded on the fibronectin coated dish, Abl is transiently recruited to nascent focal 
contacts and is activated (276).  Abl phosphorylates a number of focal adhesion proteins, 
including paxillin, p130CAS and CrkII (475).  Interestingly, Abl phosphorylates CrkII at 
tyrosine 221, which is a negative regulation site for CrkII activity (261).  Abl induced CrkII 
phosphorylation disrupts the CrkII/p130CAS/paxillin complex.  The cells expressing CrkII 
Y221F not only promote the assembly of CrkII/p130CAS/paxillin complex but also increase 
the activation of Rac (1).  This may explain why Abl inhibits the cell migration. 
1.6.3  MAPK Family 
MAPKs, including JNK, p38 and ERK are activated when cells attach to extracellular 
matrix.  Activation of MAPKs induces the phosphorylation of focal adhesion proteins, which 
regulate the dynamics of focal adhesions and cell survival. 
ERK is required for cell adhesion and cell migration (207).  A number of focal 
adhesion proteins are phosphorylated by ERK.  ERK phosphorylates FAK at serine 910, 
which impairs the interaction between FAK and paxillin (212).  However, the physiological 
function of ERK induced FAK phosphorylation is still unknown.  ERK also phosphorylates 
paxillin at serine 83 following HGF stimulation (228).  Phosphorylation of serine 83 
promotes the interaction between FAK and paxillin and activates FAK.  FAK dependent 
activation of PI3K and Rac following HGF stimulation is greatly impaired in cells expressing 
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paxillin S83A mutant (221).  Spreading and migration defects have also been identified in 
these cells.  Interestingly, besides being an ERK substrate, paxillin also works as a scaffold 
protein to facilitate the MAPK cascade activation (227).  This may explain the defective 
ERK activation in paxillin null fibroblasts (172).  In addition to phosphorylation of serine83, 
phosphorylation of serine126 and serine 130 are also dependent on ERK activation (482).  
ERK also regulates calpain mediated proteolysis of FAK (56).  This is critical for focal 
adhesion turnover and cell migration.  Besides the above mechanisms, ERK also regulates 
the dynamics of focal adhesions via MLCK (468). 
JNK is a well known regulator of gene transcription.  Several lines of evidence 
indicate that JNK is also involved in regulating cytoskeleton rearrangement.  JNK inhibitors 
impair random migration of the fish keratocytes (210).  Activated JNK is localized within 
focal adhesions (11).  Paxillin was identified as a JNK substrate.  JNK directly 
phosphorylates paxillin at serine 178 following stimulation by growth factors, which 
promotes cell migration possibly by regulating focal adhesion dynamics.  Another study also 
suggests that JNK induced paxillin phosphorylation is required for neurite extension (494). 
In addition to ERK and JNK, P38 also phosphorylates paxillin at serine 83 in 
neuronal cells following NGF stimulation (206).  Neurite outgrowth is blocked in cells 
expressing paxillin S83A mutant.  Hence MAPKs work together to coordinate cytoskeleton 
reorganization.  
1.6.4  PKC Family 
PKC is activated following integrin activation.  PKC is proposed to regulate tyrosine 
phosphorylation of FAK following the integrinαvβ5 signaling (277).  An important focal 
adhesion protein, vinculin is regulated via conformational switch (236).  PKC interacts with 
28 
 
open vinculin and phosphorylates vinculin at serine 1033 and serine 1045 (470,510).  
Deletion of the critical motif which is required for the lipid mediated vinculin conformation 
switch blocks PKC mediated vinculin phosphorylation.   
1.6.5  PAK 
PAK plays a critical role in regulating cytoskeleton dynamics (25).  It localizes not 
only to the cells leading edge but also to focal adhesions.  PAK regulates actin dynamics via 
multiple mechanisms, such as the activation of the LIMK/cofilin/ADF pathway.  PAK also 
promotes focal adhesion turnover via the phosphorylation of paxillin (335).  PAK 
phosphorylates paxillin at serine 273 to promote the association between paxillin and GIT1, 
which in turn stabilizes the GIT1/PIX/PAK signaling complex at the leading edge.  The 
paxillin S273A mutant exhibits evident defects in cell migration, protrusion, and focal 
adhesion turnover.        
1.6.6  ILK 
ILK localizes within focal adhesions and forms a protein complex with Pinch and 
Parvin (484).  The ILK/Pinch/Parvin complex associates with integrins and regulates 
adhesion signaling.  The ILK null mouse is embryonic lethal.  ILK null fibroblasts exhibit 
defects in cell spreading, focal adhesion biogenesis and stress fiber formation (381).  
Interestingly, the kinase domain of ILK is atypical when compared to the traditional serine 
and threonine kinases.  Some studies propose that ILK phosphorylates AKT and GSK3 to 
regulate their activities (106).  However, these conclusions are still controversial since the 
phosphorylation of these kinases is not impaired in ILK null cells (382). 
1.6.7  Lipid Kinases 
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Phospholipids are very important messengers regulating in actin nucleation and 
cytoskeleton reorganization. Both PIP2 and PIP3 are major lipid molecules involves in 
adhesion signaling (218).  PIP3 dependent GTPase activation is required for actin 
polymerization.  PIP2 also regulates actin polymerization and focal adhesion dynamics.  
However, unlike PIP3, PIP2 associates with a number of scaffold proteins to induce the 
conformation switch of these proteins.  For example, PIP2 is required for N-WASP to switch 
to the open conformation, which promotes the Arp2/3 dependent actin polymerization (324).  
In cos7 cells, the levels of PIP2 and PIP3 are greatly increased following the attachment to 
fibronectin (252).  This implicates these phospholipids in adhesion signal transduction.  As 
the most important kinases to control phospholipid levels, PI3K and PIP5K, play a critical 
role in adhesion signaling.      
1.6.7.1  PI3K 
Though PI3K is not constitutively accumulated within focal adhesions, the regulatory 
p85 subunit of PI3K directly associates with the auto-phosphorylation site of FAK (77).  
Activated FAK might recruit PI3K to focal adhesions following attachment to fibronectin.  
However, another study suggests that adhesion induced PI3K activation is independent of 
FAK activity (456).  Adhesion induced PIP3 production is inhibited when cells are treated 
with a PI3K inhibitor (250).  Moreover, adhesion induced activation of MEK, ERK and AKT 
also depends on PI3K activity.  Pharmacological studies suggest that PI3K is required for cell 
attachment, adhesion and motility (369).   
1.6.7.2  PIP5K 
   Depletion of PIP2 by a PIP2 specific antibody induces the disassembly of focal adhesions 
(153).  PIP2 associates with multiple focal adhesion proteins to regulate their activities (301).  
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A PIP2 binding site was identified within the talin FERM domain (149).  PIP2 promotes 
binding of talin to integrinβ1, which in turn facilitate the talin focal adhesion targeting.  A 
PIP2 binding site was also identified within the vinculin tail domain.  PIP2 dissociates the 
head-tail interaction of vinculin and promotes its interaction with other binding partners, such 
as talin (152).  Interestingly, one of the PIP5K isoforms, PIP5Kγ 661 localizes within focal 
adhesions by an association with talin (108,300).  PIP5Kγ 661 is tyrosine phosphorylated and 
activated via FAK signaling, which provides a mechanism for PIP2 generation following 
attachment to extracellular matrix.   
1.7  Adhesion Signaling Proteins in Innate Immunity 
1.7.1  Innate Immunity System  
When pathogens attack a host, the innate immune system provides a quick and 
sensitive defense against the invasion (234).  When compared with the adaptive immune 
system, the innate immunity responds to the pathogens in a very short time, e.g. several 
hours.  The immune cells specifically interact with a range of molecular structures of a given 
type which exists only on the pathogens.  These “markers” induce a series of innate immune 
responses to destroy the pathogens and activate the adaptive immune system.  Cells 
stimulated with the pathogens produce specialized chemokines and cytokines, which recruit 
immune cells to the sites of infection.  The stimulated cells also activate the complement 
cascade to mark and destroy the microbes.  Most importantly, the phagocytotic cells identify 
and clear the pathogens by phagocytosis, a receptor mediated internalization process.  The 
internalized pathogens are finally destroyed in phagosomes.  The debris of the pathogens is 
then presented on the surface of phagocytotic cells via MHC, which activates the specific T 
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cells with matching TCRs.  The process of phagocytosis-antigen presentation-T cell 
activation builds a bridge to connect adaptive immunity with the innate immune response.  
1.7.2  TLR Signaling 
Although the innate immune response has been identified for more than one century, 
the mechanism was a big puzzle until the 1990s.  The discovery of toll like receptors shed 
some light on innate immunity (270).  TLR4, an IL-1R family receptor, was first identified to 
be required for gram negative bacteria induced inflammation response.  LPS, the cell wall 
component of the gram negative bacteria, also proved to be the TLR4 ligand.  A series of 
TLR family receptors and their ligands were identified in the following years.  In general, 
different TLRs recognize discrete sets of PAMPs to activate the innate immune responses.  
Interestingly, the TLRs are not only expresses in the hematopoietic cell lineage but also exist 
in some other tissues, such as endothelial and epithelial cells.  This indicates that the innate 
immune response might be induced immediately following the pathogens invasion.  Hence, 
TLR signaling is the most important mechanism to recognize and destroy the pathogens in 
innate immunity.  
Due to its essential role in innate immunity, defects in TLR signaling will induce 
multiple diseases (78).  Animal model studies suggest that TLR signaling is involved in 
inflammation, cancer, airway diseases and autoimmune disease.  SNP analysis also suggests 
that genetic changes of TLRs are also associated with the above diseases (147).  Thus 
therapeutic modification of TLR signaling is a novel approach to many innate immunity 
related diseases.  
1.7.2.1  Molecular Mechanism of TLR Signaling 
32 
 
When a host is infected with pathogens, the PAMP of pathogens interacts with 
specific TLRs, which activate the intracellular pathway and induce gene transcription.  
Ligand specificity is the most important issue in TLR signaling since defects in PAMP 
recognition may lead to auto-immune defects or hyporesponse to pathogen invasion.  The 
LRRs within the N-terminus of TLRs are critical for receptor ligand specificity.  In addition 
to the arrangement of LRRs, the cooperation between different receptors also contributes to 
the specificity of TLRs binding affinity.  Combinations of different TLRs greatly increase the 
pathogen reorganization diversity.  Some non-TLR family receptors also form a receptor 
complex with TLRs to promote TLR signaling (270).   
Intracellular signal transduction of TLR signaling is generally defined as MyD88 
dependent pathway and MyD88 independent pathways (6).  In MyD88 mediated signal 
transduction, activated TLRs recruits MyD88 via the TIR domain and induce the assembly of 
MyD88/IRAK/TRAF6 complex.  This signal complex subsequently activates NF-κB 
dependent gene transcription and the MAPK cascade.  In the MyD88 independent pathway, 
another scaffold protein, TRIF is required for the IRF3 dependent gene transcription.  
Interestingly, the TLR signaling mediated NF-κB activation is dependent on MyD88 in the 
early stage of stimulation.  However, the TRIF dependent pathway is critical for delayed NF-
κB activation.  Different pathways are utilized to make specific responses to pathogen 
diversity.  For example, LPS induced TLR4 signaling activates the downstream pathway via 
both MyD88 dependent and independent pathways. However, the viral dsRNA induced 
TLR3 signaling only activates the TRIF dependent pathway.  
TLR mediated gene transcription is also regulated via epigenetic modification.  A 
number of studies suggest that chromosome modification plays a key role in selectively 
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promote monocyte adhesion to the endothelial layers, which is a critical step for leukocyte 
transmigrate to the inflammatory site.  LPS also regulates other cytoskeleton related immune 
responses, such as phagocytosis (163).  Adhesion signaling proteins are involved in LPS 
signaling.  Tyrosine phosphorylation of Pyk2 and Paxillin is enhanced in monocytes and 
macrophages following LPS stimulation (473).  LPS induced paxillin tyrosine 
phosphorylation is mediated by both the MyD88 dependent and independent pathways (186).  
However, activation of FAK following LPS stimulation is independent of MyD88 (502).  
Interestingly, FAK forms a complex with TLR4 in enterocytes (269).  LPS stimulation 
induces serine phosphorylation of FAK.  The LPS/FAK signaling works as a brake to block 
cell migration.  In addition to cytoskeleton rearrangement, the TLR4 signaling mediated gene 
transcription is also regulated by adhesion molecules.  FAK is necessary for LPS induced IL-
6 production (503).  A similar defect in IL-6 production was also identified in cells 
stimulated with TNF-α (144,404).   This suggests that FAK regulates a common pathway 
related to IL-6 production, such as MAPK cascade.   
A novel interplay between integrin signaling and TLR4 signaling was proposed 
recently.  Integrin induced PIP2 synthesis is critical for LPS signaling (239).  TLR4 signaling 
is blocked following PIP2 depletion.  PIP2 is also required for TRIAP membrane 
translocation.  Membrane targeting of TRIAP facilitates the association between MyD88 and 
TLR4, which is a critical step for TLR4 signaling.  Accordingly, TLR4 signaling is abolished 
in TRIAP null cells expressing a TRIAP PIP2 binding site mutant. 
1.7.3  Phagocytosis 
Phagocytosis is a receptor mediated internalization process, which ubiquitously exists 
in different kinds of organisms (453).  In innate immunity, phagocytosis is involved in the 
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clearance of the microbes.  Phagocytosis is also required for clearing apoptotic cells, which is 
critical for prevention of autoimmune diseases and inflammation.  As an important infection 
defense mechanism, microbe mediated phagocytosis plays multiple roles in both innate 
immunity and adaptive immunity.  The phagocytes not only take up pathogens but also 
destroy them via superoxide and proteases in phagosomes.  In some specific receptor 
mediated phagocytotic mechanism, the phagocytotic signaling activates cytokine and 
chemokine production, which are critical for inflammatory responses.  Most important of all, 
phagocytosis directly connects the innate immunity to adaptive immunity.   
As in TLR signaling, phagocytosis receptors recognize the microbe via certain 
specific markers.  However, unlike the TLR signaling, most of phagocytosis receptors 
associate with some opsonins which are coated on the surface of microbe.  The phagocytosis 
of a microbe is mostly mediated by two sets of opsonin/receptor combinations.  
Internalization of immunoglobulin opsonized microbes is mediated by Fc receptors; 
internalization of complement opsonized microbes is mediated by complement receptors.  
Phagocytosis of a microbe is also mediated by some other receptors, such as CD14 and 
Mannose receptors, which recognize PAMPs instead of opsonins.    
1.7.3.1  Fc Receptor Mediated Phagocytosis 
Fc receptor belongs to a family of proteins that exhibit high affinity to the 
immunoglobulins.  However, not all Fc-receptors are involved in phagocytosis, e.g. FcγRIIB 
inhibits phagocytosis.  Upon stimulation, SFK are activated and induce the tyrosine 
phosphorylation of the ITAM motif in the cytoplasmic tail of the FcγR.  Then Syk associates 
with the tyrosine phosphorylated ITAM and activates downstream signals, which includes 
Rho GTPase activation and PI3 kinase signaling.  In the Rho GTPase family, CDC42 and 
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Rac regulate phagocytotic cup formation and closure respectively.  However, the function of 
RhoA in FcγR mediated phagocytosis is still controversial due to the inconsistent results 
from different kind of cells.  PI3K signaling is critical for the phagosome formation.  It could 
be also involved in other stages of phagocytosis, such as pseudopod extension (150,431).      
1.7.3.2  Adhesion Proteins in Fc Receptor Mediated Phagocytosis 
Cytoskeleton rearrangement is a critical process in Fc Receptor mediated 
phagocytosis.  Just like focal adhesions, actin and tyrosine phosphorylated proteins are 
enriched within the phagocytotic cup in a Fc receptor mediated phagocytosis (8).  A number 
of focal adhesion proteins, such as paxillin, α-actinin and vinculin are found in the 
phagocytotic cup.  Tyrosine phosphorylation of paxillin and Pyk2 is greatly enhanced 
following the activation of Fc receptors (244). All these studies suggest that adhesion 
signaling proteins might regulate Fc receptor mediated phagocytosis.  However, the function 
of these proteins in Fc receptor mediated phagocytosis is still unclear. 
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Figure 1.6  Stretch model of FAK activation. FAK is in a closed (inactive) conformation 
prior to stimulation.  The N-terminus of FAK interacts with the receptors via an undefined 
mechanism (Y) and the C-terminus is tethered to the actin cytoskeleton via adaptor proteins 
(X, likely paxillin).  When physical stimuli are applied, FAK is stretched to an open (active) 
conformation and transmits downstream signals. 
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Figure 1.7  FAK and angiogenic signaling pathways.  Multiple signals induce FAK 
activation in angiogenesis.  Colored arrows denote FAK activation pathways, with pathways 
that act in a concerted fashion to activate FAK indicated in the same color.FAK coordinates 
cell survival, proliferation and migration to promote vessel formation.  Solid arrows indicate 
survival and proliferation signaling pathways demonstrated in endothelial cells.  Dotted lines 
represent signaling pathways demonstrated in other cell types. 
   
CHAPTER 2 
GSK-3- and ERK-Dependent Phosphorylation of Paxillin Regulates 
Cytoskeletal Rearrangement 
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 2.1  Abstract 
Paxillin is a 68-kDa focal adhesion associated protein that plays an important role in 
controlling cell spreading and migration.  Phosphorylation of paxillin regulates its biological 
activity and thus has warranted investigation.  Serine 126 and serine 130 were previously 
identified as two major ERK-dependent phosphorylation sites in Raf transformed fibroblasts.  
Here serine 126 is identified as a phosphorylation site induced by LPS stimulation of 
RAW264.7 cells.  A number of other stimuli, including adhesion and CSF induce serine 126 
phosphorylation in RAW264.7 cells, and NGF treatment induces serine 126 phosphorylation 
in PC12 cells.  The kinase responsible for phosphorylation of this site is identified as GSK-3.  
Interestingly, this GSK-3-dependent phosphorylation is regulated via an ERK-dependent 
priming mechanism, i.e. phosphorylation of serine 130. Phosphorylation of S126/S130 was 
required to promote spreading in paxillin null cells and LPS induced cell spreading of RAW 
264.7 cells was inhibited by expression of the paxillin S126A/S130A mutant.  Furthermore, 
this mutant also retarded NGF induced PC12 cell neurite outgrowth.  Hence, phosphorylation 
of paxillin on serine 126 and 130, which is mediated by an ERK/GSK-3 dual kinase 
mechanism, plays an important role in cytoskeletal rearrangement. 
2.2  Introduction 
Paxillin is a 68-kDa focal adhesion associated protein that functions as a scaffolding 
protein assembling signaling molecules into complex downstream of integrins (38,388).  It 
plays an important role in regulating cell spreading and migration.  The paxillin knock out 
mouse exhibits embryonic lethality, which suggests that paxillin plays an essential role in 
development (171).  Paxillin contains five LD motifs in the N-terminal half of the molecule.  
These peptide motifs mediate protein-protein interactions and bind a number of proteins 
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including FAK and vinculin (37,451).  Four LIM domains are found in the C-terminal half of 
paxillin, two of which are required for the discrete localization of paxillin to focal adhesions 
(33).   
Multiple stimuli induce phosphorylation of paxillin, including growth factors, 
integrin-dependent cell adhesion to extracellular matrix and other ligands (36,388).  Two 
major tyrosine phosphorylation sites, Y31 and Y118, have been identified in the N-terminal 
half of paxillin (396).  Phosphorylation of these sites modulates docking of SH2 domain 
containing proteins, such as CRK, and is important for regulation of cell motility (360,497).  
In addition to tyrosine phosphorylation, serine and threonine phosphorylation sites have been 
identified in paxillin.  Serine residues 188 and 190 are phosphorylated following integrin 
ligation (22).  Threonines 398 and 403 in LIM2 and serines 457 and 481 in LIM3 are 
phosphorylated following cell adhesion and stimulation with angiotensin II (34,35).  
Phosphorylation of these LIM domain residues regulates focal adhesion localization of 
paxillin and/or cell adhesion to fibronectin.  Though the upstream kinases responsible for 
phosphorylation of many of these sites remain unidentified, several kinases have been shown 
to directly phosphorylate paxillin.  JNK phosphorylates threonine 178 and phosphorylation of 
this site functions in the regulation of cell migration (209).  Two kinases, p38 MAP kinase 
and ERK, have been reported to phosphorylate serine 83 in murine/rat paxillin (205,223).  
This site is not precisely conserved in human paxillin, but p38 phosphorylates a similar 
sequence at serine 85 in the human homologue.  P38-dependent phosphorylation of this site 
regulates neurite outgrowth in PC12 cells and ERK-dependent phosphorylation of the site 
regulates epithelial morphogenesis.  Two additional serine phosphorylation sites in the N-
terminal domain of paxillin, serines 126 and 130, were identified in Raf transformed cells 
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and phosphorylation is apparently mediated by the Raf/MEK/ERK pathway (483).  However, 
it is unclear whether ERK directly phosphorylates these two sites and the function of 
phosphorylation of these sites has not been determined. 
Glycogen synthase kinase 3 (GSK-3) was first identified as the enzyme that 
phosphorylates and regulates glycogen synthase (127).  The two isoforms, GSK-3α and 
GSK-3β, share high similarity in structure but are not redundant in function (116). GSK-3 is 
now known to phosphorylate a broad range of substrates and control many processes in 
addition to glycogen metabolism.  GSK-3 plays a key role in regulating the Wnt signaling 
pathway and the control of cell proliferation (351).  GSK-3 has also been suggested to 
regulate microtubule stability through phosphorylation of three microtubule/tubulin 
associated proteins, Tau, MAP 1B and CRMP-2 (161,180,499).  Regulation of GSK3 activity, 
via regulation of microtubule dynamics is believed to play an important role in the regulation 
of neuronal cell axon polarity (508).  GSK-3 has also been suggested to control actin 
cytoskeleton rearrangement since it can regulate formation of long lamellipodia in human 
keratinocytes (255).   
Unlike many other kinases, GSK-3 is constitutively active in cells and initiation of 
downstream signaling is not modulated by activation of the kinase, but by modification of the 
substrate resulting in its interaction with GSK-3 (24).  GSK-3 prefers a primed substrate, 
which has been previously phosphorylated by a priming kinase, and the priming 
phosphorylation increases the efficiency of substrate phosphorylation of most GSK-3 
substrates by 100-1000-fold (135).  In several instances the detailed mechanism of GSK-3 
substrate phosphorylation has been elucidated.  For example, casein kinase-2 is required to 
prime glycogen synthase to promote the sequential multi-site phosphorylation by GSK-3 
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(134), and casein kinase-1 was identified as a priming kinase promoting GSK-3 mediated β-
catenin phosphorylation (306).  
Here we identify paxillin, a focal adhesion associated protein, as a GSK-3 substrate.  
Serine 126 is identified as a phosphorylation site induced by LPS stimulation of RAW264.7 
cells.  Phosphorylation of this site is regulated by ERK, but is directly mediated by GSK-3.  
LPS induced cell spreading was partially inhibited in cells expressing the paxillin 
S126A/S130A mutant and this mutant was defective for promoting fibroblast spreading on 
fibronectin.  Furthermore, we found ERK/GSK-3 mediated phosphorylation of paxillin is 
also involved in NGF induced PC12 cell neurite outgrowth.  These data suggest that 
phosphorylation of paxillin at serine residues 126 and 130 plays an important role in the 
control of cytoskeleton rearrangements and provides insight into the molecular mechanism 
via which GSK-3 controls remodeling of the actin cytoskeleton.  
2.3  Materials and Methods 
Cells.  RAW264.7 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) 
containing 10% fetal bovine serum (FBS).  HEK293T cells were maintained in DMEM-F12 
containing 10% FBS.  PC12 cells were maintained as described previously (204).  Primary 
murine peritoneal macrophages, isolated following thioglycollate injection (a kind gift from 
Dr. Glenn Matsushima), were maintained in RPMI 1640 containing 5% FBS for 1 week prior 
to LPS stimulation.  Paxillin null cells were a generous gift from Dr. Sheila Thomas and were 
maintained in DMEM containing 15% FBS.  In some experiments, RAW264.7 cells were 
starved in DMEM without serum overnight, then stimulated with LPS (1 μg/ml) (Sigma, St. 
Louis, MO), PMA (100 ng/ml) (Calbiochem, San Diego, CA), or M-CSF (1.32 nM) 
(PeproTech, Rocky Hill, New Jersey).  PC12 cells were starved in DMEM containing 1% 
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FBS for 6 hr.  The cells were then stimulated with 100 ng/ml NGF (Calbiochem, San Diego, 
CA).  In some experiments cells were pretreated with the indicated doses of LiCl, U0126 
(Calbiochem, San Diego, CA), GSK-3 inhibitor IX (Calbiochem, San Diego, CA) or GSK-3 
inhibitor I (Biosource, Camarillo, CA) for 1 hr before stimulation.  In some experiments PP2 
(Calbiochem, San Diego, CA) was added 20 min before stimulation.  
Molecular biology.  The MEK constructs were gifts from Dr. Channing Der.  The EGFP-
paxillin β plasmid was a gift from Dr. Ken Jacobson (208).  EGFP-paxillin derived point 
mutations were created by PCR using the Quik-Change mutation kit (Stratagene, La Jolla, 
CA).  Sequence analysis was performed on each mutant to verify the intended point 
mutations and that no unintended mutations were present.  These analyses were performed in 
the UNC-CH Genome Analysis Facility on a model 3730 DNA Analyzer (Perkin Elmer, 
Applied Biosystems Division) using the ABI PRISMTM Dye Terminator Cycle Sequencing 
Ready Reaction Kit with AmpliTaq DNA Polymerase, FS (Perkin Elmer, Applied 
Biosystems Division).  The control siRNA and siRNA targeting GSK-3β (SMARTpool®) 
were from Dharmacon (Lafayette, CO). 
Stable and transient transfection.  RAW264.7, PC 12, HEK293T and paxillin null cells 
were transfected using Lipofectamine plus according to the manufacturer’s instructions 
(Invitrogen Carlsbad, CA).  To establish stable transfectants, RAW264.7 cells were 
incubated in fresh medium containing 10% FBS for 48 hr and then selected with 400 μg/ml 
G418.  After 10 days, surviving cells were cultured in medium containing 10% FBS with 200 
μg/ml G418. GFP expressing cells were further enriched by cell sorting by FACS.  Despite 
this double selection procedure, the resulting population was heterogeneous, containing both 
GFP positive and negative cells.  Further, EGFP-paxillin expression was lost upon passaging.  
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For this reason, studies with these cells were restricted to biochemical studies examining 
regulation of phosphorylation of the exogenous EGFP-paxillin constructs and single cell 
biological assays where expression of the EGFP-paxillin constructs could be validated by 
fluorescent microscopy.  Stable populations of paxillin null cells re-expressing wild type or 
S126A/S130A paxillin were established by infection with pBABE retroviral vectors 
encoding these constructs followed by selection with puromycin.  RAW264.7 cells were 
transfected with 75nM siRNAs using TransitTKO according to the manufacturer’s 
instructions (Mirus Madison, WI).  After 24 hours, the cells were starved in serum-free 
DMEM overnight, then stimulated with LPS. 
Cell Spreading Assay.  Paxillin null cells and variants re-expressing wild type and mutant 
paxillin were serum starved overnight, trypsinized and plated onto fibronectin coated dishes 
in serum-free medium.  After various times, the cells photographed and the relative area of 
individual cells (>50 per experiment) was determined using Image J software.  RAW264.7 
cells expressing wild type or mutant EGFP paxillin fusion proteins were plated on 35-mm 
petri dishes and cultured overnight, then starved in serum free medium for 12 hr. The cells 
were then stimulated with 1 μg/ml LPS and cultured for 3 hr. Cells were examined using a 
Zeiss Axiovert 200 microscope.  Transfected cells were identified as green cells by 
fluorescent microscopy and the morphology of the transfected cells scored by phase contrast 
microscopy.  Round phase bright, refractile cells were scored as unspread.  Phase dark and 
nonrefractile cells, and cells that had obviously become elongated (exhibiting a ratio of 
length to width of greater than 2:1) were defined as spread.  At least 100 green cells were 
scored in each experiment.   
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Cell Lysis, Protein Analysis, and Immunoprecipitation.  Cells were lysed in ice-cold 
modified RIPA buffer (418).  Lysates were clarified, and protein concentrations were 
determined using the bicinchoninic acid (BCA) assay (Pierce, Rockford, IL).  For 
immunoprecipitations, the paxillin antibody (BD Biosciences, San Jose, CA) or the PS126 
antibody was incubated with 500 μg of cell lysate at 4°C for 1 hr or 16 hr.  Immune 
complexes were precipitated at 4°C for 1 hr with protein A-Sepharose beads (Sigma, St. 
Louis, MO).  For immunopreciptiations using the paxillin monoclonal antibody, the beads 
were coated with AffiniPure rabbit anti-mouse IgG (Jackson ImmunoResearch Labs, West 
Grove, PA).  Immune complexes were washed twice with ice-cold lysis buffer, and once with 
ice-cold PBS. Beads were resuspended in sample buffer, boiled to elute the proteins, and the 
samples were analyzed by Western blotting.  The paxillin phosphospecific antibodies, PS126, 
PY31, PY118 and pERK antibodies were from Biosource (Camarillo, CA).  The ERK and 
ERK2 antibodies were from Santa Cruz Biotech (Santa Cruz, CA).  The PS83 antibody was a 
generous gift from Drs. Ishibe and Cantley (Yale University). 
Immunofluorescence.  Paxillin null fibroblasts were transiently transfected with plasmids 
encoding GFP-paxillin fusion proteins and cultured overnight.  The cells were then 
trypsinized, held in suspension for 45 minutes and plated onto fibronectin coated coverslips 
for 60 minutes prior to fixation.  PC12 cells were plated on collagen coated coverslips and 
stimulated with NGF for various times prior to fixation.  Cells were fixed in 3.7% 
formaldehyde and permeabilized with 0.5% Triton X-100.  Serine 126 phosphorylation was 
detected using PS126 and a rhodamine or fluorescein conjugated anti-rabbit antibody 
(Molecular Probes Eugene, OR) as previously described (93).  The cells were visualized 
using a Nipkow-type spinning disk confocal scan head attached to an IX81inverted 
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microscope (Olympus Dulles, VA) equipped with a 60X 1.45 NA objective, a CCD camera, 
and controlled by AQM Advance 6 software. 
2.4  Results 
LPS induces paxillin phosphorylation in macrophages.  Paxillin, a major focal adhesion-
associated protein, becomes tyrosine phosphorylated upon LPS stimulation of human 
monocytes and other macrophage cell lines (474).  To examine phosphorylation of paxillin in 
RAW264.7 cells, the cells were serum starved overnight, and then stimulated with 1 μg/ml 
LPS for 60 minutes prior to lysis.  Paxillin was immunoprecipitated from cell lysates and the 
immune complexes analyzed by Western blotting.  The most striking observation from this 
experiment was the evident retardation of the relative mobility of paxillin following LPS 
stimulation (Fig 2.1A), which suggests that paxillin may be phosphorylated following LPS 
stimulation.  To determine if the LPS induced shift in gel mobility of paxillin was in fact due 
to phosphorylation, paxillin immune complexes from LPS stimulated RAW264.7 cells were 
incubated with calf intestine alkaline phosphatase for half an hour.  Phosphatase treatment 
decreased the apparent molecular weight of paxillin to the original level and lower, 
suggesting that the LPS induced molecular weight shift was due to phosphorylation and that 
basal levels of phosphorylation of paxillin also produced a small shift in the apparent 
molecular weight of the protein.  To directly examine tyrosine phosphorylation of paxillin, 
site-specific antibodies were used to probe Western blots of cell lysates from LPS-stimulated 
and unstimulated RAW264.7 cells.  The two major tyrosine phosphorylation sites of paxillin, 
tyrosine 31 and tyrosine 118, were phosphorylated in response to the LPS stimulation (Fig 
2.1B).  In addition to tyrosine phosphorylation, it was also likely that LPS induced 
serine/threonine phosphorylation of paxillin.  In particular, serine 126 was an excellent 
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candidate as an LPS induced site of phosphorylation since phosphorylation of this site has 
been correlated with a shift in the electrophoretic mobility of paxillin (478).  A 
phosphorylation site-specific antibody recognizing PS126 was used to probe lysates of 
stimulated and unstimulated cells.  Whereas paxillin from unstimulated cells was weakly 
recognized by the PS126 antibody, LPS stimulation induced a dramatic increase in signal 
(Fig 2.1B).  Phosphorylation of serine 83 was also induced in response to LPS.  In order to 
confirm the specificity of the PS126 antibody, its ability to recognize wild type paxillin and 
an S126A mutant of paxillin was examined.  RAW264.7 cell line derivatives stably 
expressing EGFP-paxillin or EGFP-paxillinS126A were established by drug selection using 
G418.  GFP expressing cells were further enriched by cell sorting by FACS.  These two cell 
populations were challenged with LPS and cell lysates blotted with the PS126 antibody (Fig. 
2.1C).  As observed with endogenous paxillin, the wild type EGFP-paxillin was recognized 
weakly by this antibody in unstimulated cells and the signal was profoundly increased upon 
LPS stimulation.  In contrast, EGFP-paxillinS126A was not recognized by the PS126 
antibody under either set of conditions.  These results demonstrate that this antibody 
specifically recognizes paxillin that is phosphorylated on serine 126.  To establish the 
generality of the observation that serine 126 phosphorylation was induced by LPS, primary 
cultures of peritoneal macrophages and two additional macrophage cell lines, J774 and Bac1, 
were also analyzed.   After LPS stimulation serine 126 was phosphorylated in each of these 
cell types (Fig. 2.1D), which suggests that this phosphorylation event is a general response to 
LPS signaling in macrophages.  To estimate the stoichiometry of phosphorylation at serine 
126, the PS126 antibody was used to immunoprecipitate paxillin following LPS stimulation 
of RAW264.7 cells.  The amount of paxillin recovered in the immune complex and the 
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amount remaining in the supernatant was examined by Western blotting.  From these studies 
it is estimated that 30-40% of paxillin is phosphorylated on serine 126 following LPS 
stimulation. 
Serine 126 phosphorylation is ERK dependent.  Serine 126 and serine 130 were first 
identified as paxillin phosphorylation sites in Raf transformed NIH 3T3 cells (480).  In this 
scenario, additional evidence demonstrated that this phosphorylation event occurred 
downstream of the Raf-MEK-ERK pathway.  It is well established that ERK is activated in 
macrophages after LPS stimulation (420).  To begin to address the role of ERK in LPS-
induced paxillin phosphorylation, serine 126 phosphorylation was temporally compared with 
ERK activation following LPS stimulation of RAW264.7 cells.  ERK was strongly activated 
at 40 and 60 minutes following LPS stimulation, as assessed by blotting with a 
phosphorylation specific ERK antibody (Fig 2.2A).  Phosphorylation of serine 126 was 
increased after 40 minutes and more dramatically increased following 60 minutes of 
stimulation.  Thus the kinetics of ERK activation is consistent with a role in controlling 
phosphorylation of paxillin at serine 126.  Furthermore, treatment of cells with two different 
MEK inhibitors, PD98095 and U0126, efficiently blocked the LPS induced phosphorylation 
of paxillin on serine 126 (Fig 2.2B, C). These findings demonstrate that the LPS induced 
activation of ERK is required for the induction of paxillin phosphorylation on serine 126.  To 
determine if activation of the ERK signaling pathway is sufficient to induce serine 126 
phosphorylation, wild type MEK1 or constitutively active MEK1 were transiently transfected 
into 293T cells.  The latter induced activation of ERK and phosphorylation of paxillin at 
serine 126 (Fig. 2.2D).  These results demonstrate that serine 126 phosphorylation is 
regulated by ERK signaling. 
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Serine and tyrosine phosphorylation of paxillin are independent.  Recently serine 83 of 
paxillin was identified as a direct ERK phosphorylation site (224).  An intriguing mechanism 
regulating ERK-dependent phosphorylation of serine 83 has been proposed.  Phosphorylation 
of paxillin at tyrosine 118 creates a docking site for ERK, which recruits ERK into complex 
facilitating serine 83 phosphorylation (226).  In order to investigate whether a similar 
mechanism is used in the regulation of serine 126 phosphorylation in response to LPS in 
macrophages, a paxillin mutant was analyzed.  RAW264.7 cells were transfected with EGFP-
paxillin or EGFP-paxillinY31F/Y118F, a mutant in which the two major tyrosine 
phosphorylation sites of paxillin have been substituted with phenylalanines.  The cells were 
challenged with LPS and then lysates were blotted with the PS126 antibody.  LPS induced 
phosphorylation of the mutant on serine 126 (Fig 2.3A).  While there was an apparent 
increase in serine 126 phosphorylation of the mutant relative to wild type, this was likely due 
to the increased expression level of the mutant.  Notably the EGFP-paxillinY31F/Y118F 
mutant was not defective for serine 126 phosphorylation.  Furthermore, treatment with PP2, a 
Src kinase inhibitor, potently blocked the LPS induced phosphorylation of tyrosine 118, but 
had little effect on serine 126 phosphorylation (Fig 2.3B).  These findings demonstrate that 
serine126 phosphorylation occurs independently of phosphorylation at tyrosine 118.  Given 
the proximity of serine 126 to tyrosine 118, it was also of interest to determine if serine126 
phosphorylation could affect phosphorylation at tyrosine 118.  This was tested using a 
pharmacological approach.  U0126 blocked serine 126 phosphorylation without affecting 
phosphorylation at tyrosine 118 (Fig 2.3C).  These data suggest that LPS induced paxillin 
phosphorylation at serine 126 and tyrosine118 are independent and controlled by separate 
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mechanisms.  It further suggests that the mechanisms regulating ERK mediated serine 83 and 
serine 126 phosphorylation are distinct.  
Paxillin serine 126 phosphorylation can be induced by different stimuli.  Since paxillin 
phosphorylation at serine 126 is mediated by the ERK pathway, which plays a key role in 
many signaling pathways, it was of interest to determine whether the ERK mediated paxillin 
phosphorylation at serine 126 was specific for LPS signaling or occurred in response to other 
stimuli that activate ERK.  ERK is activated upon integrin-dependent cell adhesion to 
extracellular matrix proteins (401).  Further, paxillin was shown to become serine 
phosphorylated in response to adhesion to extracellular matrix in macrophages (102).  To 
examine cell adhesion-dependent phosphorylation, RAW264.7 cells were trypsinized, 
incubated in suspension at 37oC for half an hour, and then replated on fibronectin for half an 
hour at 37oC prior to lysis.  Phosphorylation at serine 126 decreased when cells were held in 
suspension.  Upon cell adhesion, phosphorylation of paxillin at serine 126 was induced (Fig 
2.4A).  Serine 126 was also phosphorylated in RAW264.7 cells following PKC activation by 
stimulation with PMA (Fig 2.4B).  Treatment of RAW264.7 cells with CSF, an important 
cytokine controlling macrophage function, also modestly induced phosphorylation of serine 
126 (Fig 2.4C).   Phosphorylation of serine 126 is also likely induced by growth factors that 
signal via receptor tyrosine kinases (477).  Interestingly, the phosphorylation level of S126 
was elevated following NGF stimulation in PC12 cells (Fig 2.4D).  Each of these stimuli 
activate ERK and in each case inhibition of this signaling pathway with MEK inhibitors 
blocks phosphorylation of serine 126 in response to the stimulus.  These findings suggest that 
serine 126 phosphorylation is a general response to activation of the ERK pathway. 
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Phosphorylation of serine 126 is abolished by GSK-3 inhibitors.  Though the data 
demonstrate that residue 126 is a major serine phosphorylation site in paxillin that is 
dependent upon ERK activation, there is no evidence that this site is directly phosphorylated 
by ERK.  Further, the sequence flanking serine 126 does not conform to a consensus ERK 
phosphorylation site.  Note however, that serine 130 has also been identified as a paxillin 
phosphorylation site in Raf transformed NIH 3T3 cells (481).  Upon phosphorylation of 
serine 130, serine 126 resembles a consensus GSK-3 phosphorylation site, SXXX(P)S.  It 
therefore appeared likely that paxillin was phosphorylated by GSK-3 at serine 126. To 
examine whether serine 126 phosphorylation was dependent upon GSK-3, RAW264.7 cells 
were incubated with LiCl, which is an inhibitor of GSK-3, for 1 hr prior to simulation with 
LPS.  Phosphorylation at serine 126 was blocked by LiCl in a dose dependent manner (Fig 
2.5A).  In addition to LiCl, two other pharmacological inhibitors of GSK-3, GSK-3 inhibitor 
IX and GSK-3 inhibitor I, were tested. Both efficiently inhibited paxillin phosphorylation at 
serine 126 in RAW264.7 cells in response to LPS (Fig 2.5B, C).  Further LiCl also blocked 
serine 126 phosphorylation in NGF stimulated PC12 cells (Fig 2.5D).  It is interesting to note 
that ERK activation is unattenuated in all samples treated with GSK-3 inhibitors.  To further 
test the role of GSK-3β in regulating serine 126 phosphorylation, an siRNA approach was 
used.  RAW264.7 cells were transfected with a control siRNA or a pool of siRNAs targeting 
GSK-3β.  Western blotting demonstrated knockdown of GSK-3β, but not GSK-3α 
expression (Fig 2.5E).  Transfected cells were stimulated with LPS and inhibition of GSK-3β 
reduced the induction of serine 126 phosphorylation on paxillin, but had no effect upon ERK 
activation (Fig 2.5E).  The GSK-3β independent phosphorylation of serine 126 is likely 
mediated by GSK-3α.  Although serine 126 phosphorylation downstream of multiple stimuli 
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is ERK-dependent, it is also GSK-3 dependent, and GSK-3 appears to operate downstream of 
ERK.  These findings are consistent with the hypothesis that ERK phosphorylates paxillin at 
serine 130, priming paxillin for subsequent phosphorylation by GSK-3 at serine 126. 
Phosphorylation of paxillin is mediated by an ERK/GSK-3 dual kinase mechanism.  In 
order to examine whether paxillin can be directly phosphorylated by GSK-3 in vitro, the N-
terminal half of paxillin was expressed in E. coli as a GST fusion protein, called GST-N-C3.  
Recombinant GSK-3β was incubated with GST-N-C3 in kinase reaction buffer containing 
ATP, and the phosphorylation of serine 126 monitored by Western blotting with the 
phospho-specific antibody.  There was little evidence of serine 126 phosphorylation on GST-
N-C3 following incubation with GSK-3β (Fig 2.6A).  This again is consistent with the 
hypothesis that this GSK-3 site in paxillin is primed by phosphorylation by another kinase.  
ERK was a candidate for this kinase as phosphorylation of 126 in vivo was ERK-dependent 
and the sequence around serine 130 resembles an ERK phosphorylation site.  ERK failed to 
directly phosphorylate serine 126.  To test whether ERK functions as a priming kinase for 
GSK-3-dependent phosphorylation of paxillin, GST-N-C3 was pre-incubated with ERK in 
vitro, prior to incubation with GSK-3β in the in vitro kinase reaction and phosphorylation 
measured by blotting with PS126.  Under these conditions, serine 126 phosphorylation was 
dramatically increased (Fig 2.6A).  To confirm that GSK-3-dependent phosphorylation in 
vitro was dependent upon serine 130 phosphorylation, a GST-N-C3 variant with a 
substitution of alanine for serine 130 was also analyzed.  While GST-N-C3 was 
phosphorylated at serine 126 when incubated in vitro with ERK and GSK-3, GST-N-
C3/S130A was not (Fig 2.6B), demonstrating the requirement of the priming site for GSK-3-
dependent phosphorylation in vitro.  To further determine if ERK could phosphorylate serine 
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130 in vitro, recombinant ERK was incubated with GST-N1-C1A in kinase reaction buffer 
containing [γ32P] ATP.  Wild type GST-N1-C1A was efficiently phosphorylated by ERK in 
vitro, whereas the S130A variant of GST-N1-C1A was marked defective for phosphorylation, 
exhibiting approximately 50% of the level of phosphorylation of the wild type protein (Fig. 
2.6C).    Further, the paxillin S130A mutant was expressed transiently as an EGFP-fusion 
protein in PC12 cells and phosphorylation of serine 126 in response to NGF stimulation 
measured by Western blotting.  While wild type EGFP-paxillin was phosphorylated on serine 
126 upon NGF stimulation, the S130A mutant was not phosphorylated in response to NGF 
(Fig 2.6D).  These data suggest that paxillin is phosphorylated by ERK at serine 130, both in 
vitro and in vivo, and that this phosphorylation event primes paxillin for phosphorylation by 
GSK-3 on serine 126 (Fig 2.6E).   
Localization of paxillin phosphorylated on serine 126.  Paxillin null fibroblasts were used 
for the initial studies.  The cells were transiently transfected with EGFP-paxillin or EGFP-
paxillinS126A, then fixed and stained with the PS126 antibody (Fig. 2.7A).  Cells expressing 
the wild type and mutant EGFP fusion proteins were identified by fluorescent microscopy.  
The cells expressing wild type EGFP-paxillin stained positive with the PS126 antibody, 
exhibiting nuclear, cytoplasmic and focal adhesion staining.  As the untransfected cells in the 
population also exhibited nuclear staining, this is apparently non-specific (data not shown).  
Besides this background staining, the PS126 staining was similar to the EGFP-paxillin 
localization.  The localization of the mutant protein was similar to EGFP-paxillin, however, 
cells expressing EGFP-paxillinS126A exhibited only the background nuclear staining with 
the PS126 antibody.  These data suggest that PS126 exhibits sufficient specificity in 
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immunofluorescence experiments that it can be used to determine the localization of paxillin 
that is phosphorylated on serine 126.  
NGF stimulated PC12 cells were also fixed and stained with the PS126 antibody (Fig. 
2.7B). PS126 staining is dramatically increased after LPS stimulation and was located at the 
tips of developing neurites several hours after NGF treatment.  After 30 hours of NGF 
stimulation, long neurites had grown and PS126 staining was enriched near the tips of these 
neurites.  These studies demonstrate the localization of paxillin that is phosphorylated on 
serine 126 at dynamic sites of cytoskeleton remodeling and suggest the potential role of 
serine 126 and serine 130 phosphorylation of paxillin in controlling NGF induced neurite 
outgrowth.  
ERK/GSK-3 mediated phosphorylation of paxillin is involved in cell spreading.  To 
address the function of phosphorylation of paxillin at residues 126 and 130, paxillin null 
fibroblasts stably expressing wild type paxillin or the S126A/S130A mutant were established.  
The pBABE retroviral vector, engineered to encode the paxillin constructs, was used to infect 
the paxillin null cells and the infected cells selected using puromycin.  Western blotting 
demonstrated expression of the wild type and mutant proteins (Fig. 2.8A).  Further the wild 
type protein was phosphorylated on serine 126 in cells growing in culture, whereas the 
mutant was not (Fig. 2.8A).  Paxillin null cells exhibit a defect in cell spreading on 
fibronectin that can be rescued by re-expression of wild type paxillin (170).  To quantify 
spreading, cells were serum starved overnight, then plated on fibronectin and photographed 
at various times.  The area of spread cells was determined using the Image J software.  The 
null cells and wild type paxillin re-expressers increase in area over time, but at each time 
point the average area of paxillin expressing cells was approximately 25% greater that the 
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average area of the null cells (Fig. 2.8B).  In contrast, cells expressing the S126A/S130A 
mutant spread slower than wild type expressing cells, only exceeding the average area of the 
null cells after 60 minutes on fibronectin.  Thus phosphorylation of these sites is required for 
the paxillin-dependent spreading of fibroblasts on fibronectin. 
LPS induces distinct changes in cell morphology and actin organization in monocytes 
and macrophages.  Serum starved RAW264.7 cells are round and phase bright when 
examined by phase contrast microscopy, whereas many LPS stimulated cells are phase dark 
and spread or exhibit an elongated phenotype (data not shown).  To begin to address the role 
of serine 126 phosphorylation in the control of cell spreading, MEK and GSK-3 were 
inhibited with U0126 and LiCl respectively.  LPS stimulated RAW264.7 cell spreading was 
inhibited by both compounds (data not shown).  To directly explore the role of paxillin in 
regulation of this phenotype, RAW264.7 cells were stably transfected with EGFP-paxillin or 
EGFP-paxillinS126A/S130A and the cells were stimulated with LPS to induce spreading.  
Transfected cells were identified as green cells by fluorescent microscopy and the 
morphology of both the transfected and untransfected cells scored by phase contrast 
microscopy (Fig 2.8C).  Approximately 25% of the cells expressing EGFP-paxillin exhibited 
a spread/elongated morphology (Fig 2.8D).   This frequency of spreading was very similar to 
that observed for untransfected cells in the same culture.  In contrast, cells expressing EGFP-
paxillinS126A/S130A exhibited only 10% cell spreading/elongation following LPS 
stimulation.  This mutant is apparently functioning in a dominant negative fashion to inhibit 
the action of endogenous wild type paxillin, suggesting that phosphorylation at serines 126 
and 130 is important for optimal spreading.  Therefore, ERK/GSK-3 mediated 
63 
 
phosphorylation of paxillin is involved in the control of LPS induced RAW264.7 cell 
spreading.  
ERK/GSK-3 mediated phosphorylation of paxillin is involved in NGF induced PC12 
cell neurite outgrowth.  Both GSK-3 and ERK are required for NGF induced neuronal cell 
neurite outgrowth (43,367).  To assess the role of ERK/GSK-3-mediated paxillin 
phosphorylation in neurite extension, PC12 cells were transiently transfected with EGFP-
paxillin or EGFP-paxillinS126A/S130A, and the NGF-induced neurite extension of these 
cells was examined after 36 hours.  Transfected cells were identified as green cells by 
fluorescent microscopy and neurite extension examined by phase contrast microscopy (Fig 
2.9A).  Approximately 36% of the PC12 cells expressing EGFP-paxillin exhibited neurites 
longer than two cell bodies and 29% of cells produced neurites longer than three cell bodies 
(Fig 2.9B).  Neurite extension in nontransfected cells in the same culture exhibited a similar 
morphological response to NGF.  In contrast, cells expressing EGFP-paxillinS126A/S130A 
exhibited a retardation in neurite extension.  Only 23% of the cells expressing EGFP-
paxillinS126A/S130A had neurites longer than two cell bodies and 16% of the cells had 
neurites longer than three cell bodies.  Cells transiently transfected with EGFP-
paxillinS126D/S130D exhibited similar NGF induced neurite extension as observed in 
untransfected and EGFP-paxillin transfected cells.  These findings suggest that 
phosphorylation of paxillin at serine residues 126 and 130 is involved in the control of NGF-
induced neurite extension. 
2.5  Discussion 
 
GSK-3 is a key regulatory component of a large number of cellular processes and 
aberrant control of GSK-3 regulated pathways plays a role in a number of human diseases, 
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such as diabetes, Alzheimer's disease and cancer (115,238,350). More than 40 proteins are 
phosphorylated by GSK-3, and these substrates include metabolic proteins, cytoskeleton 
proteins and transcription factors (114).  Here we identify a new GSK-3 substrate, the focal 
adhesion associated protein paxillin.  GSK-3 phosphorylates paxillin at serine 126 and 
requires priming by phosphorylation of serine 130.  Our findings suggest that GSK-3 
mediated serine 126 phosphorylation is a general response to activation of the ERK pathway 
and is controlled by ERK-dependent priming.  Using a mutant of paxillin that cannot be 
phosphorylated at serines 126 and 130 as a tool to explore the function of these 
phosphorylation events, we provide evidence that phosphorylation of these sites controls cell 
spreading and neurite extension in a macrophage and neuronal cell line respectively. 
Paxillin phosphorylation at serine 126 is ERK dependent but the site is not a direct 
ERK phosphorylation site, in contrast to serine 83, which is directly phosphorylated by ERK 
(220,259).  Interestingly, phosphorylation of serine 83 depends upon phosphorylation of 
paxillin at tyrosine 118, which creates a docking site for ERK and consequently 
phosphorylation of paxillin at serine 83 (225).  The ERK-dependent phosphorylation of 
serine 126/130 is mediated by a distinct mechanism.  Pharmacological inhibitors that block 
paxillin tyrosine phosphorylation did not block serine 126 phosphorylation.  Further, a 
paxillin mutant with phenylalanine substitutions for the major sites of tyrosine 
phosphorylation, Y31F/Y118F, was phosphorylated at serine 126 following LPS stimulation.  
These data suggest that there are two different ERK mediated paxillin phosphorylation events 
and that these occur via two different mechanisms, one of which is dependent upon paxillin 
tyrosine phosphorylation (serine 83) and the other independent (serine 126/130).  Thus 
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tyrosine phosphorylation provides an intriguing mechanism to direct site selective 
phosphorylation of paxillin by ERK. 
 ERK has been identified as a priming kinase for GSK-3 mediated paxillin 
phosphorylation at serine 126.  In addition to paxillin, this ERK/GSK-3 dual kinase 
mechanism of phosphorylation has been reported for HSF-1, and results in the inactivation of 
HSF-1 (85,187).  Another ERK dependent mechanism of GSK-3 activation has also been 
reported, in which ERK can operate through a downstream kinase to activate GSK-3 (159). 
However, this mechanism is unlikely to control ERK/GSK-3 mediated paxillin 
phosphorylation at serine 126 for several reasons.  First, on its own the active form of GSK-3 
cannot phosphorylate serine 126 of paxillin in vitro.  Second, expression of constitutively 
active GSK-3 cannot induce serine 126 phosphorylation in vivo (data not shown).  Third, 
disruption of the priming site, serine 130, can inhibit serine 126 phosphorylation both in vivo 
and in vitro.   These results suggest that paxillin is phosphorylated by an ERK/GSK-3 dual 
kinase mechanism, and that the major regulatory event is substrate priming for GSK-3 
phosphorylation by ERK. 
 Why do cells use such a complicated regulatory mechanism to control GSK-3 
mediated substrate phosphorylation?  The requirement for the precise temporal and spatial 
regulation of downstream signaling may be the answer to this question.  Signaling events 
might only be transduced under local conditions where the priming kinase is activated and 
where GSK-3 remains active due to the absence of inhibitory signals regulating GSK-3 
serine phosphorylation.  In macrophages, LPS induces PI3K/AKT activation resulting in the 
phosphorylation-dependent inactivation of GSK-3.  This results in the nuclear accumulation 
of β-catenin and transcription of genes regulated by the β-catenin/Lef complex (331).  In 
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contrast, GSK-3 mediated paxillin phosphorylation is stimulated by ERK activation via a 
priming mechanism upon LPS stimulation.  Thus two different downstream signaling 
pathways controlled by LPS have opposing effects on GSK-3 signaling, one impairing β-
catenin phosphorylation and the other promoting paxillin phosphorylation.  Similarly, in 
neuronal cells, both activation and inhibition of GSK-3 regulated signaling processes are 
apparently required to promote neuronal cell polarity and axon extension.  The 
dephosphorylation of two GSK-3 substrates, APC and CRMP-2, is required for axon 
extension and concomitantly the phosphorylation of MAP1b by GSK-3 is required 
(104,160,500,509).  We have now shown that paxillin is phosphorylated by GSK-3 
downstream of NGF stimulation and that phosphorylation of paxillin is required for efficient 
neurite outgrowth.  These paradoxical observations can be reconciled if populations of active 
and inactive GSK-3 are spatially segregated within the cell. 
 Paxillin plays an important role in neurite outgrowth since a number of mutants act in 
a dominant negative fashion to retard this process.  Expression of a paxillin variant lacking 
the LD4 motif inhibits the neurite extension of PC12 cells upon EGF stimulation (230).  
Expression of the paxillin p38 MAPK phosphorylation site mutant S85A also strongly 
inhibits the neurite outgrowth of PC12 cells following NGF stimulation (202).  It has been 
reported that both GSK-3 and ERK activity are required for neurite outgrowth (44,368), and 
phosphorylation of paxillin at serine 126 and 130 via GSK-3 and ERK is also important for 
NGF-induced neurite extension in PC12 cells.  Collectively this data suggests that multiple 
sites of phosphorylation on paxillin, which are regulated by different kinases, may all 
function in the control of neuronal cell polarity.  This is an intriguing mechanism where 
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multiple signaling pathways may converge on the same substrate to regulate a biological 
response. 
 How ERK/GSK-3 mediated phosphorylation of paxillin modulates cytoskeleton 
rearrangement remains to be elucidated.  Since serine 126 and 130 are in proximity to the 
LD2 motif, it seems likely that phosphorylation regulates binding to other proteins. However, 
our results and other published data suggest phosphorylation of paxillin at these sites does 
not appreciably alter the binding of paxillin to any proteins that are known to dock to LD2 
(data not shown) (479).  It is also possible that paxillin phosphorylation is involved in control 
of the activity of paxillin associated signaling molecules.  In paxillin null cells, the associated 
tyrosine kinase FAK exhibits a defect in tyrosine phosphorylation, suggesting a role for 
paxillin in controlling its activity (169).  However, null cells re-expressing wild type paxillin 
or the S126A/S130 mutant exhibit similar levels of FAK phosphorylation (data not shown).  
Perhaps paxillin phosphorylation modulates the activity of other associated enzymes 
including the ArfGAP, PKL/Git1, and the Rac exchange factor, Cool-1/Pix.  Interestingly, 
phosphorylation of serine 83 of paxillin has been linked to the control of Rac activity in 
epithelial cells (219).  Investigation of the mechanism of control of downstream signaling 
pathways by serine 126/130 phosphorylation of paxillin will be the focus of future 
investigations.   
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Figure 2.1  LPS induces paxillin tyrosine and serine phosphorylation. (A) RAW264.7 
cells were serum starved overnight (lane 1), then stimulated with 1 μg/ml LPS for 1 hr (lanes 
2, 3) prior to lysis.  Paxillin was immunoprecipitated from 500 μg of cell lysate. Half of the 
immune complex from the LPS stimulated sample was incubated with calf intestine alkaline 
phosphatase for half an hour (lane 3).  The immune complexes were then analyzed by 
Western blotting.  (B) Cell lysates from unstimulated (lane 1) and LPS stimulated (lane 2) 
RAW264.7 cells were Western blotted using phosphospecific (top 4 panels) or paxillin 
antibodies (bottom panel).  (C) RAW264.7 cell line derivatives stably expressing EGFP-
paxillin (lanes 1, 2) or EGFP-paxillinS126A (lanes 3, 4) were serum starved (lanes 1, 3) or 
starved and then stimulated with LPS (lanes 2, 4).  Cell lysates were blotted with the PS126 
(top) or paxillin antibody (bottom).  The positions of the exogenous EGFP-paxillin and 
endogenous paxillin are indicated.  (D)  Primary peritoneal macrophages (lanes 1-6) were 
stimulated with LPS (1 μg/ml) for the indicated times prior to lysis.  J774 cells (lanes 7, 8) 
and Bac1 cells (lanes 9, 10) were starved (lanes 7, 9) or stimulated with LPS (1 μg/ml)(lanes 
8, 10) for 1 hr prior to lysis.  Lysates were blotted with PS126 and paxillin antibodies.  (E)  
Lysates from RAW 264.7 cells stimulated with LPS were analyzed.  50 μg of lysate was 
directly analyzed (lane 1) or 500 μg of lysate was immunoprecipitated using PS126.  Ten 
percent of the immune complex (lane 2) and supernatant (lane 3) was analyzed by Western 
blotting for paxillin. 
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Figure 2.2  LPS induced paxillin serine 126 phosphorylation is ERK-dependent. (A) 
RAW264.7 cells were serum starved overnight (lane 1), and then stimulated with 1 μg/ml 
LPS for the indicated time (lane 2-4).  Cell lysates were blotted with the PS126, paxillin, 
pERK and ERK2 antibodies.  (B) RAW264.7 cells were serum starved overnight (lane 1), 
and then pretreated with the MEK inhibitor PD98095 at the dose shown for 1 hr. Cells were 
stimulated with LPS (1 μg/ml) for 1 hr.  Cell lysates were blotted with PS126, paxillin, 
pERK and ERK antibodies.  (C)  RAW264.7 cells were treated as in B, except MEK was 
inhibited with 20 μM U0126.  (D)  Wild type or constitutively activated MEK was 
transiently expressed in 293 cells and lysates were blotted with the PS126, paxillin and 
pERK antibodies. 
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Figure 2.3  Paxillin serine and tyrosine phosphorylation are regulated by separate 
pathways.  (A) RAW264.7 cell line derivatives transiently expressing EGFP-paxillin (lanes 
1, 2) or EGFP-paxillinY31F/Y118F (lanes 3, 4) were stimulated with LPS (lanes 2, 4) and 
cell lysates blotted with the paxillin and PS126 antibodies.  The positions of the exogenous 
EGFP-paxillin and endogenous paxillin are indicated.  (B) RAW264.7 cells were serum 
starved overnight (lane 1), and then pretreated with the Src inhibitor PP2 at the doses shown 
for 20 min.  Cells were stimulated with LPS (1 μg/ml) for 1 hr.  Cell lysates were blotted 
with PS126, PY118, paxillin, pERK, or ERK antibodies.  (C) RAW264.7 cells were serum 
starved overnight (lane 1), and then were pretreated with U0126 at the dose shown for 1 hr.  
Cells were stimulated with LPS (1 μg/ml) for 1 hr.  Cell lysates were blotted with paxillin 
and PY118 antibodies.  
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Figure 2.4  Paxillin serine 126 phosphorylation is induced by multiple stimuli.  (A) 
RAW264.7 cells were trypsinized, incubated in suspension at 37oC for half an hour (lane 2), 
then replated on fibronectin coated plates (50 μg/ml) for half an hour (lane 3) at 37oC prior to 
lysis.  Cell lysates were blotted with paxillin and PS126 antibodies.  (B) and (C) RAW264.7 
cells were serum starved overnight (lane 1), and then were stimulated with PMA (100 
ng/ml)(lane 2 in panel B), LPS (1 μg/ml) (lane 2 in panel C) and CSF (1.32 nM) (lane 3 in 
panel C) for 1 hr. Cell lysates were blotted with paxillin, PS126 and pERK antibodies.  (D) 
PC12 cells were starved in DMEM containing 1% FBS for 6 hr, treated with 20 µM U0126 
for 1 hr (lane 3), and stimulated with 100 ng/ml NGF for 2 hr (lanes 2, 3).  Cell lysates were 
blotted with PS126, paxillin and pERK antibodies. 
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Figure 2.5  Phosphorylation of serine 126 is abolished by GSK-3 inhibitors. (A, B & C) 
RAW264.7 cells were serum starved overnight (lane 1), then pretreated with LiCl, GSK-3 
inhibitor IX or GSK-3 inhibitor I at the dose indicated for 1 hr.  Cells were stimulated with 
LPS (1 μg/ml) for 1 hr.  Cell lysates were blotted with the indicated antibodies.  (D) PC12 
cells were starved in DMEM containing 1% FBS for 6hr, treated with the indicated drug for 
1hr, and stimulated with 100 ng/ml NGF for 2 hr.  Cell lysates were blotted with the 
indicated antibodies.  (E)  RAW264.7 cells were transfected with the control or GSK-3β 
siRNAs, starved and stimulated with LPS.  Lysates were blotted for PS126, paxillin, pERK 
and GSK-3α/β. 
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Figure 2.6  Phosphorylation of paxillin is mediated by ERK/GSK-3 dual kinase 
mechanism. (A) Recombinant GST-N-C3 was incubated with active GSK-3 and ERK1, 
alone or in combination, in 50 µl of kinase reaction buffer at 30°C for 60 min. Samples were 
resolved by SDS-PAGE, and immunoblotted using the PS126 or paxillin antibodies. (B) 
GST-N1-C1A was incubated with ERK in kinase reaction buffer containing γ[32P]-ATP and 
the samples resolved by SDS-PAGE.  The autoradiograph and Coomassie stained gel are 
shown.  (C) The wild type GST-N-C3 or GST-N-C3 variant containing an alanine 
substitution for serine 130 were treated as in A.  (D) PC12 cells transiently expressing EGFP-
paxillin (lanes 1, 2) or EGFP-paxillinS130A (lanes 3, 4) were challenged with NGF (lanes 2, 
4) and cell lysates were blotted with the paxillin and PS126 antibodies.  The positions of the 
exogenous EGFP-paxillin and endogenous paxillin are shown.  (E) A model for 
phosphorylation of paxillin by ERK/GSK-3 dual kinase mechanism is show. 
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Figure 2.7  Subcellular localization of the serine 126 phosphorylated form of paxillin in 
fibroblasts.  (A)  Paxillin null fibroblasts were transiently transfected with EGFP-paxillin 
(top panels) or the EGFP-paxillinS126A mutant (bottom panels).  Twenty-four hours later, 
the cells were trypsinized, held in suspension for 45 minutes and then plated onto fibronectin 
coated coverslips for 60 minutes in serum-free medium.  Localization of the protein was 
visualized by fluorescent microscopy (left panels).  Localization of paxillin that was 
phosphorylated on serine 126 was determined by immunofluorescence using the PS126 
antibody (right panels).  (B) PC12 cells were serum starved (left panel) and stimulated with 
NGF (100 ng/ml) for 3 hours (middle panel) or 30 hours (right panel). Cells were fixed and 
immunostained using the PS126 antibody.  
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Figure 2.8  ERK/GSK-3 mediated phosphorylation of paxillin is involved in cell 
spreading.   (A) Lysates from paxillin null cells or cells re-expressing wild type or 
S126A/S130A paxillin were analyzed by Western blotting for paxillin (top panel) or PS126 
(bottom panel).  (B)  Cells were serum starved overnight and then plated on fibronectin.  At 
various times the area of spreading cells was determined using Image J software (>50 cells 
per experiment) and the average from 3 experiments plotted.  The data at each time point was 
analyzed using one-way ANOVA (P<0.0001 at each time) and the Dunnett post test (for wild 
type expressing cells P<0.01 at each time; for S126A/S130A P<0.05 only at 60 minutes).  (C) 
RAW264.7 cells or derivatives stably expressing EGFP-paxillin or EGFP-
paxillinS126A/S130A were challenged with 1 μg/ml LPS as described. Cell spreading was 
recorded after 3 hr of LPS stimulation.  Phase contrast images (left panels) and fluorescent 
images (right panels) of cells transfected with EGFP-paxillin (top panels) or EGFP-
paxillinS126A/S130A (bottom panels) are shown.  (D) GFP negative, untransfected cells and 
GFP positive cells expressing exogenous paxillin were scored as spread or unspread and 
expressed as percentage of cells spread. Greater than 100 GFP positive cells were scored in 
each experiment.  The data was plotted as the mean ± SE from three experiments.  The P 
value is less than 0.05 (unpaired student t-test).   
 
78 
 
 
Figure 2.9  ERK/GSK-3 mediated phosphorylation of paxillin is involve in NGF 
induced neurite outgrowth.  (A)  PC12 cells transiently expressing EGFP-paxillin or 
EGFP-paxillinS126A/S130A were plated on collagen-coated petri dishes and treated with 
100 ng/ml NGF.  Neurite outgrowth was recorded after 36 hr of NGF stimulation.  Phase 
contrast images (left panels) and fluorescent images (right panels) of cells transfected with 
EGFP-paxillin (top panels) or EGFP-paxillinS126A/S130A (bottom panels) are shown.  (B) 
Quantitative analysis of neurite outgrowth from three independent experiments is shown. In 
each experiment, greater than 100 GFP negative, untransfected cells (light grey bars) and 
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GFP positive cells from the EGFP-paxillin (white bars), EGFP-paxillinS126A/S130A (black 
bars) and EGFP-paxillinS126D/S130D (dark grey bars) transfected populations were scored.  
The data was plotted as the mean ± SE from three experiments.  In each group the wild type 
and S126A/S130A data was analyzed using one way ANOVA and Dunnett post test (for each: 
ANOVA, P<0.0002; Dunnett, P<0.01). 
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3.1  Abstract 
Focal adhesion kinase is an essential kinase that regulates developmental processes 
and functions in the pathology of human disease.  An intramolecular autoinhibitory 
interaction between the FERM and catalytic domains is a major mechanism of regulation.  
Based upon structural studies, a FRET based FAK biosensor that discriminates between 
autoinhibited and active conformations of the kinase was developed.  This biosensor was 
used to probe FAK conformational change in live cells and the mechanism of regulation.  
The biosensor demonstrates directly that FAK undergoes conformational change in vivo in 
response to activating stimuli.  A conserved FERM domain basic patch is required for this 
conformational change and for interaction with a novel ligand for FAK, acidic phospholipids.  
Binding to PIP2-containing phospholipid vesicles activated and induced conformational 
change in FAK in vitro, and alteration of PIP2 levels in vivo changed the level of activation 
of the conformational biosensor.  These findings provide direct evidence of conformational 
regulation of FAK in living cells and novel insight into the mechanism regulating FAK 
conformation. 
3.2  Introduction 
Focal adhesion kinase (FAK) is an essential non-receptor tyrosine kinase since FAK 
null mice exhibit embryonic lethality (145).  In endothelial cells FAK is required for the 
proper development of the vasculature (26,413), and in neurons FAK regulates netrin-
mediated axon outgrowth and dendrite formation (330,378).  In addition to these roles in 
development, FAK is also implicated in the pathology of disease.  FAK expression is 
required in cardiomyocytes to promote hypertrophy and fibrosis in response to cardiac stress 
and potentially plays a role in the development of heart disease (111,355).  Overexpression of 
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FAK is observed in many types of cancer (146), and experiments using animal models have 
implicated FAK in tumor formation and metastasis in a number of neoplasms, including 
cancer of the brain, breast and skin (322,326,458).   
Despite the importance of FAK in controlling multiple developmental and 
pathological events, the molecular mechanism of regulation remains incompletely elucidated.  
Like many kinases post-translation modification, particularly phosphorylation, is a major 
regulatory mechanism.  Tyrosine 397 is the major site of auto-phosphorylation and mutation 
of this site abrogates the biological activity of FAK (387).  This site primarily serves a 
scaffolding function, providing a docking site for a number of proteins containing SH2 
domains, including Src and PI3K (386).  The interaction with FAK occupies both the SH2 
and SH3 domains of Src preventing intramolecular inhibitory interactions resulting in 
stabilization of Src in its active conformation (440).  Complex formation also serves to direct 
Src to its substrates, which include FAK itself.  Activated Src phosphorylates FAK on 
multiple sites including two tyrosine residues in the activation loop, Y576 and Y577, which 
function in regulating catalytic activity (48).   
A number of protein-protein interactions also regulate FAK activity.  FIP200 is a 
negative regulator of kinase activity (452).  The interaction of FIP200 with FAK is complex, 
with multiple FIP200 binding sites in FAK (4).  This complex dissociates upon cell adhesion, 
which is a stimulus leading to FAK activation (2).  The interaction of FAK with growth 
factor receptors positively regulates FAK signaling.  Stimulation of fibroblasts promotes 
FAK binding to the EGF and PDGF receptors, which is required for EGF- and PDGF-
induced chemotaxis (425).  Stimulation of cells with HGF promotes the direct association of 
FAK with the Met receptor and this interaction is required for HGF induced activation of 
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FAK (82).  A potential ligand-binding site within the N-terminal domain of FAK, consisting 
of a series of basic residues, is required for maximal activation of FAK and subsequent 
downstream signaling following cell adhesion to fibronectin (120).  This same site forms the 
binding site for tyrosine phosphorylated Met receptor (81), and thus this sequence is required 
for activation of FAK in response to diverse stimuli. 
Multiple studies support a model of regulation whereby the FAK FERM domain 
interacts with the FAK catalytic domain to impair catalytic activity in the inactive state.   
Truncation of the FERM domain increases FAK tyrosine phosphorylation and/or kinase 
activity (69,233,400,406,447).  Further, the FERM domain can interact in trans with the 
catalytic domain in vivo and inhibit its activity (95).  Mutation of K38 within the FERM 
domain disrupts the FERM/kinase domain interaction, and when introduced into the full-
length molecule activates FAK (89).  The molecular details of the FERM/catalytic domain 
interaction were revealed by X-ray crystallography (294).  In this complex, the FERM 
domain blocks the active site of the kinase domain inhibiting access to the ATP and substrate 
binding sites.  Further, the activation loop lies within the cleft between the FERM and kinase 
domains.  These studies support a model of FAK activation entailing a switch from 
autoinhibited to active conformation, however, the challenging task of testing this model 
under physiological conditions in living cells has yet to be undertaken. 
In this paper, we report the development of two biosensors that can measure two 
important facets of FAK activation in live cells; 1) phosphorylation of Y397, which reflects a 
FAK scaffolding function, and 2) a conformational change associated with FAK activation.  
The novel conformational biosensor directly demonstrates that a conformation change in 
FAK occurs in living cells upon FAK activation.  The biosensor was further used to probe 
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the spatial regulation of FAK and mechanisms involved in controlling conformation changes.  
Acidic phospholipids are identified as novel ligands for FAK.  PIP2-containing vesicles alter 
FAK conformation in vitro and modulating PIP2 levels alters FAK conformation in vivo.  
These findings support the model that FAK is regulated via interaction with lipid ligands and 
provides mechanistic insight into the observation that acidic phospholipids are required for 
FAK activation (59,248,302,315). 
3.3  Materials and Methods 
Cell culture.  293T cells were maintained in DMEM F-12 medium containing 10% FBS and 
HeLa cells in DMEM containing 10% FBS. Cells were transfected using Lipofectamine Plus 
(Invitrogen) according to manufacturer’s instructions.  HeLa cells were starved in DMEM 
overnight prior to stimulation with ligands.  To measure adhesion dependent activation cells 
were maintained adhered to substrate or incubated in suspension at 37oC for 1 hour prior to 
lysis. 
Molecular Biology.  To generate CFAK the full length FAK cDNA was inserted into ECFP-
C1, in frame with CFP.  Citrine was generated from the EYFP-C1 vector by mutation of 
glutamine 69 to methionine (188).  To generate citrine-dSH2, two Src SH2 domains were 
sequentially introduced into the citrine construct.  This was achieved by PCR amplification 
of the cSrc SH2 domain (553-894) and insertion of two copies of the SH2 coding sequence 
between the XhoI and PstI sites within citrine vector.  To generate FAK conformation 
probes, six-nucleotide insertions encoding a Not I site were introduced into different sites of 
CFAK. Citrine was amplified with primers containing Not I sites and the PCR product was 
introduced into the Not I site within CFAK.  All mutations were generated using the 
QuickChange mutagenesis strategy. The full-length constructs were analyzed by sequencing 
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to verify the intended mutations and ensure that no unintended mutations were present.  The 
expression construct for PIPKIα was the generous gift of Richard Anderson (University of 
Wisconson) and a YFP-SopB construct was a generous gift of Jorge Galán (Yale University).  
For this study, the SopB encoding sequences were amplified by PCR and subcloned into 
pcDNA3.1. 
Fluorometric measurements of FRET.  For live cell fluorometric measurements, 293 cells 
expressing different constructs were typsinized and suspended in PBS. The cells were 
analyzed using a Fluorolog SPEX 168 fluorometer or a Spectrofluorophotometer RF-1501 
(Shimadzu). The cell suspension was excited at 425 nm and an emission scan was acquired 
from 450 to 550 nm. The spectra of different samples in a single experiment were normalized 
to CFP emission of a reference spectrum. 
Measuring FRET by Microscopy.  HeLa cells expressing biosensors were plated on 
fibronectin (Sigma 5 ug/ml) coated coverslips (Lucas Highland). After incubation at 37oC for 
one hour the cells were transferred to the microscope’s heated chamber (Warner Instrument 
Corporation  TC-344B) in Ham’s F-12 K medium without phenol red (Biosource), 25 mM 
HEPES, pH 7.4 and 5% FBS.  Images were collected using a Zeiss 100X 1.3 N.A. lens, a 
Zeiss Axiovert 100TV microscope, a Cool Snap ES digital camera and Metamorph software 
(Universal Imaging). The filters and dichroic mirror setting for FRET images were 1) CFP: 
D436/20, D470/40; 2) FRET: D436/20, HQ535/30; and 3) YFP: HQ500/20, HQ535/30 
(359).  The CFP, FRET and YFP images were recorded using 2*2 binning.  For ligand 
stimulation, transfected HeLa cells were serum starved overnight, transferred to the 
microscope’s heated chamber and imaged, before and after ligand stimulation, in HBSS 
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buffer with 20 mM HEPES, pH 7.4 and 2 g/l glucose. At each time point, images were 
collected using a Zeiss 40X 1.3NA Plan NeoFluor lens and 4*4 binning. 
For photobleaching assays, HeLa cells expressing the FAK biosensor were 
illuminated to excite CFP and imaged in both the CFP and FRET channels at 11-second 
intervals. The YFP acceptor was photo bleached by pulse illumination for 6 seconds at each 
11-second interval. The mean intensity from the whole cell was measured at each time point 
and normalized to the zero time point at the initiation of photobleaching.  For laser scanning 
confocal microscopy, 293 cells expressing the donor (CFAK), acceptor (citrine-dSH2) or 
both were analyzed.  Images were recorded using a LSM 510 laser scanning confocal 
microscope (Zeiss) in lambda stack mode.  For photo bleaching, the cells were photo 
bleached at 488 nm. The emission spectra following stimulation at 458 nm were recorded 
before and after photobleaching.  
Image processing and analysis.   Images were processed as previously described 
(67,73,258,358).  CFP, FRET, and citrine images were background subtracted and registered. 
For the FAK conformation biosensor, the background subtracted CFP image was divided by 
the background subtracted FRET image to get a pixel-to-pixel CFP/FRET ratio image. The 
CFP images were thresholded to generate a binary mask with a value of zero outside the cell 
and a value of one inside the cell. The CFP/FRET ratio images were multiplied with the 
mask and displayed in pseudocolors scaled from the lowest to the highest signal within the 
cell, eliminating pixels outside the 5-95% range on the intensity histogram, to provide a more 
reasonable estimate of the biosensor’s useful dynamic range.  For the FAK auto-
phosphorylation biosensor, the images were processed using the following equation, 
Corrected FRET (FRETC)= FRET-a*CFP-b*citrine, (487) 
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where a is the percentage of CFP bleed through (determined from cells expressing only CFP-
FAK), b is the percentage of citrine bleed through (determined from cells expressing only 
expressing citrine-dSH2).   
To quantify the focal adhesion and cytoplasm FRET values, two segmented images 
were generated using a threshold function.  Two segmented images were used to generate 
binary masks for focal adhesions and the cytoplasm.  The FRET ratio images were multiplied 
with the two masks to generate the ratio images for focal adhesions and cytoplasm.  To 
determine the relationship between focal adhesion FRET value and distance to the cell 
margin, the focal adhesion binary mask was used to generate an individual segmented region 
around each focal adhesion. The segmented regions for focal adhesions were loaded to the 
focal adhesion CFP/FRET ratio image.  The individual focal adhesion parameters, including 
average intensity and x,y value of each focal adhesion, were exported to Excel to generate a 
focal adhesion database.  The cell margin was plotted based on the registered CFP image and 
transformed to a set of x and y values using Image J. The set of margin x and y values were 
imported into Excel.  The minimal margin distance was measured by determining the 
minimal value of  ???? ? ???? ? ??? ? ????, where x1,y1 are the coordinates of each focal 
adhesion and x2,y2 are the coordinates of each point at the margin of the cell. 
Lipid Binding Assays.  Lipid vesicles were prepared by mixing chloroform-dissolved 
phospholipids (Avanti Polar Lipids) in the appropriate ratios keeping the PE/PC mass ratio as 
3:1, while other lipids were supplemented to the final concentration indicated.  The mixture 
was dried using a speed vacuum for 15 min. The dried lipid mixture was suspended and 
sonicated in lipid binding buffer (40 mM Hepes pH 7.5, 2 mM DTT,150 mM NaCl) to a final 
concentration 2.5 μg/μl.  For cosedimentation, 4 μg of GST fusion protein was incubated 
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with 250 μg of lipid vesicles on ice for 1 h. The mixtures were subsequently centrifuged at 
110,000g for 1 hr at 4°C. The supernatants were collected.  The pellets were suspended in 
100 µl SDS buffer and boiled for 2 min to dissolve.  Both the supernatants and pellets were 
mixed with Laemmli sample buffer and boiled for 5 min.  The samples were analyzed by 
SDS-PAGE and Coomassie Blue staining.  For fluorescence polarization the purified FERM 
domain (65) was incubated with BODIPY labeled phosphoinosotides with C6-acyl chains 
(62).   Increasing concentrations of purified protein was added to 12.5 nM fluorescent 
phosphoinositide in buffer containing 20 mM HEPES pH 7.0, 150 mM Nacl and 5 mM β-
mercaptoethanol. Anisotropy measurements were taken at 21oC using a Beacon 2000 
fluorescence polarization instrument. Binding curves and dissociation constants were 
determined using the program Prism (GraphPad Software Inc.). 
Protein purification and kinase assay.  The GST-fusion proteins were induced and purified 
as previously described (119,316).  For immune complex kinase assays, FAK and its variants 
were immunoprecipitated using the BC4 polyclonal antiserum or GFP antibody and the 
immune complexes incubated with 2 μg of GST-paxillin-N-C3 using previously described 
kinase reaction conditions (317).  The reaction was terminated by the addition of sample 
buffer and phosphorylation of paxillin examined by Western blotting. 
Expression of the recombinant fragment of FAK containing the FERM and catalytic 
domains has been described (293).  For in vitro kinase assays using recombinant proteins, 
200 ng of the recombinant FAK fragment and 1 μg Src (SH3+SH2+Kinase) were incubated 
with liposomes in kinase reaction buffer (100 mM Tris pH7.5, 100 mM MgCl2, 50 μM ATP) 
for 30 min. The reaction was terminated by the addition of sample buffer and 
phosphorylation of recombinant FAK was examined by Western blotting. 
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Protein analysis.  Cells were lysed in ice-cold modified radioimmunoprecipitation assay 
buffer. Lysates were clarified, and protein concentrations were determined using the 
bicinchoninic acid assay (Pierce, Rockford, IL). Immunoprecipitations were performed using 
a polyclonal FAK antibody (BC4) or a GFP monoclonal antibody (Roche).  For Western 
blotting the FAK antibody (447) and phosphotyrosine antibody (4G10) were from Millipore, 
the PY576 antibody from Biosource and the paxillin polyclonal antibody was previously 
described (438). 
3.4  Results 
Development of a FAK autophosphorylation biosensor.  Tyrosine397 is the major FAK 
autophosphorylation site, which is critical for FAK function and serves as a scaffolding site 
to recruit other proteins into complex. To visualize FAK autophosphorylation status in living 
cells, a genetically encoded FRET-based biosensor was developed.  As a similar biosensor 
has been described (20), it will only be briefly introduced.  CFP was fused to the FAK N-
terminus to serve as the FRET donor and citrine, a variant of YFP, was fused to two Src SH2 
domains to serve as the FRET acceptor (Fig. 3.1A).  Since phosphorylation of tyrosine 397 
regulates Src SH2 domain binding to this site, CFAK should only interact with citrine-dSH2 
and produce a FRET signal when the former is phosphorylated at tyrosine 397.  The 
interaction between CFAK and citrine-dSH2 was confirmed by co-immunoprecipitation (data 
not shown).  Citrine-dSH2, but not citrine alone, co-immunoprecipitated with CFAK and this 
interaction was abolished when tyrosine 397 in CFAK was substituted with phenylalanine.  
Upon co-expression in 293 cells, CFAK and citrine-dSH2 co-localized peripherally near the 
membrane (data not shown).  In contrast, CFAK-Y397F and citrine dSH2 were not co-
localized.  These data demonstrate that the interaction between CFAK and citrine-dSH2 
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depends upon phosphorylation of tyrosine 397.  FRET was measured in several ways.  
Initially, cells were scraped from the tissue culture dish and FRET was measured in cells in 
suspension using a fluorometer.  These measurements were made rapidly upon removing the 
cells from the dish (within 10 min), before exogenously expressed FAK could be inactivated 
and dephosphorylated.  No FRET signal was detected in 293 cells expressing CFAK or 
citrine-dSH2 alone, whereas a strong FRET signal was detected in cells co-expressing both 
proteins (Fig 3.1B and Fig 3.8). Notably, no FRET signal was detected in cells co-expressing 
CFAK-Y397F and citrine-dSH2.   Note that similar results were obtained when adherent 
cells were lysed and the lysates, rather than suspended cells, were analyzed (data not shown).  
Expression levels of the wild type and mutant biosensor were comparable (Fig 3.9A).  FRET 
was also measured microscopically.  As a further control, acceptor photobleaching was used 
to validate the FRET signal in vivo. HEK293 cells co-expressing CFAK and citrine-dSH2 
were photobleached using an Argon laser (488nm). A series of fluorescent images were 
collected by laser scanning confocal microscopy and the average pixel intensity of the 
photobleached area at the CFP and FRET emission wavelengths was determined.  As shown 
in Fig. 3.1C, photobleaching the FRET acceptor resulted in a decrease in the acceptor signal 
and an increase in the CFP donor signal, which was caused by the interruption of energy 
transfer from CFAK to citrine-dSH2.  
Development of a FAK conformational biosensor.  The structure of the FERM/catalytic 
domain complex confirms the role of the FERM domain in autoinhibition of catalytic activity 
and suggests that a transition from the autoinhibitory conformation to an open, active 
conformation is a required step for FAK activation. A FRET based FAK probe was 
developed to monitor such a conformational change in living cells. As shown in Fig 3.2A and 
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B, CFP was fused in the N-terminus of FAK and citrine was inserted into the linker between 
the FERM and catalytic domains to generate the CYFAK413 biosensor.  As a control, citrine 
was inserted at the C-terminus of the catalytic domain to generate the CYFAK700 construct. 
The emission spectrum of these constructs following stimulation with the CFP excitation 
wavelength was determined using a fluorometer.  Again measurements were made rapidly 
after taking the cells into suspension and similar results were found using lysates from 
adherent cells.  A strong FRET peak was detected in cells expressing CYFAK413 (Fig 3.2C).  
In contrast a very weak FRET signal was detected in cells expressing CFAK700.  Co-
expression of CFAK and YFAK, in which the CFP and citrine are presented in trans, did not 
yield a FRET signal in this assay.  In addition to the fluorometer assay, CYFAK413 was 
characterized by microscopy and FRET validated by acceptor photobleaching. Upon 
photobleaching, the citrine intensity decreased and the CFP signal increased, confirming that 
FRET was occurring (Fig. 3.2D).  The 12% increase in CFP signal upon acceptor 
photobleaching is similar to that reported for the vinculin conformation biosensor (72). 
To test whether the FRET signal of CYFAK413 was regulated by conformational 
change mutational studies were performed.  The major contacts between the FERM and 
catalytic domains are centered around F596 of the catalytic domain, which binds in a 
hydrophobic pocket on the FERM domain (Fig 3.2E).  Mutation of Y180 and M183, which 
form part of the hydrophobic pocket of the FERM domain, results in activation of FAK in 
vitro and in vivo (292).  These activating mutations were engineered into CY413FAK and as 
shown in Fig. 3.2F, this mutant showed reduced FRET compared to the wild type probe. In 
addition to this mutant, other activating mutations that disrupt the FERM/catalytic domain 
interaction were also introduced into the FAK conformational probe (Fig. 3.2G). Each of 
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these mutants also exhibited a low FRET/CFP ratio compared with the wild type probe.  The 
expression of these mutant biosensors was comparable to the wild type biosensor (Fig. 3.9B).  
These findings demonstrate that the FRET signal of this biosensor depends upon the 
interaction between the FERM and catalytic domains and that changes in FRET reflect 
changes in conformation.  
Lysine 38 is a FERM domain residue that is required for the interaction between the 
FERM and kinase domains (88).  Thus it was surprising when the crystal structure of the 
autoinhibited FERM/catalytic domain complex revealed that K38 did not directly contact the 
catalytic domain.  Instead, K38 appears to interact with acidic residues within the linker 
extending between the FERM and catalytic domains (291).  To further explore the role of 
K38 in FAK regulation, the K38A mutation was introduced into the CYFAK413 biosensor.  
Interestingly, this mutant also showed a low FRET/CFP ratio similar to that seen in 
CYFAK413 variants with mutations that directly disrupt the FERM/catalytic domain 
interaction (Fig. 3.2G).  This finding supports a role for K38 in stabilizing the inactive 
conformation of FAK, perhaps through interactions with the linker.  
The biochemical characteristics of CYFAK413 were examined to determine if 
incorporation of the fluorescent probes altered catalytic activity and if CYFAK413 was 
regulated in a manner similar to wild type FAK.  The catalytic activity of CYFAK413 was 
tested using an in vitro, immune complex kinase assay.  As shown in Fig. 3.3A, the kinase 
activity of CYFAK413 was modestly higher than wild type FAK, presumably due to the 
insertion of citrine in the linker, since CYFAK413 kinase activity was also higher than 
CFAK, which has CFP fused to the N-terminus of FAK.  Notably, the activity of CYFAK413 
was much lower than the activated variant CYFAK413-Y180A/M183A. To examine cell 
93 
 
adhesion dependent regulation, cells expressing CYFAK413 or CFAK were lysed and 
tyrosine phosphorylation examined following immunoprecipitation and Western blotting.  
Both CFAK and CYFAK413 were phosphorylated on tyrosine in adherent cells and exhibited 
reduced phosphotyrosine when cells were held in suspension (Fig. 3.3B).  Thus, tyrosine 
phosphorylation of CYFAK413 was regulated by cell adhesion, similar to wild type FAK.   
In addition, the biochemical response of the biosensor to LPA stimulation was measured to 
further validate that this probe is regulated similar to wild type FAK.  Following LPA 
stimulation, the biosensor exhibited increased tyrosine phosphorylation (Fig. 3.3C).  Despite 
a modest increase in its catalytic activity, the fact that the biosensor was regulated similarly 
to wild type FAK in response to multiple stimuli suggests that CYFAK413 is a suitable 
biosensor for monitoring conformational changes in FAK in living cells.   
Monitoring spatial regulation of FAK activity in living cells.  To monitor phosphorylation 
of tyrosine 397 in live cells, HeLa cells transiently co-expressing CFAK and citrine-dSH2 
were plated onto fibronectin coated coverslips and imaged by fluorescence microscopy.  
Cells were illuminated with a CFP excitation wavelength and the CFP and citrine (i.e. FRET) 
emissions captured.  The FRETc/CFP ratio image is shown in Fig 3.4A.  CFAK localized 
prominently to focal adhesions although there was also cytoplasmic localization.  The 
distribution of FRET indicated that phosphorylation of FAK at tyrosine 397 occurs at focal 
adhesions.  Importantly, CFAK-397F exhibited a similar localization to CFAK, but there was 
no FRET signal produced in cells co-expressing CFAK-397F and citrine-dSH2.  Expression 
of the wild type and mutant biosensors was comparable (Fig. 3.9C).  The localization of FAK 
phosphorylated at tyrosine 397 to these sites was anticipated from studies using 
phosphospecific antibodies for immunofluorescence and results using a similar biosensor 
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from Geiger’s laboratory (19,379).  Strikingly, there appeared to be a heterogeneous 
distribution of phosphorylated FAK amongst the CFAK positive focal adhesions (Fig. 3.4A).  
A similar heterogeneous pattern of autophosphorylated FAK was observed by staining with a 
PY397 phosphospecific antibody (Fig. 3.10). 
The current model of FAK regulation entails an autoinhibitory interaction between 
the FERM and catalytic domains and thus activation requires a conformational change 
relieving this inhibition.  The development of the FAK conformational biosensor allows a 
direct test of this model in living cells.  HeLa cells transiently expressing CYFAK413 were 
plated onto fibronectin coated coverslips and analyzed by fluorescence microscopy.  
Stimulation with the CFP excitation wavelength produced emission of both a CFP and a 
citrine signal.  A representative CFP image and CFP/FRET ratio image are shown in Fig. 
3.4B (note that the ratio image shows open conformation as “hot” and closed conformation 
as “cold”).  The CFP/FRET ratio was elevated in focal adhesions, compared with the ratio 
seen in the cytoplasm.  As a control, the activated variant CYFAK413-Y180A/M183A was 
analyzed in parallel.  The CFP/FRET ratio was high both in focal adhesions and in the 
cytoplasm in cells expressing this control.  Expression of the wild type and mutant biosensors 
was comparable (Supplemental Fig. 3.2D).  This result demonstrates that the differences in 
CFP/FRET ratio in the CYFAK413 expressing cells were due to differences in conformation.  
The CFP/FRET ratio in focal adhesions and in the adjacent cytoplasm was quantified.  In 
CYFAK413-Y180A/M183A expressing cells this ratio was the same in focal adhesions and 
in the cytoplasm (Fig. 3.5A).  In CYFAK413 expressing cells, the CFP/FRET ratio in focal 
adhesions was comparable to that seen in CYFAK413-Y180A/M183A expressing cells but 
the cytoplasmic CFP/FRET ratio was significantly lower.  These data demonstrate that FAK 
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exists in different conformations in different regions of the cell.  While it is not surprising 
that FAK is active in focal adhesions, the CYFAK413 biosensor allows visualization of 
conformation changes in live cells, and thus provides strong support for the current model of 
FAK regulation.  
While conformationally active FAK was found in focal adhesions, there was 
heterogeneity in the CFP/FRET ratio seen in focal adhesions.  This did not correlate with 
focal adhesion size or amount of FAK in individual focal adhesions, but rather with location.  
FAK activity was higher in focal adhesions at the cell margin compared with internal focal 
adhesions and a similar pattern was observed using the autophosphorylation biosensor.  This 
relationship was examined quantitatively by plotting the minimal distance of each focal 
adhesion from the cell margin versus the CFP/FRET and FRETc/CFP ratio of the focal 
adhesion (Fig. 3.5B & C).  This analysis supports the hypothesis that there is a tendency of 
focal adhesions near the periphery of the cell to have elevated levels of 
active/autophosphorylated FAK compared with focal adhesions further removed from the 
cell margin.  Interestingly, an asymmetric FAK conformation spatial pattern was identified in 
many cells, i.e. FAK activation was elevated along one margin of the cell relative to its 
activation at the opposite margin.  These findings suggest that FAK activity is regulated 
differentially in different focal adhesions, which may play a role in the determination of cell 
polarity and directional migration.  
Temporal regulation of FAK conformation in living cells.  To study FAK conformation 
changes in response to soluble ligands, HeLa cells expressing the conformational biosensor 
were serum starved, then stimulated with LPA.  The average CFP/FRET ratio in the cell was 
determined over time and was found to increase following stimulation (Fig. 3.5D).  The 
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kinetics of conformation change in FAK paralleled the kinetics of tyrosine phosphorylation 
of the biosensor (Fig. 3.5F).  Stimulation with PDGF produced a small, transient change in 
the CFP/FRET ratio, while EGF stimulation did not produce a change in FRET under these 
conditions.  The CYFAK413-Y180A/M183A constitutively active biosensor exhibited a 
constant CFP/FRET ratio before and after stimulation with LPA (Fig. 3.5E).  These findings 
demonstrate that conformational changes occur in FAK in response to soluble ligands. 
A FERM domain basic patch is required for conformational change.  A basic patch in 
the F2 subdomain of the FERM domain of FAK was identified as a key motif for FAK 
activation in vivo in response to cell adhesion and stimulation of the Met receptor (80,118).  
This motif is on the surface of the FERM/catalytic domain complex and is close to the 
catalytic domain interaction site in the crystal structure. Thus, this motif is a potential site for 
controlling FAK conformational regulation. To determine if this basic region was required 
for conformational regulation of FAK, alanine substitutions for basic residues in this region 
were engineered into the conformational biosensor to create the 
K216A/K218A/R221A/K222A mutant (KAKTLRK).  The wild type and mutant biosensors 
were transiently expressed and FRET examined by fluorometric analysis.  The mutant 
exhibited a higher FRET/CFP ratio than the wild type biosensor suggesting that the integrity 
of the basic patch was required for optimally inducing the active conformation of FAK (Fig 
3.6A).   
Acidic phospholipids bind the basic patch within FAK FERM domain.  Given the basic 
nature of this region, potential binding partners are likely to be acidic.  Other FERM domains 
exhibit high affinity binding to phosphatidylinositol 4,5-bisphosphate (PIP2) via positively 
charged motifs (174).  The structure of the FAK FERM domain precludes PIP2 binding via 
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the precise mechanism utilized by other FERM domains (64), however an interaction via the 
basic patch of the F2 subdomain remains a possibility.  To examine binding to PIP2, a 
fluorescence polarization assay was used.  Purified FERM domain was titrated into a solution 
of BODIPY labeled PIP2 containing C6-acyl chains and anisotropy measured.  Anisotropy 
was plotted against protein concentration and the dissociation constant calculated (Fig 3.6B).  
The KD for PIP2 was 31.52 +/- 1.7 µM and for phosphatidylinositol was >200 µM.  The 
interaction of the FERM domain with lipids was further validated using a vesicle co-
sedimentation assay.  Phosphatidylethanolamine/phosphatidylcholine vesicles containing 
increasing amounts of PIP2 were incubated with a GST-FERM fusion protein.  The vesicles 
were sedimented and the amount of fusion protein in the vesicle containing pellet and the 
supernatant was determined by SDS-PAGE and Coomassie blue staining.  While the FERM 
domain bound poorly to PE/PC vesicles, approximately 50% of the FERM domain bound to 
vesicles containing 1% PIP2 and virtually all of the fusion protein associated with vesicles 
containing 5% and 10% PIP2 (Fig. 3.6C).  To further characterize lipid binding, the 
interaction of the GST-FERM domain fusion protein with vesicles containing other lipids 
was examined.  Under conditions where the protein was completely found in the pellet with 
PIP2 containing vesicles, GST-FERM associated weakly with PI containing vesicles (Fig. 
3.6D).  In contrast, the GST-FERM fusion protein bound quite well to phosphatidylserine 
containing vesicles.  Thus, the data suggest that the interaction of GST-FERM with lipids is 
dictated by charge and that the structure of the head group is less important for binding in 
vitro.   
The most likely lipid binding site on the FERM domain is the F2 subdomain basic 
patch as it is the most basic feature of the domain.  To test its role in lipid binding, the 
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KAKTLRK mutations were engineered into the FERM domain.  While the wild type GST-
FERM domain associated strongly with PIP2 containing vesicles, this mutant was defective 
for binding (Fig. 3.6E).  If the FERM domain was capable of binding lipids in vivo the 
domain might be recruited to the membrane.  The FERM domain of FAK was transiently 
expressed in HeLa cells as a YFP fusion protein and its localization examined by confocal 
microscopy (Fig. 3.6G).  The FERM domain partially co-localized with F-actin in ruffles and 
was observed at the membrane at the periphery of the cell.  This pattern of localization 
suggests that the FERM domain is capable of associating with the membrane of the cell.  
Notably, KAKTLRK mutant exhibited a cytoplasmic localization and was not frequently 
observed in ruffles or at the membrane at the periphery of the cell (Fig. 3.6F).  Expression of 
the wild type and mutant FERM domains was comparable (Fig. 3.9E).  These data suggest 
that the FAK FERM domain can interact with acidic lipids in vitro and associate with the 
membrane in vivo, and the basic patch on the F2 subdomain is required for both of these 
activities.     
PIP2 containing vesicles can activate FAK via conformational change.  Given that the 
basic patch mutants are defective for signaling in vivo and that this region can mediate 
binding to PIP2 containing vesicles, it is possible that this interaction might play a role in 
FAK activation.  This was tested using a recombinant fragment of FAK containing the 
FERM and catalytic domains.  The fragment adopts the inactive conformation in which the 
Src phosphorylation sites within the activation loop of FAK are protected from 
phosphorylation (290).  The FAK fragment was incubated with purified, active Src in lipid 
vesicle binding buffer.  Under these conditions, Src could weakly induce FAK 
phosphorylation (Fig. 3.7A).  Incubation of the FAK fragment with PE/PC vesicles 
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containing 10% PIP2 prior to phosphorylation by Src led to a dramatic increase in 
phosphorylation of FAK, whereas incubation with PE/PC vesicles did not (Fig. 3.7A).  As a 
control, phosphorylation of GST fusion protein containing the activation loop peptide from 
FAK by Src was measured and did not change in the presence or absence of PIP2 containing 
vesicles. These results are consistent with the hypothesis that lipid vesicle binding leads to a 
conformational change in FAK exposing the activation loop for phosphorylation by Src. 
Modulation of PIP2 regulates FAK conformation in vivo.  To determine if perturbation of 
PIP2 levels in vivo could alter FAK activity, the conformational biosensor was used.  To alter 
PIP2 levels, PIPKIα was coexpressed with the biosensor and the active state of the biosensor 
compared with cells expressing the catalytically inactive mutant of PIPKIα.  Co-expression 
with PIPKIα resulted in a higher CFP/FRET ratio (indicating an increase in activated FAK) 
than co-expression with the catalytically inactive variant of the enzyme (Fig 3.7B).  These 
results demonstrate that elevation of PIP2 levels in the cell promote the conversion of FAK 
into its active conformation.  Further, the basic patch in the F2 subdomain of the FAK FERM 
domain is important for this effect since the KAKTLRK mutant lacking the basic patch was 
not responsive to altering the levels of PIP2 in the cell (Fig. 3.7B).  To determine if PIP2 
levels played a significant role in regulating FAK conformation under physiological 
conditions, SopB, an inositol polyphosphate 4-phosphatase, was co-expressed with the 
conformation biosensor and the effect upon the biosensor in adherent cells was examined.  
The conformation of the biosensor in focal adhesions was compared with its conformation in 
the cytoplasm by calculating the CFP/FRET ratio, where a higher ratio reflects the active 
conformation and a lower ratio reflects the inactive conformation (Fig. 3.7C).  Expression of 
SopBcs, the catalytically inactive negative control, had little effect upon FAK conformation.  
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These cells exhibited more activated FAK in focal adhesions than the cytoplasm, similar to 
the results shown in Figure 3.5A (Fig. 3.7C).  In contrast, SopB expression resulted in a 
decrease in activated FAK.  In these cells the level of FAK activation in focal adhesions was 
only slightly higher than the level of activation in the cytoplasm.  These findings demonstrate 
that PIP2 depletion reduces FAK activation in focal adhesions suggesting that PIP2 plays a 
role in regulating the conformation of FAK in cells adherent to fibronectin. 
3.5  Discussion 
The current model of FAK regulation evokes an intramolecular autoinhibitory 
interaction between the N-terminal FERM domain and central catalytic domain.  Mutational 
and biochemical studies support this hypothesis and the crystal structure of the 
FERM/catalytic domain complex provides insight into the mechanism of inhibition (91,289).  
However, using these technologies it is not possible to probe protein conformation in vivo.  
FRET technology is a powerful tool to study protein-protein interactions in living cells.  As 
FRET efficiency is dependent upon the distance between the two fluorophores and their 
relative orientation, changes in FRET correspond to changes in distance and orientation 
between the fluorescent probes, and in the case of a single protein fused to two fluorophores 
can reflect changes in conformation (304,329,357).  Here, we have developed genetically 
encoded FRET biosensors to visualize changes in FAK conformation in vivo.  These 
biosensors have provided two important pieces of evidence in support of the autoinhibitory 
model of FAK regulation.  First, the analysis of the biosensors provides support for the 
crystal structure of the FERM/catalytic domain complex.  CFP is encoded at the N-terminus 
of FAK in these biosensors and citrine was inserted at two different sites.  Based upon the 
crystal structure, the probe insertion sites in the CYFAK413 construct are approximately 20 
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Å apart, and in the CYFAK700 construct the insertion sites are predicted to be 70 Å apart.  
As predicted from the structure, the former exhibited a high FRET signal and the latter 
produced a weak FRET signal.  Second, using the conformational biosensor, this study 
provides for the first time direct evidence that a FAK conformational switch occurs in vivo 
and is associated with FAK activation.  In focal adhesions the probe exhibited an open 
conformation, whereas probes located in the cytoplasm exhibited a closed conformation.  
This is consistent with the body of literature implicating FAK as a cell adhesion regulated 
kinase and suggests that integrin signaling contributes to the FAK conformational change.  
Moreover, another stimulus of FAK activation, LPA, induced a change in the wild type FAK 
biosensor conformation but had no effect upon a mutant biosensor that is constitutively in the 
open conformation.  These findings demonstrate that multiple stimuli regulate the 
conformation of FAK and that conformational change is a general mechanism leading to 
FAK activation. 
Spatial regulation of FAK.  The FAK biosensors provide unique tools to investigate the 
spatial regulation of FAK.  Currently, immuno-staining using FAK phosphorylation specific 
antibodies is used for this purpose (380), but this approach has some disadvantages.  
Antibody specificity is a potential problem that is often not well controlled.  Further, tyrosine 
phosphorylation of FAK does not strictly correlate with catalytic activity (407).  It is 
impossible to probe FAK activity in live cells using these approaches and it is currently 
impossible to monitor the conformation change of FAK by immunostaining. 
The two biosensors report similar patterns of autophosphorylation/conformational 
activation.  Both indicate elevated autophosphorylation/activation in peripheral focal 
adhesions compared with internal focal adhesions.  Interestingly, this pattern is similar to the 
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pattern of cell traction forces in spreading cells, i.e. greatest traction forces at peripheral focal 
adhesions (18), which is consistent with a role for FAK in sensing mechanical stimuli.  In 
addition, results using both biosensors indicate an asymmetry in 
autophosphorylation/activation of FAK in polarized cells with the highest levels in areas of 
cell protrusion.  As FAK has been reported to regulate cell polarity (442), this asymmetric 
activation pattern may define the direction of polarization.  
FAK and Lipid Binding.  The FERM domain of FAK was shown to bind acidic 
phospholipids.  PIP2 binding is a mechanism of regulation of ezrin, radixin and moesin, but 
the molecular details of the interaction differ from FAK.  In radixin, the PIP2 headgroup 
associates with a basic pocket between the F1 and F3 subdomains of the FERM domain, 
whereas the corresponding site in FAK lacks the basic pocket (63,175).  Although the F3 
subdomain of FERM domains have a protein fold similar to PH domains, the F3 subdomain 
of FAK cannot bind phospholipids since it lacks the basic pocket that mediates the 
interaction of PH domains with phospholipids.  Instead, FAK appears to bind acidic 
phospholipids through surface exposed basic residues at the tip of the F2 subdomain.  Not 
surprisingly, the FERM domain of FAK binds PIP2 with lower affinity than PH domains.  In 
contrast with the 30 µM Kd of the FERM domain, the PH domains of PLCδ and SOS-1 are 
reported to bind PIP2 with Kds of ~2 µM (PLCδ and SOS-1)(192,260,274).  The affinity of 
the PH domain of spectrin ranges from 15-50 µM depending upon buffer conditions (183).  
Thus the affinity of the FAK FERM domain for PIP2 is in the range of lower affinity PH 
domain interactions.  It is also notable that there is precedent for PIP2 binding to surface 
basic residues of proteins.  For example, PIP2 associates with the tail domain of vinculin 
through surface basic residues rather than a discrete basic pocket (17,70).   
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The F2 basic patch is required for activation of FAK in response to cell adhesion and 
following HGF stimulation (79,117).  This sequence binds acidic phospholipids, lipid 
vesicles containing PIP2 alter the conformation of FAK in vitro, and elevating PIP2 levels in 
cells results in alteration of the conformation of FAK in vivo.  Further, reduction of PIP2 
levels by expression of SopB results in decreased activation of FAK in focal adhesions in 
cells adherent to fibronectin.  These findings support the hypothesis that acidic 
phospholipids, including PIP2, are physiologically relevant FAK FERM domain ligands that 
regulate the release of autoinhibitory interactions allowing FAK to adopt its active 
conformation.  Additional evidence from the literature demonstrates that acidic 
phospholipids are important for the activation of FAK.  Activation of FAK by stimulation of 
some G-protein coupled receptors is apparently blocked by depletion of PIP2 levels (303).  
Interestingly, a splice variant of PIP5KIγ co-localizes with FAK at focal adhesions and by 
localized generation of PIP2 might regulation FAK function (107,299).  Other studies have 
suggested that the activity of PI3 kinase is required for activation of FAK in response to a 
number of different stimuli (60,251,314).  We hypothesize that these acidic phospholipids 
might regulate FAK conformation through binding to the F2 basic patch.  Following HGF 
stimulation, this same sequence mediates binding to tyrosine phosphorylated Met to facilitate 
FAK activation (84).  These results suggest the intriguing hypothesis that a single site on the 
FERM domain of FAK can associate with either acidic phospholipids or phosphopeptides to 
trigger activation. 
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Fig. 3.1  Characterization of FAK auto-phosphorylation biosensor A)  The design of the 
FAK auto-phosphorylation biosensor is shown.  When tyrosine 397 is unphosphorylated, 
CFAK does not interact with citrine-dSH2 and FRET does not occur.  When tyrosine 397 is 
phosphorylated, CFAK interacts with citrine-dSH2 and FRET occurs.  (C = CFP, Y = citrine)  
B)  The FAK wild-type auto-phosphorylation biosensor and the CFAK-Y397F control 
biosensor were expressed in HEK293 cells and analyzed by fluorometry.  CFP was 
selectively excited at 425nm and the resulting emission spectra were normalized to the CFP 
emission peak. C)  FRET in the FAK biosensor was verified by acceptor photo bleaching in 
living cells. HEK293 cells were photo bleached using 488 nm laser. The emission spectra 
produced by CFP excitation were recorded before and after photobleaching.  Shown is the 
average of 3 experiments +/- SE.    
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Fig. 3.2.  Characterization of FAK conformation biosensor. A) The design of the FAK 
conformation biosensor (CYFAK413) is shown.  In the inactive conformation the CFP and 
citrine are in proximity and FRET occurs.  In the open conformation the CFP and citrine are 
further apart, and can rotate more freely, which will result in a reduced FRET signal.  B)  
Schematic structure of the FAK biosensor and control biosensors.  CFP is fused to the N-
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terminus.  The numbers in the construct name refer to the citrine insertion site. C)  
Normalized spectra of the FAK wild-type biosensor and control biosensors were measured 
by fluorometry.  D)  FRET in the FAK conformation biosensor was verified by acceptor 
photo bleaching in living cells.  HeLa cells expressing the biosensor were imaged in both 
CFP and citrine channels following excitation of CFP at 11-second intervals.  The acceptor 
(citrine) was photo bleached by pulse illumination for 6 seconds at each 11-second interval, 
after the zero time point. The mean intensity from whole cells was measured at each time 
point and normalized to the zero time point.  Shown is the average from 3 experiments +/- 
SE.  E)  Representation of the FERM/kinase domain interface was created using Pymol and 
illustrates the key interaction between F596 in the kinase domain and a hydrophobic pocket 
in the F2 subdomain of the FERM domain (105).   F)  Normalized spectra of the FAK wild-
type biosensor and a FAK biosensor with mutations designed to disrupt the FERM/kinase 
domain interaction are shown.  G)  Normalized FRET/CFP emission ratios of FAK 
biosensors containing different mutations are shown.  The constructs were analyzed as in Fig 
3.2C, and the FRET/CFP ratios of each were normalized to the FRET/CFP ratio of the wild 
type biosensor.  Shown is the average of at least 3 experiments +/- SE.  The results were 
analyzed by one-way anova (p<0.0001) and the Tukey’s multiple comparison post test 
(CYFAK413 versus each construct, p<0.001). 
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Fig. 3.3.  Biochemical characterization of the FAK conformational biosensor.  A)  
HEK293 cells expressing empty vector (Mock) or the indicated FAK constructs were lysed 
and immunoprecipitated using a FAK antibody.  The immune complexes were incubated in 
an in vitro kinase assay utilizing recombinant GST-paxillin-N-C3 as an exogenous substrate. 
Phosphorylation of paxillin was detected using the 4G10 phosphotyrosine antibody. Equal 
amounts of substrate were verified by blotting for paxillin using a polyclonal antiserum.  
FAK in the immune complexes was verified by blotting for FAK.  B)  The wild type and 
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mutant biosensors were transiently expressed in HeLa cells and adherent cells or cells 
incubated in suspension at 37°C for 1 hour were lysed.  The biosensors were 
immunoprecipitated using a GFP antibody and the immune complexes analyzed by Western 
blotting for phosphotyrosine using 4G10.  Equal amounts of FAK in the immune complexes 
were verified by blotting for FAK.  C)  HeLa cells expressing the FAK biosensor were serum 
starved and stimulated with LPA (200 ng/ml) for 5 minutes. The biosensor was 
immunoprecipitated from cell lysates and blotted with phosphotyrosine or a FAK antibody. 
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Fig. 3.4.  Spatial regulation of FAK activity. .A) HeLa cells expressing the FAK auto-
phosphorylation biosensor or the 397F control were trypsinized and plated on fibronectin 
coated cover slips. CFP, FRET and citrine images were sequentially captured by fluorescence 
microscopy.  CFP and FRETC/CFP ratio images of the cells are shown.  The ratio images are 
pseudocolored so that hotter colors reflect an increase in FAK auto-phosphorylation.  Shown 
are representative images (n>5 cells).  The boxed area in the CFAK + Citrine-dSH2 
FRETc/CFP image is shown at higher magnification to the right.  B)  HeLa cells expressing 
the FAK biosensor or the constitutively active mutant were trypsinized and plated on 
fibronectin coated cover slips.  CFP, FRET and citrine images were sequentially captured by 
fluorescence microscopy.  CFP and CFP/FRET ratio images of the cells are shown.  Note 
that the ratio images are pseudocolored so that hotter colors reflect an increase in the open, 
active conformation.  Representative images are shown (n>15 cells).   
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Fig. 3.5  Spatial and temporal regulation of FAK conformation. A)  The average 
CFP/FRET ratio of the cytoplasm or focal adhesions in HeLa cells expressing the wild type 
biosensor or the constitutively active variant is shown (average of n=4 cells).  The focal 
adhesion and cytoplasmic values were analyzed using an unpaired t test (*, p<0.0005).  B & 
C)  The relationship between biosensor activity and focal adhesion location is shown.  The 
distance of each focal adhesion from the cell margin is plotted versus the average CFP/FRET 
or FRETC/CFP ratio, where the highest ratio has been normalized to 100 per cent.  
Representative data from single cells is shown (n=4).  r = correlation coefficient.  D & E)  
HeLa cells expressing the FAK biosensor were serum starved and simulated with LPA (200 
ng/ml), EGF (50ng/ml) or PDGF (50ng/ml).  CFP and FRET images were sequentially 
captured at 1-minute intervals.  The mean CFP/FRET ratio of cells was calculated and 
normalized to the ratio at the time of stimulation. The change in the emission ratio of the 
FAK biosensor following EGF, PDGF or LPA stimulation is shown in A.  The change in the 
emission ratio of the wild type FAK biosensor is compared with that of the constitutively 
active FAK biosensor mutant following LPA stimulation in B.  Shown is the average 
response +/- SE (n=3 cells).  F)  HeLa cells expressing the biosensor were stimulated with 
LPA and lysed at the indicated times.  The biosensor was immunoprecipitated and blotted 
with a phosphotyrosine antibody (top) or FAK antibody as a loading control (bottom). 
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Fig. 3.6  PIP2 associates with FAK FREM domain. Acidic phospholipids bind the basic 
patch within FAK FERM domain.  A)  Normalized FRET/CFP emission ratios of the wild 
type FAK biosensor and the basic patch mutant are shown. The mutant FRET/CFP ratio was 
normalized to FRET/CFP ratio of the wild type biosensor.  Shown is a representative 
experiment (n=3).  B)  The purified recombinant FERM domain was incubated with 
BODIPY-labeled phospholipids and binding measured by fluorescence polarization.  
Anisotropy (mP – millipolarization units) is plotted against FERM domain concentration.  
The average of 3 experiments +/-SD is shown.  C)  PE/PC vesicles containing increasing 
amounts of PIP2 were incubated with a GST-FERM fusion protein.  The vesicles were 
sedimented by centrifugation and the amount of fusion protein in the vesicle containing pellet 
and the supernatant was determined was SDS-PAGE and Coomassie blue staining.  D)  
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PE/PC vesicles containing 10% (mass ratio) of the indicated lipids were incubated with the 
GST-FERM fusion protein and analyzed as in A. E)  PE/PC vesicles containing PIP2 or PI 
were incubated the wild type GST-FERM domain or a basic patch mutant (KAKTLRK) and 
analyzed as in A.  F,G)  HeLa cells expressing a YFP-FERM domain fusion protein or the 
basic patch mutant (KAKTLRK) were fixed, permeablized and then stained with rhodamine- 
phalloidin.  Fixed cells were observed by laser scanning confocal microscopy.  F)  The 
percentage of cells containing the YFP-FERM constructs in ruffles or at the membrane at the 
edge of the cell were scored (average of 3 experiments +/- SD; >100 cells counted per 
experiment; **, p<0.005; *, p<0.05).  G) Representative images of cells expressing the YFP-
FERM domain (2 left panels) or the YFP-FERM KAKTLRK mutant (right panel) are shown.   
Arrows indicate YFP-FERM localization in ruffles (left panel) and at the membrane at the 
periphery of the cell (middle panel). 
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Fig. 3.7  PIP2 induces conformation change in FAK. A) A recombinant fragment of FAK 
containing the FERM and catalytic domains was incubated with Src (SH3+SH2+Kinase) in 
the presence of the indicated liposomes in kinase reaction buffer, or in buffer alone for 30 
min.  As a control substrate a GST fusion protein containing a peptide mimicking the 
activation loop of FAK was used.  The reaction was terminated by the addition of sample 
buffer and phosphorylation of the substrates was examined by western blotting with a 
phosphotyrosine antibody.  B)  The wild type biosensor and the F2 basic patch mutant 
biosensor (KAKTLRK) were co-expressed with PIP5KIα or a catalytically defective mutant 
of PIP5KIα (KD).  The CFP/FRET ratio in each case was determined by fluorometry.  The 
average of 3 experiments +/- SE is shown.  The emission ratios observed in the presence of 
wild type and catalytically inactive PIPKIα were analyzed using an unpaired t test (*, 
p<0.05).  C)  The average CFP/FRET ratio of the cytoplasm or focal adhesions in HeLa cells 
co-expressing the wild type biosensor and wild type SopB or the catalytically inactive mutant 
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SopBcs is shown (average of n=6 cells+/-SE). The focal adhesion values in SopB and 
SopBcs expressing cells were analyzed using an unpaired t test (*, p<0.0025).   
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Fig 3.8  The emission ratio of FAK auto-phosphorylation biosensor.  The FAK wild-type 
auto-phosphorylation biosensor and the CFAK-Y397F control biosensor were expressed in 
HEK293 cells and analyzed by fluorometry.  CFP was selectively excited at 425nm and the 
resulting emission spectra were measured.  Shown are the average FRET/CFP ratios 
(normalized to the wild type biosensor).  The average of 3 experiments +/- SE is shown. 
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Figure 3.9  The expression of FAK biosensors.  A) Lysates of 293 cells expressing the wild 
type or Y397F mutant autophosphorylation biosensor were probed with a GFP antibody to 
compare expression levels.  B)  Lysates of 293 cells expressing the wild type and mutant 
conformation biosensors, which are analyzed in Fig. 3.2, were Western blotted with a FAK 
antibody to compare levels of expression.  C)  Lysates of HeLa cells expressing the wild type 
or Y397F mutant autophosphorylation biosensors, which are analyzed in Fig. 3.5, were 
blotted for GFP to compare expression levels.  D)  Lysates of HeLa cells expressing the wild 
type conformation biosensor and the Y180AM183A constitutively active mutant, which are 
analyzed in Fig. 3.5, were probed with a FAK antibody to compare levels of expression.  E)  
Lysates of HeLa cells expressing the wild type FERM domain or the KAKTLRK mutant 
FERM domain, which are analyzed in Fig. 3.6, were Western blotted with a GFP antibody to 
compare expression levels.  F)  Lysates of 293 cells expressing the wild type conformation 
biosensor, the KAKTLRK mutant and PIPK5 kinase variants, which are analyzed in Fig. 3.7, 
were Western blotted for FAK to compare expression levels of the biosensor or PIP5 kinase 
to compare expression levels of the wild type and mutant proteins. 
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Fig 3.10  FAK auto-phosphorylation in focal adhesions.  HeLa cells expressing GFP-FAK 
were fixed and stained with the PY397 antibody and rhodamine labeled secondary antibody.  
The top panel shows the PY397 staining pattern.  The lower panels show a higher 
magnification of the boxed region.  The left panel is the PY397/GFP ratio image, the middle 
panel is the GFP image and the right panel is the PY397 image. 
  
CHAPTER 4 
Pyk2 Regulates Fcγ Receptor Mediated Phagocytosis in Macrophage
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4.1  Abstract 
Pyk2 is a non-receptor tyrosine kinase expressed in a variety of tissues including cells 
derived from hematopoietic lineages.  It regulates cell migration, survival and cell 
morphology.  Here we report that Pyk2 is involved in regulating Fcγ receptor (FcγR) 
meditated phagocytosis in macrophages.  Pyk2 is tyrosine phosphorylated following 
stimulation of the FcγR and this occurs through a Src family kinase and Syk dependent 
mechanism.  Further, Pyk2 is enriched in phagocytotic cups during phagocytosis of IgG 
opsonized particles.  RNAi, pharmacological and genetic approaches were used to 
demonstrate that Pyk2 is required for efficient FcγR mediated phagocytosis in a macrophage 
cell line and primary macrophages.  Biochemical studies suggest that Pyk2 regulates 
downstream tyrosine phosphorylation events during phagocytosis, most strikingly of 
cytoskeletal targets.  The results implicate Pyk2 as a regulator of FcγR-mediated 
phagocytosis and demonstrate that Pyk2 is required for optimal particle engulfment.  
4.2  Introduction 
Proline-rich tyrosine kinase (Pyk2) is a member of the focal adhesion kinase (FAK) 
family of kinases and shares a number of characteristics with FAK (15).  Pyk2, like FAK, 
contains three major domains: an N-terminal FERM domain, a central kinase domain, and a 
C-terminal domain that contains binding sites for signaling molecules and the focal adhesion 
targeting (FAT) sequence of FAK.  Pyk2 and FAK also share many binding partners.  Both 
Pyk2 and FAK are activated by a number of stimuli, including integrin-dependent cell 
adhesion, growth factors and ligands for GPCRs.  Pyk2 and FAK can regulate similar 
biological events, e.g. regulation of the cytoskeleton to control cell spreading and cell 
migration.  However, there are a number of differences between Pyk2 and FAK, and the two 
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are not simply redundant.  FAK is prominently localized to focal adhesions in adherent cells, 
whereas Pyk2 is not well localized in focal adhesions (121,398).  However, in response to 
certain stimuli, Pyk2 can dramatically re-localize to focal adhesions (305).  FAK is 
ubiquitously expressed in almost all tissues, while Pyk2 expression is restricted to specific 
tissues, like neuronal, epithelial and hematopoietic cells.  Some of these tissues express both 
FAK and Pyk2, whereas other cells like macrophages predominantly express Pyk2 and 
express FAK at relatively low levels (122).  Interestingly, pyk2-/- mice exhibit hematopoietic 
cell defects, including reduced marginal zone B cells in the spleen, defective recruitment of 
macrophages to sites of inflammation and altered macrophage morphology and 
motility(166,339).  
As “professional phagocytes” an important function for macrophages is the 
engulfment of foreign particles.  Particle engulfment can occur through multiple 
mechanisms, including direct engulfment of particles, e.g. bacteria, FcγR-mediated 
phagocytosis and complement-mediated phagocytosis (453).  These are important cellular 
anti-microbe strategies in innate immunity that are distinguished by the receptors and 
signaling mechanisms controlling particle engulfment.  During FcγR-mediated phagocytosis, 
immunoglobulin opsonized pathogens are recognized and bound by cell surface FcγR, the 
particles engulfed by the cell and the internalized pathogens are destroyed in the phagosome.  
Multiple signal pathways cooperate to orchestrate the phagocytic process, including 
pathways controlled by tyrosine kinases, lipid kinases and the Rho family of GTPases (432).  
When IgG-opsonized microbes interact with the FcγR, two members of the Src family of 
tyrosine kinases, Lyn and Hck, are activated and induce the tyrosine phosphorylation of the 
ITAM motifs in the cytoplasmic tail of the FcγR.  This creates a high affinity binding site for 
125 
 
the SH2 domains of Syk and Syk is recruited to the tyrosine phosphorylated ITAM.  Syk is 
responsible for triggering the activation of downstream signals, which includes the Rho 
family and PI3 kinase signaling pathways.  Two members of the Rho family, Cdc42 and Rac, 
are implicated in controlling cytoskeletal events associated with particle engulfment.  Cdc42 
regulates the formation of the phagocytotic cup and Rac regulates closure of the phagocytic 
cup and particle engulfment.  However, the function of RhoA in FcγR-mediated phagocytosis 
is still controversial due to the inconstant results from the different kind of cells (53,173).  
PI3K signaling is critical for the phagosome formation (433).  It could be also evolved in the 
other stages of phagocytosis, such as pseudopod extension (101).  
Since Pyk2 regulates cytoskeleton rearrangements both in macrophages and 
fibroblasts, and previous studies demonstrate that Pyk2 is activated in human macrophages 
following binding of IgG coated beads (245), it seems likely that Pyk2 may also play a role 
in controlling FcγR mediated phagocytosis.  Our data support the hypothesis that Pyk2 is 
involved in macrophage signaling during phagocytosis.  Pyk2 is activated upon ligand 
binding to the FcγR and accumulates at the phagocytotic cup during phagocytosis.  Multiple 
strategies were employed to inhibit Pyk2 in a macrophage cell line and primary 
macrophages.  These results demonstrate that inhibition of Pyk2 signaling impairs FcγR 
mediated phagocytosis.  Further, these results implicate Pyk2 in the control of tyrosine 
phosphorylation of cytoskeletal proteins and in inducing maximal activation of PI3 kinase in 
response to FcγR signaling. 
4.3  Methods 
Cells and reagents.  RAW264.7 cells were maintained in Dulbecco's modified Eagle's 
medium (DMEM) containing 10% fetal bovine serum (FBS).  HEK293T cells were 
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maintained in DMEM-F12 containing 10% FBS.  Bone marrow–derived macrophages were 
isolated and cultured as described (137).  Wortmannin and PP2 were purchased from 
Calbiochem.  The small molecule Pyk2 and FAK inhibitors, GR-222 and PF-228, were from 
Pfizer.  Phosphotyrosine (4G10) and FAK antibodies (447) were from Millipore.  
Phosphospecific antibodies recognizing FAK, ERK and Akt were from Invitrogen.  Syk, 
ERK2 and general mouse IgG antibodies were from Santa Cruz and the Akt antibody was 
from Cell Signaling.  The actin antibody was from Chemicon and the GFP antibody was 
from Roche.   
Plasmid and siRNA oligos transfection.  HEK293T cells were transfected using 
Lipofectamine Plus according to the manufacturer's instructions (Invitrogen, Carlsbad, CA).  
Raw264.7 cells were transfected with the Amaxa Nucleofector Kit V according to the 
manufacturer's instructions.  For siRNA assay, RAW264.7 cells were transfected with 100 
nM siRNA using Transit TKO® according to the manufacturer's instructions (Mirus, 
Madison, WI).  The FAK siRNA sequence is 5’-AAGAUUACCAAUGCCUCCAAA-3’.  
Pyk2 siRNA (smart pool®) is designed by Dharmacon.  All oligos were synthesized by 
Dharmacon (Lafayette, CO). 
Immunostaining and imaging.  Raw264.7 cells expressing fluorescent proteins were seeded 
on cover slips and incubated with IgG opsonized latex beads.  Cells were fixed in 3.7% 
formaldehyde and imaged using a Zeiss LSM510 confocal microscope.  Bone marrow–
derived macrophages were seeded on cover slips and incubated with IgG opsonized RBCs.  
Cells were fixed in 3.7% formaldehyde solution for 8 min.  The fixed cells were 
permeablized with 0.1% Triton X-100 for 5min.  Non-specific binding to the FcγR was 
blocked by Fc-Block®.  Pyk2 was detected using Pyk2 mAb (BD Transduction Laboratories) 
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and a fluorescein-conjugated anti-mouse antibody (Jackson ImmunoResearch Labs) as 
described previously (46).  The fixed cells were visualized using fluorescence microscopy. 
Molecular biology.  Pyk2 point mutations were created by PCR using the Quick-Change 
mutagenesis kit (Stratagene, La Jolla, CA).  Sequence analysis was performed on each mutant 
to verify the intended point mutations and that no unintended mutations were present.  Pyk2 
truncation mutants were created by subcloning PCR amplified Pyk2 fragments into the 
pcDNA or Citrine vectors.  
FcγR mediated phagocytosis and binding assays.  To prepare IgG opsonized red blood 
cells (RBCs), RBCs were washed with 100ul PBS twice.  The washed RBCs were incubated 
with rabbit-anti-sheep RBCs (1:300) for 1h at room temperature.  The opsonized RBCs were 
washed with PBS once and diluted to 4*106/ml.  Raw264.7 cells were split into 24 well 
dishes (1*105 cells/well) in culture medium for 2h. Then the cells were serum starved for 
another 2h and incubated with opsonized RBCs at 37ºC for various times.  The cells were 
washed twice with serum free medium.  RBCs that were not engulfed by the macrophages 
were lysed by incubation in distilled water for 30 seconds.  The cells were fixed in 3.7% 
paraformaldehyde.  The percentage of phagocytic cells (containing at least one red blood 
cell) was determined by counting under a microscope.  In some experiments, the 
macrophages were incubated with drugs for 1h before the assay.  The phagocytosis assay 
using IgG opsonized latex beads was performed as previous described (321).  For the binding 
assay, macrophages were incubated with opsonized RBCs at 4ºC for 20min.  The cells were 
washed twice with SFM and fixed in 3.7% paraformaldehyde.  The binding index was 
counted as the number of RBCs per cell.  
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Phagocytosis biochemical assay.  Bone marrow cells were seeded in p35 dish and incubated 
at 37oC for 7 days.  Then differentiated macrophages were serum starved overnight and 
equilibrated with assay medium (DMEM, 0.1%BSA, 10mM HEPES PH7.4) on ice.  The 
cells were incubated with the 2.4G2 monoclonal antibody (10ug/ml, BD Pharmingen) for 
30min.  After two washes with ice-cold assay medium, FcγR were clustered by addition of 
30ug/ml rabbit anti-rat IgG (Sigma) in assay medium and incubation at 37 ºC for various 
times prior to lysis.  For stimulation, ice cold cells were incubated with opsonized RBCs for 
30 min at 4 ºC and transferred to 37 ºC for various times.  The cells were washed with serum-
free medium and lysed.  
Cell lysis, protein analysis, and immunoprecipitation.  Cells were lysed in ice-cold 
modified radioimmunoprecipitation assay buffer.  Lysates were clarified, and protein 
concentrations were determined using the bicinchoninic acid assay (Pierce, Rockford, IL).  
For immunoprecipitations, antibodies were incubated with cell lysate at 4°C for 1 h. Immune 
complexes were precipitated at 4°C for 1 h with protein A-Sepharose beads (Sigma, St. 
Louis, MO) coated with AffiniPure rabbit anti-mouse immunoglobulin G (Jackson 
ImmunoResearch Labs, West Grove, PA).  Immune complexes were washed twice with ice-
cold lysis buffer and once with ice-cold PBS.  Beads were resuspended in sample buffer and 
boiled to elute the proteins, and the samples were analyzed by Western blotting.  
4.4  Results 
FcγR mediated phagocytosis induces tyrosine phosphorylation of multiple signaling 
proteins.  Clustering the FcγR in bone marrow derived macrophages using a specific 
antibody, 2.4G2, resulted in increased tyrosine phosphorylation (Fig. 4.1A).  Tyrosine 
phosphorylation was also enhanced when cells were challenged with IgG opsonized RBCs, 
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which induce FcγR mediated phagocytosis (Fig. 4.1A).  One evident tyrosine phosphorylated 
band exhibits a molecular weight similar to Pyk2 suggesting that this tyrosine kinase may be 
a substrate for phosphorylation following the activation of FcγR.  To test this possibility 
Pyk2 was immunoprecipitated from these lysates and Western blotted using a 
phosphotyrosine antibody.  The result indicates that tyrosine phosphorylation of Pyk2 was 
increased following FcγR clustering, suggesting that Pyk2 was activated during FcγR 
mediated phagocytosis (Fig. 4.1B). In addition to Pyk2, FAK was also examined.  While 
FAK is expressed at very low levels in macrophages, other phagocytic cells, such as 
neutrophils, express FAK, as do a number of macrophage cell lines, such as J774 and 
Raw264.7 cells (133).  Tyrosine phosphorylation of FAK was measured in Raw 264.7 cells 
following stimulation with IgG-opsonized RBC or FcγR crosslinking (Fig. 4.1C).  These 
results demonstrate that FAK is also tyrosine phosphorylated during FcγR mediated 
phagocytosis.  To investigate the molecular mechanism regulating Pyk2 tyrosine 
phosphorylation, primary macrophages were pre-treated with the pharmacological inhibitors 
prior to stimulation of FcγR.  Tyrosine phosphorylation of Pyk2 was blocked by both PP2 (an 
inhibitor of the Src family kinases), piceatannol (an inhibitor of Syk) and Syk inhibitor III 
(Fig. 4.1D).  All drugs blocked tyrosine phosphorylation of Pyk2 in response to crosslinking 
of FcγR.  Interestingly, tyrosine phosphorylation of Pyk2 is unimpaired upon treatment with 
wortmanin, which is an inhibitor of PI3 kinase (Fig. 4.1D).  These results suggest that 
phagocytosis induced Pyk2 tyrosine phosphorylation depends upon the SFK/Syk activation 
but not lipid signaling.  
The subcellular localization of Pyk2 during phagocytosis was also investigated.  
Raw264.7 cells co-expressing YFP-Pyk2 and the empty pECFP vector were incubated with 
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IgG opsonized beads and the fluorescent probes visualized using confocal microscopy.  YFP-
Pyk2 accumulated in the phagocytotic cup, whereas CFP was not enriched in this region of 
the cell (Fig. 4.2A).  The spatial distribution of endogenous Pyk2 was investigated in primary 
bone marrow derived macrophages.  The macrophages were incubated with IgG opsonized 
RBCs and immunostained using a Pyk2 monoclonal antibody.  Fc-Block® was used to block 
non-specific binding to the FcγR.  Phagocytic cups were visualized by phase contrast 
microscopy (Fig. 4.2B).  Endogenous Pyk2 was also enriched in phagocytotic cups during 
phagocytosis (Fig. 4.2B).  A non-specific mouse IgG was used as a negative control for the 
Pyk2 monoclonal antibody and produced no evident immunofluorescent signal in the cells.  
These results demonstrate that Pyk2 is also recruited to sites of FcγR mediated phagocytosis. 
The interaction of Pyk2 with tyrosine kinases implicated in the regulation of 
phagocytosis was tested.  Both Pyk2 and FAK are known to interact with Src and other 
members of this family of tyrosine kinases and myeloid expressed Src family kinase 
members play a role in the control of FcγR mediated phagocytosis (136).  To further explore 
these interactions, Lyn-GFP was co-expressed with Pyk2 in 293T cells and the two were 
found to associate by co-immunoprecipitation and Western blotting (Fig. 4.3A).  Pyk2 was 
recovered from Lyn immune complexes and GFP-Lyn was detected in Pyk2 immune 
complexes.  As anticipated the auto-phosphorylation site (Y402) of Pyk2, which conforms to 
a high affinity Src SH2 domain binding site, was required for this interaction (Fig. 4.3B).  
Syk is a second tyrosine kinase implicated in the regulation of FcγR mediated phagocytosis 
and a Pyk2/Syk complex transiently forms following TNF stimulation of neutrophils (177).  
The interaction of Syk with Pyk2 was therefore further investigated.  GFP-Syk and Pyk2 
were co-expressed in 293T cells and complexes examined by co-immunoprecipitation and 
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Western blotting (Fig. 4.3A).  Pyk2 was detected in Syk immune complexes and Syk was 
found in Pyk2 immune complexes.  Interestingly, the Pyk2 auto-phosphorylation site is not 
required for this interaction, which suggests that Lyn and Syk interact with Pyk2 via different 
mechanisms (Fig. 4.3B).  Very similar results were obtained with FAK.  Upon co-expression 
in 293T cells FAK associated with Lyn and Syk (Fig. 4.3C).  Further the association of FAK 
with Lyn required the autophosphorylation site of FAK (Y397) whereas binding to Syk did 
not (Fig. 4.3D).  The interaction with Syk was mediated by the N-terminal FERM domain of 
Pyk2.  Whereas wild type Pyk2 co-immunoprecipitated with Syk, a Pyk2 mutant with a 
deletion of the N-terminal domain of Pyk2 (Pyk2ΔN) failed to associate with Syk (Fig. 4.3E).  
Further, when Syk was co-expressed with the FERM domain of Pyk2, expressed as a citrine-
FERM domain fusion protein, Syk was co-immunoprecipitated with citrine-FERM (Fig. 
4.3F).  This interaction was verified using an in vitro pull down assay.  A GST-Pyk2 FERM 
domain fusion protein bound Syk from cell lysates, whereas the GST control did not (Fig. 
4.3G).  While the interaction with FAK and Src family kinases is well established, it was 
important to demonstrate that endogenous Pyk2 and Syk could form a complex.  The 
complex between the endogenous proteins was identified in Raw264.7 cells by co-
immunoprecipitation and Western blotting (Fig. 4.3H).   
The FcγR mediated tyrosine phosphorylation of Pyk2 and translocation of Pyk2 to 
phagocytic cups suggests that Pyk2 may play an important role in phagocytosis.  Similarly, 
FAK could also play an important function in phagocytosis.  This may be true in macrophage 
cell lines, like Raw264.7 cells, which express both tyrosine kinases.  However, in primary 
macrophages, which express predominantly Pyk2 and very low levels of FAK, Pyk2 seems 
the more likely candidate (Fig. 4.4A).  The function of Pyk2 in phagocytosis was 
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investigated using multiple strategies.  First, the expression of Pyk2 and FAK in Raw264.7 
cells was diminished using siRNAs.  These siRNAs effectively reduced expression of the 
target protein (Fig. 4.4B).  Two different assays were performed to evaluate phagocytosis.  
The first assay utilized IgG-opsonized latex beads and the second IgG-opsonized RBCs as 
targets for phagocytosis.  Using both assays, the phagocytic activity of Raw264.7 cells was 
evidently impaired by siRNA knockdown of Pyk2 or FAK (Fig. 4.4C and D).  Maximal 
impairment of phagocytosis was achieved when both Pyk2 and FAK were silenced in these 
cells.  However, the binding index of IgG-opsonized RBCs was not changed in these cells, 
suggesting that Pyk2 and FAK had no effect on the ability of the FcγR to bind its ligand and 
were required for a subsequent step in phagocytosis.  The second method to address the 
function of Pyk2 and FAK in phagocytosis used a pharmacological strategy.  Recently, small 
molecule inhibitors recognizing FAK (PF-228) or both FAK and Pyk2 (GR-222) were 
developed (428).  These were tested in Raw264.7 cells.  Tyrosine phosphorylation of FAK 
was dramatically impaired by both drugs, whereas Pyk2 phosphorylation was inhibited by 
GR-222, but not by PF-228 (Fig. 4.4E).  The effect of these inhibitors on FcγR  mediated 
phagocytosis was then tested in Raw264.7 cells (Fig. 4.4F).  Interestingly, phagocytosis was 
partially impaired by PF-228, which inhibited FAK but not Pyk2, and phagocytosis was 
dramatically impaired by GR-222, which targeted both kinases.  Again, inhibition of FAK 
and Pyk2 had no effect upon binding IgG-opsonized particles.  The effect of Rho kinase in 
FcγR mediated phagocytosis was also tested since Rho kinase is also potentially inhibited by 
GR-222, albeit at higher concentrations than Pyk2 and FAK.  Phagocytosis was unimpaired 
when cells were treated with Y-27632, which is consistent with previously published data 
(342).  Thus, the effect of GR-222 on phagocytosis was apparently due to its effects upon 
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Pyk2 and FAK.  The third strategy used a genetic approach to investigate the function of 
Pyk2 in primary macrophages.  The phagocytic ability of bone marrow derived macrophages 
isolated from wild type and pyk2-/- mice was compared.  The pyk2-/- macrophages exhibited a 
deficiency in the phagocytosis of IgG-opsonized RBCs that was more evident at early times 
than at later times (Fig. 4.4G).  The null macrophages exhibited binding of opsonized RBCs 
that was comparable to wild type macrophages (Fig. 4.4H).  The results of all three 
experimental approaches support the hypothesis that Pyk2 functions to regulate 
FcγR  mediated phagocytosis in macrophages.  In cells also expressing FAK, e.g. Raw264.7 
cells, FAK also plays a role in regulating phagocytosis. 
Since Pyk2 is involved in the FcγR mediated phagocytosis, it is interesting to 
understand which pathways are regulated by Pyk2 in phagocytosis.  The tyrosine 
phosphorylation pattern was compared between wild type and pyk2-/- bone-marrow derived 
macrophages.  The increased phosphorylation of some specific bands was partially impaired 
(Fig. 4.5A).  Several specific signaling pathways were examined based upon the role of 
Pyk2/FAK in regulating ERK activation, PI3K signaling and tyrosine phosphorylation of 
adhesion-associated proteins.  ERK is activated during FcγR-mediated phagocytosis and 
crosslinking of FcγR in primary macrophages.  The level of ERK activation in wild type and 
pyk2-/- macrophages was similar suggesting that Pyk2 is dispensable for FcγR-induced ERK 
activation (Fig. 4.5 B).  PI3K signaling was monitored by measuring Akt phosphorylation.  
Akt phosphorylation was dramatically increased during FcγR-mediated phagocytosis and 
crosslinking of FcγR.  There was a modest reduction in Akt phosphorylation in the null 
macrophages, suggesting that Pyk2 plays a minor role in regulating PI3K and Akt 
phosphorylation during the phagocytosis of IgG-opsonized particles (Fig. 4.5 B).  Paxillin is 
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a Pyk2 substrate that translocates to the phagocytotic cup in FcγR mediated phagocytosis 
(162,243).  The tyrosine phosphorylation of paxillin is enhanced during receptor crosslinking 
and FcγR-mediated phagocytosis.  The pyk2-/- macrophages exhibited a dramatic deficiency 
in tyrosine phosphorylation of paxillin, demonstrating an important role for Pyk2 in 
controlling paxillin tyrosine phosphorylation during FcγR-mediated phagocytosis in primary 
macrophages (Fig. 4.5B).   
4.5  Discussion 
Here, we report that Pyk2 is involved in FcγR-mediated phagocytosis.  Pyk2 is 
translocated to the phagocytotic cup and becomes tyrosine phosphorylated during 
phagocytosis.  Pyk2 interacts with two important kinases that regulate phagocytosis of IgG 
opsonized particles, Lyn and Syk.  Pharmacological studies suggest that tyrosine 
phosphorylation of Pyk2 depends on the activity of those two tyrosine kinases.  The 
activation of Pyk2 is independent of PI3K.  As pyk2-/- macrophages exhibit a modest 
reduction in phosphorylation of Akt, Pyk2 might play a minor role in regulating PI3K 
signaling.  These cells showed a dramatic reduction in tyrosine phosphorylation of paxillin 
during phagocytosis, demonstrating a key role for Pyk2 in regulating phosphorylation of 
cytoskeletal proteins during this process.  Most importantly, cells lacking Pyk2 or treated to 
inhibit Pyk2 catalytic activity exhibit impaired FcγR-mediated phagocytosis.  While other 
studies have alluded to a role in phagocytosis, this is the first report directly demonstrating 
that Pyk2 regulates FcγR-mediated phagocytosis.   
During FcγR-mediated phagocytosis, Pyk2 activation depends on Src family kinases 
and Syk.  The pharmacological approach does not distinguish which myeloid specific Src 
family kinase is responsible, but given the redundancy of the members of the family, it is 
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likely that both Lyn and Hck can regulate Pyk2 phosphorylation.  It is well established that 
Src family kinases associate with the focal adhesion family kinases by SH2 domain 
interactions and regulate Pyk2/FAK tyrosine phosphorylation (51,110,390,405).  Pyk2 is 
reported to associate with Syk and the related tyrosine kinase, Zap70 (178,242).  Our study 
has extended these observations to determine one mechanism of interaction between these 
kinases.  The N-terminal FERM domain of Pyk2/FAK mediates this interaction.  The FERM 
domain functions as a negative regulatory element to control catalytic activity of FAK, and 
presumably Pyk2, and also serves a scaffolding function by docking with a number of other 
proteins.  Phosphorylation of Pyk2 is reportedly controlled by Syk in a number of scenarios 
(52,449,495).  There is some concern regarding the use of piceatannol as a Syk inhibitor in 
studies exploring Pyk2 signaling, since piceatannol is known to directly inhibit the catalytic 
activity of the Pyk2-related kinase, FAK (264).  Our study supports these pharmacological 
studies by using another Syk inhibitor to document a role for Syk in controlling Pyk2 
phosphorylation during phagocytosis.  Genetic approaches have also been applied to define a 
role for Syk upstream of FAK.  For example, a variant of the RBL 2H3 mast cell line lacking 
Syk shows a defect in Pyk2 tyrosine phosphorylation in response to FcεRI signaling (336). 
Pyk2 possibly regulates phagocytosis via several different mechanisms.  Pyk2 may 
regulate signaling via phospholipids in macrophages since the pyk2-/- macrophages exhibit a 
modest decrease in Akt phosphorylation during phagocytosis.  However, the modest 
reduction indicates that Pyk2 plays a lesser role and other signaling pathways predominantly 
function in controlling PI3K signaling during phagocytosis. Other studies support a role for 
Pyk2 in the regulation of PI3K in response to other stimuli.  For example, pyk2-/- 
macrophages exhibit defects in PI3K activation in response to integrin dependent cell 
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adhesion (337).  The pharmacological inhibitors of Pyk2/FAK used in this study are 
competitive inhibitors of ATP and since they inhibit phagocytosis, the phosphorylation of 
downstream substrates is implicated in the regulation of phagocytosis by Pyk2.  Paxillin 
phosphorylation is markedly defective for phosphorylation in pyk2-/- macrophages.  This is 
potentially a mechanism of regulation of phagocytosis by Pyk2.  Tyrosine phosphorylation of 
paxillin creates binding sites for the Crk adaptor protein (395), which in turn can recruit 
guanine nucleotide exchange factors for Rho family proteins into complex.  One such 
exchange factor, the Dock180/Elmo complex, functions to promote GTP binding to Rac and 
was identified as a Crk binding protein (184).  Interestingly, CrkII and Dock180/Elmo were 
recently implicated in controlling Rac activation and FcγR-mediated phagocytosis in RAW 
264.7 cells (271).  This signaling pathway is potentially under the control of Pyk2 in primary 
macrophages and will be an important area of investigation in future studies. 
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Figure 4.1  Pyk2 is tyrosine phosphorylated in a Src family kinase- and Syk-dependent 
manner during FcγR mediated phagocytosis. A) Bone marrow derived macrophages were 
stimulated by incubation with the anti- FcγR mAb 2.4G2 followed by anti–rat IgG cross-
linking or by addition of IgG opsonized RBCs for the indicated times.  Cells were lysed, and 
equivalent amounts of cellular protein were Western blotted with pTyr (4G10) antibody.  A 
band exhibits a molecular weight similar to Pyk2 is labeled with arrow. B) Bone marrow 
derived macrophages were stimulated by incubation with the anti- FcγR mAb 2.4G2 
followed by anti–rat IgG cross-linking for the indicated time.  Pyk2 was immunoprecipitated 
using the Pyk2 mAb and Western blotted with indicated antibodies. C) Raw264.7 cells  were 
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stimulated by incubating with anti- FcγR mAb (2.4G2) followed by anti–rat IgG cross-
linking or IgG opsonized RBCs for the indicated times.  Cells were lysed, and equivalent 
amounts of cellular protein were blotted with FAK and FAK pY397 antibodies. D) BMMs 
were pretreated with DMSO or the indicated inhibitors and stimulated by incubation with 
anti- FcγR mAb 2.4G2 followed by anti–rat IgG cross-linking for the indicated time.  Pyk2 
was immunoprecipitated using the Pyk2 mAb and blotted with indicated antibodies. 
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Figure 4.2  Pyk2 accumulates in phagocytotic cups during FcγR mediated phagocytosis. 
A) Raw 264.7 cells co-expressing YFP-Pyk2 and CFP were incubated with IgG opsonized 
latex beads for 5min. The cells were fixed and visualized by laser confocal microscopy. B) 
BMMs were stimulated with IgG opsonized RBC for 5min.  Localization of Pyk2 was 
visualized by immunofluorescence using a Pyk2 monoclonal antibody.  Mouse IgG was used 
as negative control.  
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Figure 4.3  Pyk2 interacts with Lyn and Syk via different mechanisms. A-F) 293T cells 
expressing indicated constructs were lysed and immunoprecipitated with indicated 
antibodies.  The immune complexes were blotted with indicated antibodies. G) Raw264.7 
cells were lysed, precleared with GST, and then incubated with GST or GST-FERM (Pyk2).  
Endogenous Syk bound to the beads were detected by western blotting using Syk antibody.  
The equivalent amounts of GST fusion protein were visualized by Coomassie blue staining. 
H) Raw264.7 cells lysed and immunoprecipitated with a Pyk2 antibody.  The immune 
complexes were blotted with indicated antibodies.  
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Figure 4.4  Pyk2 and FAK regulate FcγR mediated phagocytosis.  A) Equivalent amounts 
of indicated cell lysates were blotted with FAK, Pyk2 and Actin antibodies. B) Raw264.7 
cells were transfected with indicated siRNA oligos. The cells were lysed after 48h and 
blotted with Pyk2 and FAK antibodies. C) Raw264.7 cells were transfected with indicated 
siRNA for 48h and then incubated with anti-BSA rabbit IgG opsonized latex beads for 
20min.  The cells were fixed and stained with rhodamine-conjugated anti-Rabbit IgG to 
visualize the non-internalized beads.  The phagocytosis index was quantified and normalized 
to the control cells.  Data represents means ±Standard deviation from three separate 
experiments.  More than 100 cells were counted per experiment.  The P value is less than 
0.01 (Dunnet assay). D) Raw264.7 cells were transfected with indicated siRNA.  The IgG 
opsonized RBC phagocytosis and binding assay were performed as described in methods.  
The percentage of phagocytosis cell and RBCs binding index were quantified and normalized 
to the control cells.  Data represent ±Standard deviation from three separate experiments.  
More than 100 cells were counted per experiment.  The P value is less than 0.01 (Dunnet 
assay). E) Raw264.7 cells were treated with DMSO, GR-222(1μM), PF-228(3 μM) for 1h 
and then cells were lysed and blotted with FAK and FAKpY397 antibodies.  Pyk2 was 
immunoprecipitated using the Pyk2 mAb and blotted with Pyk2 and p-Tyr antibodies.  F) 
Raw264.7 cells treated with DMSO, GR-222 (1μM), PF-228 (3 μM) ,for 1h.  The 
phagocytosis and binding assay were performed as described in methods. The P value is less 
than 0.01 for these groups (Dunnet assay).  Raw 264.7 cells were also treated with Y-27632 
as a control.  G) BMMs from wild type and Pyk2-/- mice were treated with IgG opsonized 
RBC.  The percentage of phagocytosis cell in indicated time points was quantified.  Data 
represent ±Standard deviation from three separate experiments.  More than 200 cells were 
counted per experiment. H) The IgG opsonized RBC binding index of BMMs from wild type 
and Pyk2-/- mice.  Data represent ±Standard deviation from three separate experiments.  
More than 200 cells were counted per experiment. 
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Figure.4.5  Pyk2 is required for FcγR mediated phagocytosis signaling. A-B).BMMs 
from wild type or Pyk2-/- mice  were stimulated by incubation with anti-FcγR mAb (2.4G2) 
followed by anti–rat IgG cross-linking or IgG opsonized RBCs for the indicated times.  Cells 
were lysed, and equivalent amounts of cellular protein were blotted with indicated antibodies. 
  
CHAPTER 5 
Future Directions 
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5.1  Future Directions For FAK Biosensor 
A FAK conformational switch has proven to be an important regulatory mechanism 
for FAK activation. The conformational auto-inhibition model was first proposed based on 
biochemical studies, which was recently supported by the crystal structure of the 
FERM/Kinase domain in complex (87,94,288,448).  Our FRET based biosensor successfully 
visualizes FAK conformation in vivo (364).  The spatial and temporal regulation of FAK 
conformational switch was revealed in our study.  However, there are a number of puzzles 
still waiting to be resolved. 
5.1.1  Where Does FAK Change Its Conformation? 
Our study suggests that FAK keeps open conformation within focal adhesions.  
However, the spatial regulation of FAK conformational switch in migrating cells is still 
unclear.  A number of technical challenges make it hard to track the FRET signals in 
migrating cells.  A long time exposure (2s per channel) of the cell to fluorescent light not 
only induces photo damage of the cell but also induces the photobleaching of fluorescent 
proteins.  Moreover, the different photobleaching dynamics of CFP and Citrine might bring a 
systemic error into the final analysis.  However, some novel technologies in microscopy may 
solve this problem.  TIRF is a technology which illuminates a very thin layer of the 
specimen, e.g. 200nm.  This greatly diminishes the photo bleach and phototoxity.  TIRF 
microscopy based FRET technology has been used to track the interaction of membrane 
receptors (130,376).  Hence, TIRF based FRET system may also benefit the study of FAK 
conformation during cell migration.  To handle the photobleaching dynamics of different 
fluorescent proteins, a programmed photobleaching corrections method is used (193).  
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However, the photobleaching correction is a case-by-case issue.  The FAK biosensor based 
photobleaching correction is waiting to be developed.    
Keeping focal adhesions in focus is another challenge for FRET analysis of migrating 
cell because even a small zoom variation may introduce a deviation in FRET value.  This 
problem might be solved by the developing auto-focus strategy (411).    
In addition to the migrating cells, the spatial regulation of FAK in some specific 
biological processes should be investigated.  For example, FAK is involved in regulating the 
E-cadherin mediated cell-cell junctions (our unpublished data).  The N-terminal FERM 
domain is required for FAK cell junction targeting. Although it is hard to detect the 
activation of FAK in whole cell lysates, it is possible that the FAK is only activated within 
cell-cell junctions after the association of the FERM domain with some unknown partners. 
This interaction in turn promotes the conformational transition of FAK.  Hence, it is 
important to monitor FAK conformational status within cell-cell junction.  FAK has also 
been proposed to play critical role in neurite extension and sorting (232,284,310,373).  It will 
be interesting to understand the spatial regulation of FAK activity within the axons.  
5.1.2  When Does FAK Change Conformation? 
Our study suggests that not only integrin signaling but also LPS induces a FAK 
conformational switch.  Interestingly, PDGF was found to induce a fluctuation in FRET 
signal, which suggests that FAK might be transiently activated following PDGF stimulation.  
A number of other ligands should also be tested, including netrin, which is implicated in 
activating FAK via the DCC1 receptor (285,309,371).  Met is another candidate that induces 
FAK conformational change (83).  Met directly associates with FAK via its FERM domain.  
Interestingly, the basic residues within the FERM domain are required for Met/FAK 
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interaction.  The FAK variant with these residues mutated exhibits a closed conformation 
when compared to wild type FAK (47).  Hence, it is quite possible that Met might directly 
associate with FAK and promote its conformational switch following HGF stimulation. 
5.1.3  How Does FAK Change Conformation? 
The initiation of FAK activation has been a big puzzle.  Based on FAK structure and 
FRET studies in FAK, FAK conformational transition seems to be the first step in FAK 
activation.  However, there is still a gap between the receptors and FAK.  How does the 
activation of receptors induce FAK conformational switch?  PIP2 is proposed as a possible 
ligand that induces FAK conformational change.  This is a reasonable explanation since PIP2 
generation is observed following integrin activation (247).  In addition to PIP2, PIP3 should 
also be tested for its potential role in FAK regulation since PIP3 is required for integrin 
mediated FAK activation.  However, FAK conformational switch could be induced by 
multiple mechanisms.  It is possible that FAK conformation switch is directly regulated by its 
interaction with some receptors.  For example, the FERM domain of FAK directly associates 
with the integrinβ1 and β3 cytoplasmic tails (394).  Moreover, the peptide which mimics the 
integrinβ1 cytoplasmic tail activates FAK in vitro (98).  Thus it is possible that the 
FERM/integrin interaction might trigger FAK conformational switch.  In addition to 
receptors, other FERM domain binding partners should also be investigated.  Interestingly, 
FIP200 was proposed to inhibit the FAK activity via association with both the FERM and 
kinase domains (3).  It is possible that the FIP200 connects the FERM and kinase domains to 
maintain the auto-inhibition conformation.  This is also worth being investigated. 
5.1.4.  Why Does FAK Change Conformation? 
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It is interesting to know why FAK is regulated by such a complex mechanism.  Here 
we propose a hypothesis that FAK may works as a converter to transfer a physical signal to a 
chemical signal.  As discussed in the introduction, some physical stimuli, such as shear stress 
may induce the stretch of FAK, which in turn disrupts the FERM/Kinase interaction and 
activates FAK.  This is an interesting hypothesis since FAK is an essential protein in 
mechanotransduction.  The FAK stretch activation model will be tested both in vivo and in 
vitro.  For in vitro assay, the C-terminal of purified FAK conformation biosensor will be 
immobilized on a surface coated with FAK C-terminus antibody.  Then the N-terminus of 
FAK will be pulled by the magnetic beads coated with FERM domain antibody, e.g. 447.  
The FRET signal change will be monitored by the laser confocal microscopy.  For in vivo 
assays, cells expressing biosensor will be tested in a flow shear stress assay.  The FAK 
conformational switch will be monitored by FRET microscopy.  In addition to the flow 
assay, laser tweezers or magnetic tweezers assay may also help us to understand the FAK 
conformation switch following physical stimulation (462). 
5.1.5  Other Conformational Measurement Strategies 
Due to the size of inserted GFP variant, the FAK conformation biosensor slightly 
increases its kinase activity when compared to wild type FAK.  This problem might be 
solved by novel a dye, FlAsH, which becomes fluorescent when it binds to recombinant 
proteins containing a tetracysteine (TC) motif Cys-Cys-Pro-Gly-Cys-Cys (164).  Due to 
similar excitation and emission spectrum, the FlAsH can be used to replace Citrine in FAK 
biosensor (194).  The six amino acid insertion has little side-effects compared to the GFP 
variant.  However, the binding specificity of FlAsH is a technical challenge for FRET assay 
in living cells.  The labeling method needs to be improved to reduce the background noise. 
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Though the FRET based conformation biosensor makes it possible to visualize FAK 
conformation status in vivo, the limitations of the biosensor can never be overlooked.  The 
complexity of observation and analysis may limit the application of FRET technology in 
some cases (363).  An alternative method should also be developed to monitor FAK 
conformation.  A conformation specific antibody will be a good tool to identify FAK 
conformation status.  Such antibodies have been successfully used to identify activated 
integrins and stretched p130CAS (211,383).  A FAK conformation specific antibody could 
be screened from the existing N-terminal or Kinase domain FAK antibodies.  This can then 
be used to track FAK activation by immunoprecipitating that specific conformational FAK 
from cell lysates.  This antibody can also be used to stain the fixed cells to visualize the 
spatial FAK activation pattern.   
5.1.6  FRET Biosensor in a High Throughput Screen 
The first generation kinase inhibitors have mostly been designed based upon the ATP 
binding site of the kinases.  However, due to structural similarity of the various kinase ATP 
binding sites, it is hard to achieve a highly specific drug to target a single kinase.  As 
mentioned in the introduction, the kinase activities of a number of kinases are regulated by 
distinct conformational regulatory mechanisms.  The conformation based kinase inhibitor 
will be a promising direction for next generation drug design (287).  Hence, the FRET based 
conformational biosensor has a great potential application for being used in high throughput 
screens.  The target protein conformation within living cells can be read out by fluorescence 
microplate reader in real time.  The FRET based FAK activity measurement will be a quick 
and simple assay, which makes it suitable for large scale screen.  A number of chemically 
modified FRET biosensors have been used in HTS (196,334).  However, the response 
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sensitivity is the bottleneck for the application of genetic encoded biosensors in HTS.  In 
future, this problem might be solved by the development of new genetic coding fluorescence 
proteins, which might enhance the efficiency of energy transfer.   
5.2  Downstream Effects of Paxillin Serine126/130 Phosphorylation 
Our study suggests that the ERK/GSK-3 induced paxillin serine126/130 
phosphorylation is involved in cytoskeleton reorganization (45).  However, the downstream 
pathways regulated by paxillin serine 126/130 phosphorylation are still unknown.  
Interestingly, Kobayashi et al proposed that GSK-3 is required for focal adhesion turn over 
(254).  Also GSK-3 inhibitors (LiCl and SB216763 ) suppress the activation of FAK and 
Rac.  It is possible that GSK-3 regulates focal adhesion dynamics via phosphorylation of 
paxillin.  To test this hypothesis, the focal adhesion disassembly rate of cells expressing 
paxillin S126A/S130A should be determined.  
5.3  Downstream Effects of Pyk2 Activation in Fcγ Receptor Mediated Phagocytosis 
Our study suggests that Pyk2 is required for Fcγ receptor mediated phagocytosis, 
possibly via tyrosine phosphorylation of paxillin and activation of PI3K.  Though PI3K is 
well known as a critical regulator in Fcγ receptor mediated phagocytosis, the role of paxillin 
in phagocytosis is still unknown (12).  It is possible that Pyk2 induced tyrosine 
phosphorylation of paxillin is required for Rac activation since tyrosine phosphorylation of 
paxillin is required for Rac activation in cell migration (222,361).  Hence, the 
Pyk2/paxillin/Rac signaling should be tested in phagocytosis.   
5.4  The Role of Pyk2 in Other Types of Phagocytosis 
In addition, the role of Pyk2 in other types of phagocytosis should also be tested.  Our 
preliminary study suggests that Pyk2 is not required for complement mediated phagocytosis.  
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However, Pyk2 is involved in Yersinia uptake in macrophage cell lines (39).  So the role of 
Pyk2 in bacterial uptake should be tested in Pyk2 null cells.  Moreover, it is interesting to 
understand the role of Pyk2 in apoptotic cell phagocytosis.   
5.5  The Role of Pyk2 in Immune Cell Migration 
Immune cell migration plays a critical role in immunological pathology.  For 
example, leukocytes exit from circulation to the peripheral tissues during inflammation.  This 
plays a critical role in both innate and adaptive immune responses.  The defect in leukocyte 
integrinβ2 induces leukocyte adhesion deficiency.  Patients with this deficiency suffer from 
recurrent bacterial infections and impaired wound healing.  In addition, some diseases 
including multiple sclerosis are related to the cytotoxity of macrophages and TH1 cells.  
Restriction of the inflammation induced macrophage influx may attenuate these diseases 
(313).   
A number of studies suggest that Pyk2 is required for cell migration of different 
immune cells.  In leukocytes, the defects in macrophage influx were identified in Pyk2 null 
mice following carageenen induced acute inflammatory response (341).  Our preliminary 
study also identified a similar defect in Pyk2 null mice following thioglycolate induced 
inflammatory response.  Interestingly, neutrophil migration was unimpaired in above studies.  
The chemotaxis defect was identified in bone marrow macrophages isolated from Pyk2 null 
mice.  Both the formation and contractility of lamellipodia is greatly impaired in these cells.  
Integrin induced PI3K and RhoA activation is also blocked in Pyk2 null macrophages.  
Lymphocytes in the Pyk2 null mice lack the marginal zone B cells, which is at least partially 
induced by a migration defect in B cells (168).  Interestingly, a similar phenotype was 
identified in wild type mice which were treated with a drug to inhibit the GPCR signaling, 
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which suggests that Pyk2 may regulate B cell migration by regulating GPCR mediated 
chemotaxis.  A chemotaxis defect was also identified in Pyk2 null B cells in vitro.  No 
evident defects in T cell development and homing have been identified in T cells in vivo.  
However, Pyk2 is also implicated in regulating T cell migration in vitro (343).  
As a potent regulator of cell migration, Pyk2 is essential for immune cell trafficking, 
especially for macrophage influx during inflammation.  Understanding macrophage 
migration in inflammation is very important for the pathology of multiple diseases.  Due to 
the complexity of the macrophage trafficking and the multiple effects of Pyk2 in cell 
migration, the role of Pyk2 in immune cell migration should be deciphered at each step of 
leukocyte trafficking. 
Circulating leukocytes are first tethered by some receptors expressed on the surface of 
endothelial cells.  Pyk2 is activated following integrinβ2 activation when neutrophils are 
tethered by CHO cells expressing E-selectin (444).  This suggests that Pyk2 may regulate the 
E-selectin mediated leukocyte tethering.  Moreover, Pyk2 is required for integrinαMβ2 
mediated neutrophil adhesion to adherent platelets (129).  Little is known about the role of 
Pyk2 in monocyte tethering and rolling process.  Pyk2 null monocytes should be tested to 
understand this mechanism  
The tethered leukocytes are activated by chemokines, which induce leukocyte 
spreading and firm adhesion to endothelial cells.  Pyk2 plays a critical role in this process.  
Pyk2 null macrophages exhibit migration defects in response to MIP-1 and SDF-1 (340).  
Both Ca2+ signaling and IP3 generation are impaired in Pyk2 null macrophages following 
MIP-1 stimulation.  However, considering the differences between monocytes and 
macrophages, it will be interesting to examine Pyk2 activation in vivo.  
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Activated leukocytes transmigrate across the endothelial barrier to reach the site of 
inflammation.  Pyk2 might play a critical role in both leukocytes and endothelial cells during 
transmigration.  For endothelial cells, Pyk2 is required for ICAM-1 mediated tyrosine 
phosphorylation of VE-cadherin, which is required for neutrophil transmigration (9).  
Moreover, Pyk2 is also required for tyrosine phosphorylation of β-catenin.  This is induced 
by the disruption of VE-cadherin mediated cell-cell adhesion (454).  Pyk2 is required for Rac 
activation in NK cells during transmigration (154).  NK cells expressing a dominant negative 
of Pyk2 exhibit defects in transmigration.  However, we still know little about the role of 
Pyk2 in leukocyte transmigration.  Transplantation of Pyk2 null bone marrow cells into wild 
type mice should be a possible strategy to exclude the effects of Pyk2 on endothelial cells.  In 
addition to the migrating through endothelial cell junctions, the leukocytes also migrate 
through endothelial cells themselves (128).  When circulating leukocytes are arrested, the 
endothelial cell forms a big protrusion cup to engulf the leukocyte.  The phenotype of this 
cup is quite similar to the phagocytotic cup, which indicates that these two processes may 
share similar mechanisms.  Pyk2 may also regulate the leukocyte transcellular migration.  
The migration defects in Pyk2 null mice were only identified in macrophages but not 
neutrophils, which suggests that the Pyk2 plays distinct roles in different subsets of immune 
cells.  One possible explanation is that FAK may complement Pyk2 function in neutrophils.  
Due to the absence of evident FAK expression, deletion of Pyk2 induces evident defects in 
macrophages (124).  Interestingly, the defects in macrophage but not neutrophil migration in 
inflammation has been identified in transgenic mice expressing integrinα4 Y991A, which 
disrupts the interaction between integrinα4 and paxillin (132).  Furthermore, the disruption of 
154 
 
integrinα4/paxillin interaction blocks FAK/Pyk2 activation (377).  Hence 
integrin/paxillin/Pyk2 might work together to regulate macrophage migration.   
With the development of intravital microscopy technology, it is possible to visualize 
leukocyte trafficking in living animals, which helps us dissect the leukocyte migration 
process in a real in vivo environment (323).  Such imaging of Pyk2 null mice will helps us 
explain the inflammation induced macrophage influx defect among other defects. 
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